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ABSTRACT 
 
TRACKING AND QUANTIFYING NANOPARTICLE  
CONTRAST AGENTS USING MAGNETIC RESONANCE IMAGING 
Richard Wong, Ph.D. 
Cornell University 2012 
 
MRI is a powerful technique that is commonly used in clinical settings.  It is non-invasive, does 
not employ ionizing radiation, and is capable of high spatial and temporal resolution, making it ideal for 
a wide variety of imaging applications, both for active diagnostic applications and preventative 
medicine.  The strategies described in this thesis further increase the diagnostic ability of MRI by 
selectively delivering contrast enhancing nanoparticles to areas of interest, either through changes in 
cellular, organ, and systemic behavior as a result of disease states, or through biospecificity conferred by 
surface-bound targeting ligands.  In doing so, this allows MRI to accurately probe systemic processes or 
cellular targets previously not available as diagnostic indicators, and has the potential to dramatically 
expand the spectrum of biological characteristics that can be visualized and quantified using MRI.  The 
work in this study represents a step towards the creation of specialized, use-specific diagnostic agents 
that have the potential to improve the accuracy and speed of clinical diagnoses. 
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[T]he end of the line.  All trains finish there.  They don’t go on anywhere. 
 
-The Sun Also Rises, Ernest Hemmingway 
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INTRODUCTION 
MR imaging uses powerful magnetic and radio frequency fields to align, alter, and observe the 
nuclear magnetization of hydrogen atoms in the water of the body.  Due to the varying nature of these 
magnetic properties across the spectrum of tissue and other material found in the body, it becomes 
possible to generate images by exploiting this differential.  Contrast in the resulting images reflects this 
difference and provide a relative measure by which tissue types can be distinguished. 
To further increase the contrast between tissue types, various types of contrast agents may be 
used to alter the magnetism in a localized area.  Materials such as paramagnetic gadolinium-containing 
(Gd) liposomes (1, 2) or micelles (3-5), and superparamagnetic iron oxide (SPIO) nanoparticles (6, 7) can 
be used to alter the magnetic properties of the surrounding water.  Used in conjunction with strategies 
to localize these contrast agents in specific areas of interest and imaging sequences designed to fully 
maximize the differences induced by these contrast agents, contrast agents can be used as probes to 
selectively highlight structures and phenomena indicative of a variety of biological conditions.  In 
particular, SPIO nanoparticles have become established for use in liver imaging (8), lymph node 
characterization (9), diagnosis of tissue inflammation (10, 11), and stem cell labeling (12-16). 
This dissertation explores two distinct strategies with respect to the delivery of contrast agents: 
untargeted and targeted nanoparticles for use in MR imaging.  First, untargeted SPIO-based 
nanoparticles were evaluated for use as an indicator for the onset and progression of sepsis.  With no 
conferred specificity towards any antigen or receptor within the body, these nanoparticles are typically 
uptaken by immune system-related cells and are eliminated from the body. (17)  As upregulation of this 
uptake behavior is often correlated with specific systemic conditions such as sepsis and systemic acute 
inflammation, correlating nanoparticle biodistribution and organic-specific update with the progression 
of sepsis offers insight into the onset and progression of these conditions. 
 
 
2 
 
 
Second, the delivery of contrast agents was enhanced with the use of surface-bound targeting 
proteins to produce contrast agents specific to cellular targets closely associated with acute 
inflammation, sepsis, and cancer.  The first approach began with the development of a human 
interleukin-based ligand scaffold that produces homodimeric targeting ligands, aimed at augmenting 
effective binding efficiency through an increase in avidity, or heterodimeric protein complexes, aimed at 
broadening the targeting spectrum through multiple-site specificity.  This scaffold was then utilized to 
construct high affinity SPIO-based nanoparticles specific against a specific mutated form of p53 found in 
a broad range of cancer cell lines, resulting in a generalized cancer detection contrast agent suitable for 
detection of various cancer cell lines in vitro. 
The second approach to targeting contrast agent delivery consists of the design and 
implementation of a leukocyte mimetic nano-micelle encapsulating SPIO.  Designed with a goal of high 
specificity against ICAM-1, an surface-expressed intercellular adhesion molecule often overexpressed in 
tumor cells, tumor vascular microenvironment, and acute inflammation, this contrast agent was 
successfully use in visualizing acute inflammation in vitro and in vivo using MRI. 
In all approaches, nanoparticle distribution was tracked and quantitatively measured using 
magnetic resonance imaging and by employing recently developed techniques in quantitative 
susceptibility mapping. 
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CHAPTER 1 - BACKGROUND 
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1.1 MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging (MRI) is a widely used non-invasive imaging modality that allows for 
visualization of cross-sectional slices or three-dimensional volumes of an object through the use of 
powerful magnetic fields and radio frequency (RF) energy to align, alter, and observe the nuclear 
magnetization of hydrogen atoms that make up the subject of interest.   
 
1.1.1 Precession 
A nucleus that contains an odd number of protons and/or of neutrons have an intrinsic magnetic 
moment and angular momentum about their axes, typically referred to as a “spin.”  Under typical 
conditions, the magnetic moments of the nuclei of a bulk volume are randomly oriented, resulting in no 
net magnetic moment for the volume.  However, when an external magnetic field is applied, the spins 
align relative to the applied field in one of two orientations: parallel to the applied field, or antiparallel 
to the applied field.  As the parallel state has a slightly lower energy state, this results in slightly more 
spins aligned parallel to the applied field, and results in a net magnetic moment in the volume. 
 The bulk magnetization when exposed to an applied magnetic field can be expressed using the 
Bloch equation 
 
𝑑𝐌
𝑑𝑡
= (γ𝐌 × 𝐁) − (𝑀z − Mz0)𝐳�
𝑇1
−
𝑀𝑥𝒙� + 𝑀𝑦𝒚�
𝑇2
 , [1.1] 
where 𝐌 is the bulk magnetization, 𝐁 is the applied external magnetic field , 𝑀𝑥 is the x component of 
𝐌, 𝑀𝑦 is the y component of 𝐌, 𝑀𝑧 is the z component of 𝐌, 𝑀𝑧0 is the equilibrium magnetization that 
results when the volume is placed in the applied field, and vectors 𝒙�, 𝒚�, and  𝒛� represent the unit vectors 
along the x, y, and z axes, respectively.  Constants 𝑇1 and 𝑇2 represent the rates of longitudinal and 
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transverse relaxation, respectively.  Constant 𝛾 is the nucleus-specific gyromagnetic ratio, expressed in 
MHz/T. 
 Typically, the vectors of the x-y transverse plane are represented using complex notation, where 
the x component is represented by the real component and the y component is represented by the 
imaginary component.  Thus, the transverse magnetization can be represented as 
 𝑴𝑥𝑦 = 𝑀𝑥 + 𝑗𝑀𝑦 = �𝐌𝑥𝑦�𝑒−𝑗𝜙 , [1.2] 
where 𝑗 = √−1.   
 If 𝑩0 is assumed to be purely in the longitudinal direction, the first term of Bloch’s equation (Eq. 
1.1) can be expressed as 
 
𝑑𝑀𝑥
𝑑𝑡
= 𝛾𝑀𝑦𝐵𝑧 
𝑑𝑀𝑦
𝑑𝑡
= 𝛾𝑀𝑥𝐵𝑧 . [1.3] 
Defining  
 𝜔0 = 𝛾𝐵𝑧 , [1.4] 
where 𝜔0 is the frequency of procession of the nucleus in the precense of applied 𝐁𝟎, we obtain 
 
𝑀𝑥(𝑡) = 𝑀𝑥(0) cos𝜔0𝑡 + 𝑀𝑦(0) sin𝜔0𝑡 
𝑀𝑦(𝑡) = −𝑀𝑥(0) sin𝜔0𝑡 + 𝑀𝑦(0) cos𝜔0𝑡 , [1.5] 
for initial conditions 𝑀𝑥(0) and 𝑀𝑦(0).  Expressed in complex notation, this becomes 
 𝑴𝑥𝑦 = 𝑴𝑥𝑦(0)𝑒−𝑗𝜔𝑡 , [1.6] 
for initial condition 𝑴𝑥𝑦(0).  Intuitively, this describes the precession of the magnetization vector about 
the applied magnetic field at a resonant frequency 𝜔0. 
 The second term of Bloch’s equation (Eq. 1.1) can be likewise expressed as 
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 𝑀𝑧(𝑡) = 𝑀0 + (𝑀𝑧(0) −𝑀𝑧0)𝑒−𝑡/𝑇1 , [1.7] 
for initial condition 𝑀𝑧(0), where 𝑀𝑧(𝑡) is the longitudinal magnetization at the time of interest.  
Intuitively, this describes longitudinal relaxation, and describes the regrowth of longitudinal 
magnetization from 𝑀𝑧(0) at 𝑡 = 0 to 𝑀𝑧0 as 𝑡 approaches ∞. 
 The third term of Bloch’s equation (Eq. 1.1) can be expressed as  
 𝑴𝒙𝒚(𝑡) = 𝑴𝑥𝑦(0)𝑒−𝑡/𝑇2 [1.8] 
for initial condition 𝑴𝑥𝑦(0), where 𝑴𝑥𝑦(𝑡) is the transverse magnetization at the time of interest.  
Intuitively, this describes the decay of transverse magnetization from 𝑴𝑥𝑦(0) at 𝑡 = 0 to 0 as 𝑡 
approaches ∞. 
 
1.1.2 Excitation 
If a second magnetic field 𝑩1 is applied, the magnetization will precess about the vector sum of 𝑩0 and 
𝑩1.  If 𝑩1 is applied in the orientation of the transverse plane, the magnetization vector will begin 
rotating away from the longitudinal axis and towards the transverse plane.  However in the context of 
MRI, 𝑩0 is typically much larger than 𝑩1.  Thus, 𝑩1 contributes only a small effect on the angle of 
precession, as the magnetization vector will quickly rotate out of orthogonality with 𝑩1.  If instead 𝑩1 is 
applied such that it rotates in the transverse plane at the same frequency as the longitudinal procession 
frequency 𝜔0, 𝑩1 will remain orthogonal to the magnetization vector at all times, causing the 
magnetization vector to rotate or “tip” towards the transverse plane.  The angle by which the 
magnetization vector is tipped towards the transverse plane is known as the “flip angle,” and can be 
calculated as the integral of 𝑩1 over time.   
Intuitively, 𝑩1, applied in the form of a radio frequency (RF) pulse, can be used to selectively 
excite nuclei only of a particular resonant frequency.  This notion can be exploited to allow for the 
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selective excite nuclei in a spatially selective manner through the use of a spatially linear field gradient.  
If, for instance, a spatially linear field gradient 𝑮𝑧 is produced along the z-axis, the precession of spins 
will vary linearly along the z-axis in according to 
 𝜔(𝑧) = 𝛾(𝐵0 + 𝐺𝑧) , [1.9] 
producing an “envelope” by which nuclei can be selectively excited based on spatial location.  Gradient 
fields can be similarly applied along all three cardinal axes, allowing for spatial selection in three-
dimensional space. 
 
1.1.3 Signal Detection 
After excitation by 𝑩1, the magnetization vector precesses about both 𝑩0 and 𝑩1, and as a result 
produces a temporally varying magnetic field.  This in turn induces a temporally varying current in 
nearby conductors according to Faraday’s law of induction.  The observable signal can be written as: 
 𝑆(𝑡) = � 𝑪(𝒙)𝝆(𝒙)𝑒−𝑗𝜔0𝑡𝑒−𝑡/𝑇2𝑑𝒙∞
−∞
 [1.10] 
where 𝐒(𝑡) is the observed signal at time 𝑡 after excitation by 𝑩1, 𝒙 is a vector describing spatial 
position, 𝑪(𝒙) is the coil sensitivity at position 𝒙, and 𝝆(𝒙) is the transverse magnetization at position 𝒙 
immediately after excitation by 𝑩1.  Intuitively, this describes the growth of observable signal upon 
excitation by 𝑩1, followed by subsequent decay as the transverse magnetization decays and longitudinal 
magnetization regrows. 
 
1.1.4 Spatial Encoding 
If a spatially varying magnetic field Δ𝐵(𝒙) is applied across the subject, the frequency of procession will 
vary as 
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 𝜔(𝒙) = 𝛾�𝐵0 + Δ𝐵(𝒙)� , [1.11] 
allowing for the encoding of spatial information in the frequency of the emitted radio waves.   In the 
presence of Δ𝐵(𝒙) , the observable signal can be rewritten as: 
 𝑆(𝑡) = � 𝑪(𝒙)𝝆(𝒙)𝑒−𝑗𝛾�𝐵0+Δ𝐵(𝒙)�𝑡𝑒−𝑡/𝑇2𝑑𝒙∞
−∞
 . [1.12] 
If the signal is demodulated by center frequency 𝜔0, the observable signal can be expressed as: 
 𝑆(𝑡) = � 𝑪(𝒙)𝝆(𝒙)𝑒−𝑗𝛾Δ𝐵(𝒙)𝑡𝑒−𝑡/𝑇2𝑑𝒙∞
−∞
 . [1.13] 
In practical application, the magnetic field variation is a linear field gradient that can vary over time, and 
can be expressed as: 
 𝒙𝑮(𝑡) = Δ𝐵(𝒙, 𝑡), [1.14] 
where 𝑮(𝑡) is a vector representing the spatial magnetic field gradient at time 𝑡.  The observable signal 
can then be expressed as: 
 𝑆(𝑡) = � 𝑪(𝒙)𝝆(𝒙)𝑒−𝑗𝛾 ∫ 𝐺(τ)𝑑𝜏𝒙𝑡0 𝑒−𝑡/𝑇2𝑑𝒙∞
−∞
 . [1.15] 
If the effects 𝑇2 decay 𝑒−𝑡/𝑇2 are neglected and the observable signal is reparametized by: 
 𝒌(𝑡) = 𝛾� 𝐺(𝜏)𝑑𝜏𝑡
0
 , [1.16] 
the observable signal can be represented by: 
 𝑆(𝑘) = � 𝑪(𝒙)𝝆(𝒙)𝑒−𝑗𝑘𝒙𝑑𝒙∞
−∞
 . [1.17] 
Intuitively, the observed signal can be interpreted as a Fourier transform of 𝑪(𝒙)𝝆(𝒙), where the 
Fourier transform is defined as 
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 𝐹(𝑘) = � 𝑓(𝑥)𝑒−𝑗𝑘𝑥𝑑𝑥∞
−∞
 . [1.18] 
 
Thus, the observed signal represents coefficients of the spatial Fourier transformer of the object being 
imaged, with the spatial frequency of each coefficient corresponding to the integral of the gradient 
waveform up to that point. 
 
1.1.5 Image Reconstruction 
The image can be reconstructed through an inverse Fourier transform of the observed signal.  In 
application, it is not feasible to sample all Fourier coefficients necessary to perfectly reconstruct the 
object, and thus the reconstruction can be approximated by a continuous inverse Fourier transform: 
 𝝆�(𝒙) = 1(2𝜋)𝑛 � 𝑆(𝒌)𝑒𝑗𝒌𝒙𝑑𝒌∞−∞  , [1.19] 
where 𝝆�(𝒙) is an estimation of the magnetization distribution weighted by the coil sensitivity function 
and 𝑛 is the number of dimensions over which the Fourier transform is taken.  As the image 
reconstruction is performed on discrete samples, the reconstruction can be approximated by 
 𝝆�(𝒙) = �𝑺(𝒌𝒊)𝑒𝑗𝒌𝑖𝒙𝐷(𝒌𝑖)
𝑖
 , [1.20] 
where 𝑖 is an index of the acquired Fourier coefficients, 𝐷(𝒌𝒊) is the local sampling density around the 
point 𝒌𝑖.  In practical application, sampling is performed on a regular Cartesian grid for a three-
dimensional data set, and the estimation can be approximated by 
 𝝆�(𝑥,𝑦, 𝑧) = 1
𝑁𝑥𝑁𝑦𝑁𝑧
� � � 𝑆(𝑚,𝑛,𝑝)𝑒2𝜋𝑥𝑚/𝑁𝑥𝑒𝑗2𝜋𝑦𝑛/𝑁𝑦𝑒𝑗2𝜋𝑧𝑝/𝑁𝑧𝑁𝑧−1
𝑝=0
𝑁𝑦−1
𝑛=0
 .𝑁𝑥−1
𝑚=0
 [1.21] 
 
 
10 
 
 
 
1.2 CONTRAST AGENTS 
Due to the varying nature of physical properties across the spectrum of heterogeneous tissue and other 
materials found in the body, it becomes possible to exploit this differential to generate images.  In MRI, 
contrast can be derived from material differences such as longitudinal, or spin-lattice, relaxation rate 𝑇1,  
transverse, or spin-spin, relaxation rate 𝑇2, and proton density 𝑃𝐷.  Through strategic pulse sequence 
design and parameter selection, images can be acquired that more strongly accentuate the differences 
in one or more of these material properties, providing a relative measure by which heterogeneous 
tissue types can be distinguished.  For example, T1-weighted sequences will produce images that derived 
contrast based on a greater sensitivity towards differences in 𝑇1, intuitively described as the rate by 
which the nuclei of a material can dissipate the energy gained by an excitation pulse.  As described 
previously, 𝑇1 can be represented by the second term of the Bloch equation (Eq. 1.1): 
 𝑀𝑧(𝑡) = 𝑀0 + (𝑀𝑧(0) −𝑀𝑧0)𝑒−𝑡/𝑇1 , [1.22] 
for initial condition 𝑀𝑧(0), where 𝑀𝑧(𝑡) is the longitudinal magnetization at the time of interest.  Water 
in bulk phase has a long T1 relaxation time, and will typically appear dark in images produced by a T1-
weighted sequence, whereas fat-based tissue have comparatively short T1 relaxation times, and will 
typically appear bright, while water-based tissues will appear gray.  Clinically, T1-weighted images are 
commonly used to distinguish between gray matter and white matter of the brain by exploiting 
differences in fat deposition between the two tissue types.  Sequences such as spin echo (SE) and 
gradient echo (GRE) are commonly used to acquire T1-weighted images. 
On the other hand, T2-weighted sequences will produce images that derive contrast based on a greater 
sensitivity towards differences in 𝑇2, intuitively described as the rate by which the nuclei of a material 
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lose phase coherence following excitation.  As described previously, 𝑇2 can be represented by the third 
term of the Bloch equation: 
 𝑴𝒙𝒚(𝑡) = 𝑴𝑥𝑦(0)𝑒−𝑡/𝑇2 [1.23] 
for initial condition 𝑴𝑥𝑦(0), where 𝑴𝑥𝑦(𝑡) is the transverse magnetization at the time of interest.  
Fluids have slow 𝑇2 relaxation rates and will typically appear bright in images produced by a T2-weighted 
sequence, whereas water and fat-based tissue will appear gray.  Clinically, T2-weighted images are 
commonly used to imaging edemas, by which abnormal collections of fluid can be readily identified 
against normal tissue.  Sequences such as spin echo (SE) and gradient echo (GRE) are commonly used to 
acquire T2-weighted images.   
However, images acquired in this manner using GRE sequences are in reality weighted by 𝑇2∗, 
the apparent time constant of the non-equilibrium nuclear spin magnetization decay due to loss of 
phase coherent among spins.  Due to physical limitations in MR scanner design and the presence of 
magnetic susceptibility effects, the generation of a perfect magnetic field is not possible, causing 
magnetic field inhomogeneities that cause nuclei to process at slightly different frequencies.  This results 
in a rapid loss of phase coherence and, as a result, a loss of transverse magnetization.  𝑇2∗ can be 
approximately related to 𝑇2 by 
 
1
𝑇2
∗ ≅
1
𝑇2
+ Δ𝜔2  , [1.24] 
where Δ𝜔 = 𝛾Δ𝐵.  As a result, 𝑇2∗ is always less than 𝑇2. 
Numerous strategies in pulse sequence design and pulse sequence parameter selection can be 
employed to fully exploit differences in signal production based on 𝑇1, 𝑇2, 𝑇2∗, and 𝑃𝐷, details of which 
can be found in various external references.  
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The differences in material properties relevant to generating imaging contrast can be further 
enhanced through the use of contrast agents.  Paramagnetic and superparamagnetic materials have the 
effect of decreasing 𝑇1, 𝑇2, and 𝑇2∗ relaxation times of protons in the immediate vicinity of the molecule, 
and if delivered in a specific and selective manner, can have the effect of increasing imaging contrast for 
structures of interest. 
 Paramagnetic contrast agents, such as those based on gadolinium, contain species with 
unpaired electrons, with paramagnetic metal ions showing increasingly suitable effect as the number of 
unpaired electrons in the ion increases.  In addition, the electron spin-relaxation time must also match 
the Larmor frequency of the protons.  These criteria make paramagnetic heavy metal ions such as Fe3+, 
Mn2+, and Gd3+ ideal for use as 𝑇1 contrast agents.  While paramagnetic heavy metal ions are toxic in 
their native form, it is possible to generate thermodynamically and kinetically stable ion-ligand 
compounds.  The most common  𝑇1 contrast agent in clinical use today is Gd-DTPA, marketed in the US 
market as gadopentetic acid or Magnevist.  Gd-DPTA is the complex of gadolinium (as Gd3+) and 
diethylenetriaminepentacetate (as DTPA5-) in which the gadolinium ion is surrounded by three nitrogen 
atoms and five oxygen atoms from carboxylate groups, with a water molecule occupying a ninth 
coordinate site.  As the gadolinium ion has seven unpaired electrons with parallel spins, Gd-DTPA is 
strongly paramagnetic, which DTPA chelation significantly reduces the toxicity otherwise found in 
unchelated Gd3+.  Gd-DTPA is commonly used to image blood vessels and of inflamed or diseased 
edemic tissue.  Gd-DTPA has also demonstrated use in imaging intracranial lesions with abnormal 
vascularity in the blood-brain barrier. 
A second class of contrast agents based on superparamagnetic iron oxide (SPIO), which consist 
of nonstoichiometric microcrystalline magnetite cores  that are coated with dextranes or siloxanes.  The 
magnetite cores are typically constructed from a mixture of FeO or Fe2O3, and Fe2O3, and formed 
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through partial oxidation of Fe2+, resulting in a cation-deficient, inverse-spinel phased core.  SPIO-based 
contrast agents are typically significantly more effective at reducing relaxation times of neighboring 
nuclei than paramagnetic contrast agents.  While, like paramagnetic contrast agents, these class of 
contrast agents have both a 𝑇1, 𝑇2, and 𝑇2∗-shortening effect, clinically SPIO-based contrast agents are 
predominantly used in T2*-weighted imaging.  SPIO compounds are also non-toxic and quickly cleared 
from the patient, making them ideal for clinical application. 
 
1.3 QUANTITATIVE SUSCEPTIBILITY MAPPING 
Magnetic resonance imaging quantitative susceptibility mapping (MRI-QSM) is a technique by which 
arbitrary magnetic susceptibility distributions can be discerned using magnetic resonance signal phase 
information, typically discarded in a typical image reconstruction.  As the net volume magnetic 
susceptibility relates linearly with the concentration of a diamagnetic or paramagnetic material 
contained within it, quantitatively mapping magnetic susceptibility across a volume of interest can 
provide valuable information about the location and susceptibilities of differing materials, and would 
prove particularly useful in the quantification of paramagnetic contrast agents, such as those 
constructed from gadolinium and super paramagnetic iron oxide (SPIO). 
Volume magnetic susceptibility 𝛸𝑣 is a dimensionless proportionality constant that indicates the 
degree of magnetization of a material in response to an applied magnetic field, and can be defined by 
the relationship 
 𝐌 = 𝛸𝑣𝐇 , [1.25] 
where M is the magnetization of the material, measured in amperes per meter, and H is the magnetic 
field strength, measured in amperes per meter.  Further, magnetic induction B is related to H by the 
relationship  
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 𝐁 =  𝜇0(𝐇 + 𝐌) = 𝜇0(1 + 𝛸𝑣)𝐇 = 𝜇𝐇 , [1.26] 
where 𝜇0 is the magnetic constant, 𝑎𝑛𝑑 (1 + 𝛸𝑣) is the relative permeability of the material.  Thus, it 
can be shown from Maxwell magnetostatic equations and the Lorentz correction for media effects that 
the susceptibility distribution affects the field component along the main magnetic field according to 
 𝛿𝐵(r⃑) = 14𝜋�𝜒(𝑟′) 3 cos2 𝛼 − 1|𝑟′ − 𝑟|3 𝑑3𝑟′, [1.27] 
where 𝑟 is the spatial coordinate vector, 𝛼 is the angle between 𝑟′ − 𝑟 and the applied field, and 𝛿𝐵 is 
the relative difference field given by  
 𝛿𝐵(𝑟) = 𝐵𝑧(𝑟) − 𝐵0𝐵0  , [1.28] 
where 𝐵𝑧 is the local magnetic field component along the main magnetic field.  The induced field can be 
expressed as a convolution of the susceptibility distribution with the unit dipole response 
 
3 cos2 𝛼 − 14𝜋|𝑟|3  , [1.29] 
and in the Fourier domain becomes a pointwise multiplication with a kernel 
 ΔB�𝑘�⃑ � = �13 − 𝑘𝑧2𝑘2� ⋅ Χ�𝑘�⃑ �, [1.30] 
where Δ𝐵 is the Fourier transform of the normalized field shift 𝛿𝐵, Χ is the Fourier transform of 𝜒, (1/3 − (𝑘𝑧2)/𝑘2 ) is the dipole response to an external magnetic field in the Fourier domain, 𝑘 is the 
magnitude of a Fourier domain coordinate vector 𝑘�⃑ , and 𝑘𝑧 is the projection of 𝑘�⃑  onto the direction of 
the main magnetic field. (18) 
 While this relation provides a straightforward method of predicting the normalized field shift 
𝛿𝐵(𝑟) that result from a known susceptibility distribution 𝜒(𝑟), it is more practically relevant to solve for 
the inverse, to determine the susceptibility distribution given a known induced magnetic field.  Solving 
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for this field-to-source “inverse problem” is complicated by the characteristic dipole response function (1/3 − (𝑘𝑧2)/𝑘2 ), which has zeroes on two conic surfaces of k-space.  Solving for Χ(𝑘�⃑ ) via direct 
inversion requires the evaluation of (1/3 − (𝑘𝑧2)/𝑘2 )−1, which is undefined at these zeroes, resulting in 
an ill-posed inversion problem.  While this problem can be sidestepped in practical application through 
careful discretization in order to avoid undefined regions, the dipole response in Fourier space may still 
be arbitrarily close to zero in space arbitrary close to the conic surface, resulting in severe noise 
propagation. (19) 
 The field-to-source inverse problem can be solved by various methods.  Two such methods are 
the Calculation of Susceptibility Through Multiple Orientation Sampling (COSMOS), a multi-orientation 
sampling approach, and Morphology Enabled Dipole Inversion (MEDI), a method by which magnitude 
information is used to regularize the corresponding susceptibility map. 
 
1.3.1 Calculation of Susceptibility Through Multiple Orientation Sampling 
MRI-QSM Calculation of Susceptibility Through Multiple Orientation Sampling (COSMOS) solves the 
field-to-source inverse problem by oversampling the subject from multiple orientations. (18)  Because 
the zero cone surface in the Fourier domain is fixed with regard to the main magnetic field, it is possible 
to resample data by first rotating the subject with respect to the main magnetic field, exposing data 
previously obscured by the zero cone surface while also reducing the effect of noise amplification in 
space near to the cone surface.  Thus, the relation between the susceptibility distribution and the 
induced field can be rewritten as 
 Δ𝐵�𝑘�⃑ � = �13 − 𝑘𝑧𝑝2𝑘2 � ⋅ Χ�𝑘�⃑ �, [1.31] 
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where 𝑘𝑧𝑝 is the projection of the object coordinate vector 𝑘�⃑  onto the direction of the main magnetic 
field.  Assuming that the object is rotated by θ about the x-axis orthogonal to the main magnetic field, 
 𝑘𝑧𝑝 = 𝑘𝑧 cos θ + 𝑘𝑦 cos θ  . [1.32] 
Thus, if the object is sampled from N different angles, 
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� . [1.33] 
A Fourier domain pointwise direct inversion is applicable as long as there exists a nonzero element 
among (1/3 − 𝑘𝑎𝑥𝑖𝑠𝑛/𝑘2 ) , 𝑛 = 1, 2 …𝑁.  A set of angles θ1, … , θ𝑁 exist to fulfill this criterion for every 
point in the Fourier domain when 𝑁 ≥ 3. (18)  In practical implementation, this can be achieved through 
three samples with 120° rotation about the x-axis.   
Further information pertaining to the theory and implementation of COSMOS can be found in 
Liu 2009.  
 
1.3.2 Morphology Enabled Dipole Inversion 
While COSMOS is easily adaptable in determining the quantitative susceptibility map of relatively small 
samples, physical limitations of the bore of the MR scanner makes COSMOS impractical for sampling 
larger subjects.  Alternatively, solution to the field-to-source inverse problem can be derived through 
regularization that encodes a priori information, using a single sample.  Morphology Enabled Dipole 
Inversion (MEDI) makes use of the observation that the locations of interfaces, or “edges,” in the 
 
 
17 
 
 
susceptibility of distribution are nearly the same as those in magnitude images obtained in the same 
acquisition, and their discordance is assumed to be sparse.(20)  This can be achieved through a weighted 
𝑙1 minimization that penalizes susceptibility at voxels that do not have a corresponding interface in the 
magnitude image.  Expressed as a minimization 
 
min
𝑥
�𝑀∇χ�1 
𝑠. 𝑡. �𝑊(𝛿 − 𝐹𝐷𝜒�2 = 𝜀 , [1.34] 
where ∇ is a three-dimensional gradient operator on the vectorized susceptibility distribution 𝜒; 𝑀 is a 
binary gradient weighting diagonal matrix, where the non-negligible gradients in the magnitude image 
(define as five times greater than the background noise standard deviation in the magnitude image) and 
are equal to 1 otherwise; 𝐹𝐷 is a matrix encoding the convolution with the unit dipole field 𝐹𝐷 =
𝐹−1𝐷𝐹, where 𝐷 is the dipole kernel expressed in the Fourier domain; 𝛿 is the measured local field map, 
and 𝑊 is the data weighting matrix to account for non-uniform phase noise.  𝑊 and expected noise 
level 𝜀 are derived from the magnitude images across all echoes by calculating the error propagation 
from the phase noise to the field noise.  The solution to the minimization problem coincidences with the 
unconstrained Lagrangian problem with a properly chosen parameter 𝜆: 
 𝜒∗ = argmin𝜒�𝑀∇𝜒�1 + 𝜆�𝑊(𝛿 − 𝐹𝐷𝜒)�22 , [1.35] 
where 𝜒∗ is the solution of the susceptibility distribution to the minimization problem.  The value of 𝜆 is 
chosen such that �𝑊�𝛿 − 𝐹𝐷𝜒��2 = 𝜀. 
 Further information pertaining to the theory and implementation of MEDI can be found 
in Liu 2012.   
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CHAPTER 2 – UNTARGETED NANOPARTICLES 
 
Includes material previously published in: Wong R, Shou J, Wang Y. Probing sepsis and sepsis-like 
conditions using untargeted SPIO nanoparticles. Conf Proc IEEE Eng Med Biol Soc. 2010;2010:3053-
6.(21) 
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2.1 INTRODUCTION 
Severe sepsis is the leading cause of death in critically ill patients admitted to the medical Intensive care 
unit (ICU) in the United States (22). Substantial efforts have been devoted to finding effective 
pharmacologic therapies and improving clinical outcomes. However, to date, there has been limited, if 
any, success (23-25). A recent study on ALI/ARDS patients (26) showed that patients with sepsis-related 
lung injury continue to experience the highest fatality rates. The 28-day all-cause mortality is in excess of 
30% (26). In many cases, ALI/ARDS progresses to severe sepsis and multi-organ dysfunction/failure. 
Despite an improved ability to monitor, support, and manage these critically ill patients, the survival rate 
of severe sepsis remains only 50% to 70%. The average cost of severe sepsis is more than $22,000 per 
case, with an average length of hospitalization of 19.6 days. Severe sepsis is a major cause of morbidity 
and mortality worldwide and is the 13th leading cause of death among hospitalized patients overall in 
the U.S. The incidence of sepsis-related ALI/ARDS and severe sepsis is expected to rise during the next 
decade due to the aging population, a growing population of those who are immunosuppressed due to 
treatments or diseases, the increased use of invasive catheters and prosthetic materials, and the 
growing problem of antimicrobial resistance. In the year 2010, it is estimated that there will be 934,000 
new severe sepsis cases in the United States and 1,000,000 in the year 2020 (27). The annual costs 
associated with the treatment of patients with ALI/ARDS and severe sepsis in the U.S. alone have been 
estimated in excess of $5 billion and at $16.7 billion respectively (27).  
Current diagnosis of sepsis-induced ALI/ARDS relies heavily on bacteria culturing of patients’ 
blood and the patient’s manifestation of clinical symptoms. Bacterial culturing of patients’ blood is an 
unreliable diagnostic method for sepsis that also takes days for confirmation. It has been shown that 
only approximately 30% of clinically confirmed sepsis cases give positive identification of bacterial and 
viral infections (28). However, as the underlying biological changes of sepsis-induced ALI/ARDS and 
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severe sepsis occur hours to days before the clinical presentation of symptoms, early detection of the 
biological changes will provide crucial opportunities for early diagnosis and medical intervention of 
sepsis-induced ALI/ARDS and severe sepsis. For instance, early goal-oriented intervention is proven to 
lower the mortality rate of severe sepsis. This underscores importance of a better, rapid diagnostic 
method for sepsis-induced ALI/ARDS and severe sepsis. As an alternative to existing techniques to 
detection, we propose using MRI quantitative susceptibility mapping as a method of quantifiably 
measuring the activity of patients’ immune system as a biomarker of sepsis progression.   
It has been observed that Kupffer cells, comprising 80% of the liver’s macrophages, exhibit 
immune responses during early phases of systematic infection (17).  Macrophages utilize their pattern 
recognition receptors known as Toll-like receptors (TLRs) to sense infection by binding to certain 
microbial components (29).  The activations of certain TLRs on the surface of macrophages will 
drastically increase their phagocytic activities for particle uptakes.  Further, it has been observed that 
phagocytosis by Kupffer cells is a major mechanism by which nanoparticle-based contrast agents, such 
as Feridex, are cleared from the body (17).  Therefore, we can utilize these commonly used, the FDA-
approved contrast agents as markers in diagnosing and monitoring progression of sepsis by quantifying 
the amount of superparamagnetic iron-oxide nanoparticles uptaken by the host macrophages after 
exposure to infectious agents or their TCR-recognized components. 
 
2.2 MATERIALS AND METHODS 
2.2.1 In Vitro Observation of SPIO Uptake Using MRI 
Murine macrophages, RAW264.7 (ATCC, Manassas, VA), cultured for no more than 15 passages, were 
grown to 80% confluency in Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal Bovine Serum 
(FBS).  1 x 106 cells were seeded, were allowed to incubate overnight at 37°C, 5% CO2 and were 
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subsequently activated by a treatment of E. coli-derived lipopolysaccharide (LPS) at a concentration of 
100ng/mL in fresh media and allowed to incubate for 24 hours; untreated cells were used as negative 
controls.  Feridex IV (Bayer AG, Leverkusen, Germany), a ferumoxide solution, was then added to the 
media at a concentration of 112ug of Fe/mL and allowed to incubate for 3, 6, 9, 18, and 24 hours.  The 
media was removed by aspiration, and the cell monolayer was washed 3 times with Dulbecco’s 
Phosphate Buffered Saline (DPBS) to remove free Feridex.  Cells were trypsinized, collected and counted, 
and centrifuged into a pellet at the bottom of a 15mL centrifuge tube containing DPBS.  The centrifuge 
tube was positioned in the center, lengthwise, of a 50mL centrifuge filled with DPBS, creating a cell 
pellet suspended in the middle of a uniform DPBS solution.  The cell apparatus was scanned using a 3T 
Signa GE scanner (General Electric, Milwaukee, WI) with a custom birdcage coil and using an EFGRE 3D 
sequence, 4 TEs 3.0/3.8/5.4/10.2ms, TR 30ms, Flip Angle 30°, bandwidth 31.25 kHz, at an isotropic 
resolution of 500um3.  Images were reconstructed and iron content was determined using the COSMOS 
QSM (18) and calibrated against a phantom with known iron content.  Samples were additionally treated 
with Prussian Blue for qualitative colorimetric staining.  Representative regions of Feridex incubated cell 
cultures were photographed at 40X on an optical microscope.  
 
2.2.2 Ex Vivo Observation of SPIO Uptake Using MRI 
C57BL/6 mice were divided into 4 groups of 2 mice each.  Each group of mice were administered with 
LPS at the sub-lethal doses, as determined by previous IP injection (0, 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg) 
and injected with Feridex IV intravenously at 10 mg/kg 24 hours later.  Three hours after Feridex 
injection, mice were sacrificed.  Livers were harvested, fixed in paraformaldehyde, and stored for MRI 
analysis.  The livers were scanned using a 3T Signa GE scanner (General Electric, Milwaukee, WI) with a 
homemade birdcage coil and using an EFGRE 3D sequence, 4 TEs 3.0/3.8/5.4/10.2ms, TR 30ms, Flip 
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Angle 30°, bandwidth 31.25 kHz, at an isotropic resolution of 500um3.  Images were reconstructed and 
iron content was determined using the COSMOS methodology, as described in Liu, et al. (18)  Samples 
were additionally treated with Prussian Blue for qualitative colorimetric staining.  Representative 
regions of Feridex incubated cell cultures were photographed at 40X on an optical microscope. 
 
2.3 RESULTS AND DISCUSSION 
2.3.1 In Vitro Observation of SPIO Uptake Using MRI 
The work conducted is offered an in vitro proof of concept for the non-invasive quantitative 
measurement of SPIO uptake using QSM MRI. RAW264.7 murine monocytes were treated with 
lipopolysaccharide (LPS) to induce a sepsis-like cell condition.  Macrophages recognize LPS through their 
TLR4, resulting in an increase in phagocytosis.  The LPS-induced murine monocytes were subsequently 
incubated with the FDA-approved contrast agent Feridex IV, and were imaged using the MRI-QSM 
(Quantitative Susceptibility Mapping) COSMOS (Calculation of Susceptibility through Multiple 
Orientation Sampling) technique for the quantification of iron (18).  The total detected iron was 
obtained for each sample after 0, 3, 6, 9, 18 and 24 hours of Feridex incubation over a total of four 
independent trials; the results were scaled by the number of cells counted in each sample, and averaged 
over all trials (Figure 2.1A).  An estimation of the error of the mean was calculated with a confidence 
level of 95%.  Representative images of the intensity field, the relative difference in the intensity field, 
scaled against a reference scan and the COSMOS-QSM reconstruction are shown for select samples 
(Figure 2.1B).  Results of colorimetric staining (not shown), indicate blue-stain across all cell samples 
treated with Feridex, with color intensity roughly proportional to measurements obtained using 
COSMOS-QSM. 
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Results from COSMOS reconstruction indicate a statistically significant difference (CI = 95%) in 
the average amount of Feridex uptaken per cell after 18 and 24 hours of incubation with Feridex; LPS-
activated cells uptook, on average, 4.75 times more Feridex than non-LPS-activated control cells after an 
18 hour period, and 4.81 times more after the full 24 hour period. Non-LPS-activated cells demonstrated 
a roughly linear rate of Feridex uptake throughout the 24 hour trial (R2 = 0.977), while LPS-activated 
cells exhibited a roughly linear rate of uptake in two distinct regimes, separated at a point shortly after 9 
hours (R2 = 0.933 for first regime, R2 = 0.999 for the second regime).   These results agree with previous 
literature concerning LPS-activated RAW264.7 cells, where it was observed that the presence of LPS, at a 
concentration of 100ng/mL, maximally activate the macrophages after a comparable delay, accelerating 
the production of NO products and increasing phagocytic activity of similarly sized SPIO nanoparticles, 
when compared to that of their inactivated counterparts. (30-32)  These results are qualitatively 
supported by the colorimetric staining.  LPS-treated cell colonies show a greater concentration of 
internalized iron when compared to untreated cells, reflecting the greater degree of iron internalization 
as a result of the sepsis-like condition. 
These observations demonstrate that differences in the phagocytic activity of two macrophage 
populations under differing conditions can be readily quantified using MR techniques.  Moreover, it 
demonstrates that this rate of uptake can be differentiated on a statistically significant level using MRI-
QSM technique.  As phagocytic SPIO uptake by macrophages can be stimulated by the presence of pro--
inflammatory agents, such as LPS, this strongly suggests that this technique can be expanded to the in 
vivo measurement of macrophage activity, whereby the administration of an SPIO nanoparticle, such as 
Feridex, can be used as a marker to directly measure macrophage activity.  Tracking the biodistribution 
of these contrast agents using MRI-QSM may provide an indicator of overall immune system function as 
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a non-invasive tool to identify and diagnose systemic immune responses, such as those that occur under 
sepsis. 
 
2.3.2 Ex Vivo Observation of SPIO Uptake Using MRI  
With the demonstration of observable differences between LPS-treated RAW264.7 cells and untreated 
control cells, we have progressed to a LPS-based in vivo mouse sepsis model to determine if the same 
differential in Feridex uptake could be observed in an animal model and to judge the effectiveness of 
iron-quantification in providing an indicator for sepsis.  Iron aggregation in each liver was determined 
using COSMOS-QSM and normalized by liver mass (Figure 2.2A).  An estimation of the error of the mean 
was calculated with a confidence level of 95%.  Representative images of the intensity field, the relative 
difference in the intensity field, scaled against a reference scan, and the COSMOS-QSM reconstruction 
are shown for select samples (Figure 2.2B).  Histograms of susceptibility concentration per voxel, 
normalized by the number of overall voxels, were generated for LPS-treated mouse livers and those 
from negative controls; voxels in the 99th or greater percentile of susceptibility concentration were 
averaged for each treatment regimen (Figure 2.2C). 
Independent of analysis methodology, MRI-QSM reconstructions under all treatment regimens 
indicate a very high amount of Feridex uptaken for all samples far above the background, indicating that 
the effects of the Feridex injection can be readily observed and quantified using COSMOS. 
A statistically significant difference does not exist in total measured Feridex uptake between 
livers of mice treated with differing concentrations of LPS.  After normalizing each measurement by the 
overall mass of each liver, the difference in averages between each group differed by as much as 20%, 
but failed to be differentiated beyond a 95% confidence interval.  However, livers of LPS treated mice 
had a wider per-voxel susceptibility concentration distribution compared to that of negative controls.  
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Moreover, when comparing the 99th percentile of liver voxels ordered by increasing susceptibility 
concentration, LPS treated mice were found to have significantly higher concentrations, averaging an 
increase of 33% in LPS treated mice compared to negative controls.  This indicates that while LPS 
treatment does not significantly alter the total amount of Feridex uptake, LPS treatment has an 
observable effect on uptake behavior, leading to quantifiably greater localized concentrations of Feridex 
compared to negative controls.   
While differentiation can be drawn between observable Feridex uptake behavior between LPS 
treated mice and negative controls, the lack of measurably significant differences in total Feridex uptake 
by the liver makes this technique less attractive as a tool for clinical sepsis diagnosis.  Ordering voxels by 
increasing susceptibility concentration is highly dependent on the creation of accurate region of interest 
segmentations of the liver for each subject, as voxels of the liver containing low concentration of 
susceptibility could dramatically affect the calculation of the highest 99th percentile.  While this 
segmentation is a relatively simple task ex vivo, with organs removed and mounted in a uniform agarose 
environment, delineations between tissue are significantly more vague in vivo and could dramatically 
affect the accuracy of analysis.  Ideally, differentiation between treatment regimens should be based on 
total measured contrast agent uptake, a statistic that is more dependent on voxels of high susceptibility 
concentration rather than on correctly identifying voxels of low susceptibility and of ambiguous tissue 
type.  While Feridex is a contrast agent with no biospecificity conferred by surface ligands or chemistry, 
an SPIO nanoparticle could conceivably be constructed to increase contrast agent delivery and retention 
based on sepsis-specific mechanisms as a means of increasing contrast between treatment regimens.  
An exploration of development of potential targeting moieties, including the use of Tissue Factor (TF), 
anti-p53 T-cell receptors (TCRs), and anti-ICAM-1 integrins, and their use in conjunction with SPIO 
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nanoparticle-based contrast agents in the context of sepsis and acute inflammation detection is 
described in Chapters 3-5. 
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Figure 2.1. Comparison of Feridex uptake by RAW264.7 cells in vitro. A) Mass of Feridex uptaken by LPS-
treated RAW264.7 cells (100ng/mL) and control cells, measured using COSMOS, normalized by number 
of cells.  LPS-treated cells show a significantly increased amount of Feridex uptaken per cell. B) 
Traditional T2* weighted magnitude images, field maps, and QSM reconstructions of LPS-treated 
RAW264.7 cells incubated with Feridex, and control cells.  The presence of iron is noted by hypointensity 
in T2* weighted magnitude images, observable localized distortions in the magnetic field, and both 
presence and  quantity of iron are illustrated by positive values in QSM. 
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Figure 2.2. Comparison of Feridex uptake in mouse livers in vivo. A) Amount of iron detected by 
COSMOS, normalized for the mass of each liver.  Each group was injected with differing concentrations 
of LPS (LPS 5mg/kg, LPS 2.5mg/kg, LPS 1.25 mg/kg, and No LPS) and injected with 10mg/kg of Feridex 
after 24 hours of LPS incubation.  No statistical difference can be found between each treatment 
regimen.  B) Traditional T2*-weighted magnitude images, field maps, and QSM reconstructions of livers 
from mice treated with LPS and Feridex and imaged ex vivo.  The presence of iron is noted by 
hypointensity in T2* magnitude images, observable localized distortions in the magnetic field, and both 
presence and quantity of iron are illustrated by positive values in QSM.  C) Histogram of susceptibility 
concentration per voxel of LPS-treated mouse livers and negative controls, normalized by the number of 
overall voxels.  LPS treated mice had a wider concentration distribution than that of negative controls.  
B) 99th percentile of the susceptibility concentration values show a statistically significant difference 
between LPS and control samples (p > 0.95).  
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CHAPTER 3 – DEVELOPMENT OF IMPROVED TARGETING MOEITIES 
 
Includes material previously published in: Wong RL, Liu B, Zhu X, You L, Kong L, Han KP, et al. Interleukin-
15:Interleukin-15 receptor alpha scaffold for creation of multivalent targeted immune molecules. 
Protein Eng Des Sel. 2011;24(4):373-83. (33) 
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3.1 INTRODUCTION 
Previous studies have shown that novel dimeric targeting proteins can be created for the purposes of 
either augmenting effective affinity through formation of homodimers or broadening the spectrum of 
recognition through formation of multiple specific heterodimers.  A variety of protein interaction 
domains have been employed to generate such molecules.  Initially, leucine zipper domains were used 
as association partners for dimerization of fusion proteins.  In this approach, hydrophobic interaction of 
leucine zipper domains is mediated by regularly spaced leucines in parallel α-helices, while the 
dimerization partner is determined primarily by charged residues immediately outside of the 
hydrophobic core, that form salt bridges (34).  This interaction is exemplified by the Fos and Jun family 
of proteins, which preferentially form heterodimers without significantly affecting the binding activity of 
fused recognition domain.  This approach provides a versatile scaffold to create multimeric complexes 
(35).  However, there are limitations to this approach for development of therapeutic proteins.  Most 
prominently, Fos and Jun are intracellular proteins that accumulate almost exclusively within the 
nucleus.  Thus, soluble and secreted Fos and Jun fusions are usually produced using baculovirus or insect 
cell expression systems (36, 37), a relatively low yielding and not easily scalable manufacturing process.  
In an attempt to create functional bispecific molecules, antibody (Ab) domains linked to Fos-Jun were 
produced in bacterial or mammalian cells, but subunit homodimerization was observed,(38, 39) which 
complicated the purification process and reduced the overall yield.  
In addition to leucine zipper motifs, helix-turn-helix self dimerizing peptides, tri- and tetrameric 
subdomains of collagen and p53 have been used as scaffolds by which to create multivalent molecules 
(40-43).  These interaction domains primarily serve as molecular scaffolds and lack other functional 
activities per se.  Moreover, fusion proteins containing these domains often require further optimization 
to promote stable multimer formation and specialized production cell lines and purification methods 
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that are tedious or impose regulatory hurdles for therapeutic development.  Many of these scaffolds are 
derivatives of either nonhuman protein domains or non-native components of plasma that may exhibit 
poor pharmacokinetic properties and pose the risk of immunogenic responses that could limit their 
therapeutic potential.   
IgG domains, particularly the Fc fragment, have been used successfully as dimeric scaffolds for a 
number of therapeutic molecules including approved biologic drugs.  For example, dimerization of the 
soluble human tumor necrosis factor-α (TNF-α) receptor linked to the human IgG1 Fc domain results in 
up to 1,000 times more potent TNF-α antagonist activity than the monomeric receptor and provides the 
fusion with a five-fold longer serum half-life than the monomeric form (44).  In addition to its 
dimerization activity, the Fc fragment also provides cytotoxic effector functions through the 
complement activation and interaction with Fcγ receptors displayed on natural killer (NK) cells, 
neutrophils, phagocytes and dendritic cells (45).  In the context of anti-cancer therapeutic Abs and other 
Ab domain-Fc fusion proteins, these activities likely play an important role in efficacy observed in animal 
tumor models and in cancer patients (46).  Thus, IgG domains have been used as a scaffold to form 
bispecific Abs to improve the quality and quantity of products generated by the traditional hybridoma 
fusion technology (47, 48).  Although these methods bypass the shortcomings of leucine zipper and the 
synthetic scaffolds, there continue to be difficulties in producing bispecific Abs in mammalian cells at 
levels sufficient to support clinical development and use.  Additionally, the Fc-mediated effector 
functions of such fusions may not be adequate or appropriate in a number of therapeutic applications.  
There has been considerable interest in improving and expanding on the effector activity of the Fc 
domain and developing other means of recruiting cytolytic immune responses, including T cell activity, 
to the disease site via targeted therapeutic molecules (46, 49).     
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In an effort to develop a new, human-derived immunostimulatory multimeric scaffold, we 
focused on the use of human IL-15 (hIL-15) and IL-15 receptor domains.  Human IL-15 is a member of 
the small four α-helix bundle family of cytokines that associates with the hIL-15 receptor α-chain (hIL-
15Rα) with a high binding affinity (Equilibrium dissociation constant (KD) ~10-11 M) (50).  The resulting 
complex is then trans-presented to the human IL-2/15 receptor β/common γ chain (hIL-15RβγC) 
complexes displayed on the surface of T cells and NK cells.  This cytokine/receptor interaction results in 
expansion and activation of effector T cells and NK cells, which play an important role in eradicating 
virally infected and malignant cells (51).  Normally, hIL-15 and hIL-15Rα are co-produced in dendritic 
cells to form complexes intracellularly that are subsequently secreted and displayed as heterodimeric 
molecules on cell surfaces (52).  Thus, the characteristics of hIL-15 and hIL-15Rα interactions suggest 
that these inter-chain binding domains could serve as a novel, human-derived immunostimulatory 
scaffold to make soluble dimeric molecules capable of target-specific binding.  We have previously 
reported use of fusion proteins comprising soluble T cell receptor (TCR) proteins as disease antigen-
specific recognition domains (53, 54).  In this report, we extend these studies to describe the generation 
and characterization of a number of fusion proteins comprising TCR and CD8 binding domains as 
building blocks to demonstrate the feasibility of using hIL-15:hIL-15Rα scaffold to create both soluble 
bivalent dimers with increased functional binding affinity toward target antigens and heterodimers for 
multiple-site-specific protein complexes.  We also show that these fusion proteins retain potent hIL-15 
activity capable of stimulating immune effector cell responses. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Cell Culture 
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The HLA-A*0201-restricted, p53 (amino acids (aa) 149-157) peptide specific cytotoxic T lymphocytes 
(CTLs) were obtained from Dr. L. Sherman (The Scripps Research Institute, La Jolla, CA) (55).  The H-2Kb-
restricted, ovalbumin (OVA) (aa257-264) peptide specific CTLs, derived from OT1 transgenic mice, were 
kindly provided by Dr. L. Lefrancois (University of Connecticut, Farmington, CT).  The 293GP cell line was 
provided by Dr. R. Morgan (National Cancer Institute, Bethesda, MD).  Chinese hamster ovary (CHO), 
CTLs, T2, EL4, and 293GP cells were cultured in complete Iscove's modified Dulbecco's medium (IMDM) 
(IMDM plus 10% fetal bovine serum (HyClone, Logan, UT).  32Dβ cells (56) were cultured in IMDM 
complete medium plus 10 ng/ml rhIL-15 (kindly provided by Dr. J. Yovandich, NCI-Frederick, MD). 
 
3.2.2 Materials 
The p53 (aa149-157: STPPPGTRV), p53 (aa264-272: LLGRNSFEV), OVA (aa257-264: SIINFEKL), vesicular 
stomatitis virus (VSV)  (nucleoprotein aa52-59: RGYVYQGL) peptides were purchased from Peptide 2.0 
Inc. (Chantilly, VA).  Bacterial expression vectors for producing human β2 microglobulin (β2m) and 
soluble HLA-A*0201 molecules were provided by Dr. J. Altman (Emory University, Atlanta, GA).  All 
oligonucleotide primers were purchased from Sigma Aldrich Corp. (Woodlands, TX).  The anti-human 
TCR Cβ (BF1) 8A3.31 and W4F.5B monoclonal Abs (mAbs) and anti-mouse TCR H57-597 mAb were 
purified via protein A sepharose from the supernatants of hybridoma cells purchased from ATCC 
(Manassas, VA).  Assay reagents include anti-mouse CD8α and β mAbs (Biolegend, San Diego, CA), anti-
human IL-15 mAb (R&D Systems, Minneapolis, MN), streptavidin-horse radish peroxidase (SA-HRP) and 
streptavidin-phycoerythrin (SA-PE) (Jackson ImmunoResearch, West Grove, PA).  The pNEF38 and 
pDEF38 vectors used in this study were described previously (57).  The pMSGV-1 vector (58) with the 
puromycin resistant gene (56) was further modified by introducing the CMV promoter to enhance gene 
expression. 
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3.2.3 Methods 
3.2.3.1 Construction of scTCR fusion expression vectors  
Generation of a soluble single-chain (sc) three-domain TCR construct, c264scTCR, has been described 
previously (59).  This protein recognizes the human p53 peptide (aa264-272) presented in the context of 
HLA-A*0201.  Fusions between the c264scTCR domain and human IL-15 (hIL-15), hIL-15 N72D and D8N 
muteins or the sushi domain of human IL-15Rα (aa 1-66 of hIL-15Rα) (hIL-15RαSu) linked via a mutated 
human IgG1 hinge region were generated as described previously (56).  The hIL-15RαSu gene construct 
was further modified by the addition of sequence encoding a flexible linker and birA tag 
(GGLNDIFEAQKIEWHE) at the 3’ end of the construct by PCR.  The details of the linker sequences 
between the protein domains of the fusion proteins are provided in Supplemental Table 3-S. 
Similar scTCR fusion constructs were generated from TCR α and β chain genes cloned from 
either H-2Kb-restricted, OVA (aa257-264) peptide-specific or HLA-A*0201-restricted, p53 (aa149-157) 
peptide-specific CTLs using SMART RACE cDNA Amplification Kit (Clonetech, Mountain View, CA).  The 
resulting constructs encode an OVA peptide-specific scTCR, referred to as OT1scTCR, comprising murine 
TCR Vα linked to murine TCR Vβ–Cβ domains via a flexible peptide linker or a p53 (aa149-157) peptide-
specific scTCR, referred to as c149scTCR, comprising a murine TCR Vα–linker– murine TCR Vβ–human 
TCR Cβ fusion.  These scTCR genes were linked to the hIL-15 mutein and hIL-15RαSu/birA genes in a 
similar approach used for the c264scTCR fusions except the c149scTCR/hIL-15N72D construct did not 
contain the human IgG1 hinge region, which could be deleted without affecting IL-15 activity.  The 
OT1scTCR gene was also fused to the birA tag sequence for generation of the OT1scTCR/birA fusion.  To 
construct an OT1 TCRα/β heterodimer, the OT1 TCR Vα-Cα and Vβ-Cβ coding regions were linked to the 
hIL-15 and hIL-15RαSu/birA genes, respectively, to create the OT1TCRα/hIL-15 and OT1TCRβ/hIL-
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15RαSu/birA genes.  The 264TCRα/hIL-15D8N and 264TCRβ/hIL-15RαSu/birA genes were constructed 
using a similar approach.  For the scCD8 fusions, the murine CD8α and CD8β genes were amplified using 
the SuperScript One-Step RT-PCR method (Invitrogen, Carlsbad, CA) from total RNA extracted from T 
cells obtained from C57BL/6 mice.  A flexible linker sequence was inserted between the CD8α and CD8β 
chain genes and the scCD8 construct was fused to the hIL-15RαSu/birA gene.  The resulting 
c264scTCR/hIL-15RαSu/birA, OT1scTCR/hIL-15RαSu/birA, OT1scTCR/hIL-15D8N, OT1TCRβ/hIL-
15RαSu/birA and OT1scTCR/birA fusion genes were expressed in the neoR-based pNEF38 vector whereas 
the OT1TCRα/hIL-15 fusion was expressed in the DHFR-based pDEF38 vector.  The c149scTCR/hIL-
15N72D, 264TCRα/hIL-15D8N, 264TCRβ/hIL-15RαSu/birA and scCD8/hIL-15RαSu/birA fusion genes were 
expressed in the modified pMSGV retroviral vector. 
  
3.2.3.2 Fusion protein production and purification  
Expression vectors containing the various fusion constructs were introduced into CHO cells by either 
transfection (pNEF38 and pDEF38 vectors) or transduction (pMSGV retroviral vectors).  The retroviral 
particles carrying the pMSGV fusion constructs were generated by transfecting 293GP packaging cells as 
previously described (60).  The scTCR fusion proteins were purified from recombinant CHO cell culture 
supernatants by immunoaffinity chromatography, using the anti-human TCR Cβ mAb (BF1) 8A3.31 for 
c264scTCR fusion proteins and the anti-mouse TCR Cβ mAb H57-597 for OT1scTCR fusion proteins as 
described previously (59, 61).  The purified fusion proteins with birA tag were biotinylated with biotin 
ligase (Avidity, Denver, CO) in the presence of excess biotin, according to the manufacturer’s 
instructions.  The biotinylated fusion proteins were multimerized with SA-HRP and SA-PE for ELISA and 
flow cytometry, respectively.   
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The purified fusion proteins were analyzed by reducing SDS poly acrylamide gel electrophoresis 
(SDS-PAGE) (12% Bis Tris gel) followed by staining with SimplyBlue Safe Stain (Invitrogen).  Formation of 
hIL-15:hIL-15RαSu dimers was characterized by size-exclusion chromatography (SEC).  The purified 
protein samples (200 μl) were applied to Superdex 200HR 10/30 column (GE Healthcare, Piscataway, NJ) 
at concentration of 0.33 mg/ml in PBS.  The samples were eluted at a flow rate 0.7 ml/min.   
 
3.2.3.3 Preparation of peptide/MHC class I (pMHCI) tetramers 
The murine H-2Kb gene was cloned from total RNA extracted from C57BL/6 mouse lymphocytes as 
described above.  The extracellular region was ligated into the HLA-A*0201 heavy chain expression 
vector replacing the HLA-A*0201 coding sequence (62).  The β2m, HLA-A*0201 and H-2Kb expression 
vectors were individually transformed into E. coli and expression of the recombinant proteins were 
induced as described (62), and were expressed as insoluble inclusion bodies.  The active and soluble 
proteins in complex with the peptides were obtained by the re-folding method described at 
http://www.microbiology.emory.edu/altman/jdaWebSite_v3/ptetPrepOverview.shtml.  The p53 (aa264-
272) and (aa149-157) peptide/HLA-A*0201 reagents are referred to as A2/p53.264-272 and A2/p53.149-
157, respectively, and the OVA (aa257-264) peptide/H-2Kb is referred to as Kb/OVA.257-264. 
 
3.2.3.4 ELISA 
Immunoplates were coated with (BF1) 8A3.31 mAb for capturing c264scTCR fusion proteins or with H57-
597 mAb for capturing OT1scTCR fusion proteins.  After washing, the proteins were detected using 
various probes as detailed in the Results section.  ABTS (2,2'-azinobis [3-ethylbenzothiazoline-6-sulfonic 
acid]- diammonium salt) substrate was then added and absorbance was measured at 405 nm using a 96-
well plate reader.   
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3.2.3.5 Flow Cytometry 
For characterization of the c264scTCR fusion protein complexes, T2 cells were pulsed with p53 (aa264-
272) peptide at 37ºC for 2 h in the presence of peptide loading enhancer (PLE, Altor BioScience Corp., 
Miramar, FL).  For the OT1scTCR fusion protein complexes, murine lymphoma EL4 cells were pulsed with 
OVA peptide at 100 μg/ml and PLE at 37ºC for 6 h.  The various birA fusion proteins (complexed with SA-
PE) were added and incubated at 4ºC for 1 h.  The samples were washed two times and analyzed on a 
FACScan flow cytometer using CellQuest software (BD Biosciences, San Jose, CA).  To assess IL-15 
domain binding activity, 32Dβ cells were incubated with 320 nM of the c264scTCR fusion protein 
complexes for 30 min at 4°C.  The binding of the proteins was in turn detected with biotinylated (BF1) 
8A3.31 mAb for 15 min and SA-PE (5 μg/ml each) for 15 min.  The stained cells were analyzed by flow 
cytometry as described above.   
 
3.2.3.6 Cell proliferation assays 
Cell proliferation was measured as previously described (56).  Briefly, 32Dβ cells (1 x 104 cells/well) were 
incubated with increasing concentrations of scTCR/hIL-15 or scTCR/hIL-15 muteins in the presence or 
absence of an equal molar concentration of scTCR/hIL-15RαSu for 48 h at 37°C.  Cell proliferation 
reagent WST-1 (Roche Applied Science, Indianapolis, IN) was added during the last 4 h of cell growth 
according to the manufacturer’s procedures.  Conversion of WST-1 to the colored formazan dye by 
metabolically active cells was determined through absorbance measurements at 440 nm.  The EC50 was 
determined with the dose-response curve generated from the experimental data by nonlinear 
regression variable slope curve-fitting with Prizm4 software (GraphPad Software, La Jolla, CA). 
 
 
 
39 
 
 
3.2.3.7 Surface plasmon resonance 
The affinity constants of the OT1scTCR fusion proteins to their cognate pMHCI were determined using 
surface plasmon resonance (SPR) methodology on a BIAcore 2000 instrument (GE Healthcare).  
Biotinylated pMHCI complexes were immobilized onto the streptavidin-coated surface of a SA5 sensor 
chip (GE Healthcare) by injecting protein at 2 µg/ml in HBS buffer (10 mM HEPES, 150 mM NaCl, 3.4 mM 
EDTA, 0.005% P20 surfactant, pH 7.4) at a flow rate of 10 µl/min.  This resulted in 1000-1200 RU of 
immobilized pMHCI complexes.  The purified OT1scTCR fusion proteins were diluted to 1 µM, 0.5 µM 
and 0.25 µM in HBS.  Each concentration was injected once (50 µl) at a flow rate of 10 µl/min over a 
freshly immobilized pMHCI surface as well as over a control streptavidin surface blocked with biotin 
(baseline) and the binding curves were registered.  The dissociation constant (KD) and association (kon) 
and dissociation (koff) rates were calculated from the corrected binding curves (baseline subtracted) 
using the BIAevaluation 4.1.1 software (GE Healthcare). 
 
3.3 RESULTS 
3.3.1 Creation of Biologically Active Bivalent Dimers Using the hIL-15:hIL15Rα Scaffold 
We have previously shown that a biologically active, bifunctional fusion protein, designated as 
c264scTCR/hIL-15, could be created by fusing the N-terminus of hIL-15 to a single-chain TCR (c264scTCR) 
(56) (Figure 3.1A).  In this construct, c264scTCR was used as a functional recognition domain based on its 
specific binding activity to the p53 (aa264-272) peptide/HLA-A*0201 complex.  We constructed a similar 
fusion protein with c264scTCR and the sushi-binding domain (aa 1-66) of human IL-15Rα (hIL-15RαSu), 
which has been shown to contain the structural elements responsible for hIL-15 binding (63).  This 
fusion protein was genetically linked at the C-terminus to a birA peptide tag to allow for biotinylation 
and subsequent multimerization in the presence of streptavidin (64).  This fusion protein is designated 
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c264scTCR/hIL-15RαSu/birA (Figure 3.1B) and its expression and purification from CHO cells were similar 
to that of c264scTCR/hIL-15.  These hIL-15RαSu/birA and hIL-15 fusion proteins (and others described 
below) could be readily produced and purified from cell-culture supernatants at the 2 to 8 mg/liter level 
without much efforts of cell line screening for high producers or process optimization.  Additionally, 
analysis by reducing SDS-PAGE indicated that the purified preparations predominantly consisted of a 
protein band that migrates at a molecular weight 10 to 15 kDa greater than that calculated from the 
protein sequence, presumably due to glycosylation expected for these mammalian cell produced 
proteins (Figure 3.1C).  Based on the high specific binding activity between the hIL-15 and hIL-15RαSu 
domains, we anticipated that the fusion proteins could form a heterodimeric complex.  In addition, 
examination of the crystal structure of the human IL-15:IL-15Rα complex indicated that the N-termini of 
the two proteins are at opposite ends of the complex approximately 50 Å apart (65) (Figure 3.1A).  
Hence, fusion of the scTCR domains to these regions is not expected to block complex formation.  Initial 
evidence of binding between the c264scTCR/hIL-15 and c264scTCR/hIL-15RαSu/birA fusion proteins was 
observed in ELISAs using the plate-bound c264scTCR/hIL-15RαSu/birA to capture hIL-15 and 
c264scTCR/hIL-15 proteins (56).   
To further characterize the dimeric c264scTCR fusion protein complexes (referred to as 
c264scTCR dimer), equal molar amounts of purified c264scTCR/hIL-15 and c264scTCR/hIL-15RαSu/birA 
fusion proteins were mixed and allowed to associate at room temperature for more than 10 min.  The 
complexes and the individual protein fusions were evaluated by size exclusion chromatography.  As 
shown in Figure 3.1D, the mixture of the two fusion proteins resulted in a major peak with a molecular 
weight corresponding to dimeric form of the major species found in the individual fusion protein 
preparations.  Thus, the appearance of the larger molecular weight species in the c264scTCR dimer 
preparations is evidence that the heterodimeric complex has been generated.  The c264scTCR dimer 
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was compared with monomeric c264scTCR/birA protein for their ability to bind the TCR-specific antigen, 
p53 (aa264-272)/HLA-A*0201.  In each case, the proteins were biotinylated with biotin ligase followed 
by complexing with SA-PE to generate multimeric flow cytometry staining reagents as previously 
described (64).  When used to stain HLA-A*0201-positive T2 cells pulsed with varying concentrations of 
p53 (aa264-272) peptide, both reagents exhibited antigen-specific binding that increased in a peptide-
concentration dependent manner (Figure 3.2A).  However, the staining reagents comprising the 
c264scTCR dimer stained up to three times better than the monomer-derived c264scTCR/birA 
counterparts (Figure 3.2B).  These data suggest that dimerization through IL-15:IL-15Rα interaction 
preserves the functional activity of the scTCRs and increases the effective affinity of scTCR fusion 
complex to its cognate HLA/peptide through increased avidity.  Similar results were observed when 
biotinylation via the birA tag was directed to the C-terminus of the scTCR/hIL-15 of the complex (data 
not shown).  This demonstrates that the C termini of both the IL-15 and IL-15Rα domains are accessible 
to conjugation to molecular probes of significant size (MW of streptavidin is approximately 60 kDa) 
without interfering with either the dimerization or antigen binding domains of the fusion protein 
complex. 
These studies were extended to examine the possibility of generating bispecific molecules.  A 
second scTCR (c149scTCR) was created which recognizes an HLA-A*0201 restricted epitope of the 
human p53 protein spanning the amino acid residues of 149 to 157 (55).  The sequence encoding this 
scTCR fused to hIL-15 domain, designated as c149scTCR/hIL-15, was co-expressed in CHO cells with the 
c264scTCR/hIL-15αSu/birA fusion (Figure 3.1B).  The fusion complex generated in the supernatant of the 
recombinant CHO cell culture was immobilized using an anti-IL-15 Ab and probed either by HRP-labeled 
p53 (aa264-272) or p53 (aa149-157) peptide/HLA-A*0201 tetramers.  As shown in Figure 3.2C, the anti-
IL-15 Ab captured fusion protein complex was able to bind both of the peptide-loaded HLA tetramers.  
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The result demonstrates that the individual scTCR molecules retain functional activity when fused to the 
hIL-15:hIL-15RαSu scaffold and the spatial arrangement of hIL-15:hIL-15RαSu complex does not 
significantly interfere with the packing of the scTCR domains, which have individual molecular weights of 
approximately 40 kDa.   
To demonstrate the broad utility of the hIL-15:hIL-15RαSu scaffold for protein dimerization, we 
created a second dimeric scTCR fusion complex by pairing two single-chain OT1 TCRs, one fused to the 
N-terminus of hIL-15 and another to the N-terminus of hIL-15RαSu/birA protein (Figure 3.1B).  OT1 is a 
well-characterized TCR recognizing an epitope of OVA protein spanning the amino acid residues 257 to 
264 in the context of murine H-2Kb (66).  OT1 single-chain TCR (OT1scTCR) gene was generated and 
fused to either the hIL-15 or hIL-15RαSu/birA domain for recombinant CHO cell expression (Figure 3.1C, 
lanes 5 and 6).  The purified OT1scTCR fusion proteins were then mixed to form the OT1scTCR dimer 
protein complex.  The individual fusions and protein complex were found to have pMHCI binding activity 
in ELISA using anti-mouse TCR Cβ H57 Ab as a capture reagent and HRP-labeled, OVA (aa257-264) 
peptide-loaded H-2Kb tetramer as a probe (Supplemental Figure 3.1-S).  To distinguish the difference in 
binding activity between the OT1scTCR dimer and OT1scTCR/birA monomer, we conducted flow 
cytometry analysis similar to those described above for the c264scTCR dimers but with H-2Kb-positive 
EL4 cells loaded with OVA (aa257-264) peptide.  As shown in Figure 3.3, SA-PE tetramers comprising the 
OT1scTCR dimer indeed stained significantly better than those comprising monomeric OT1scTCR/birA 
fusions.  We also performed surface plasmon resonance assays to assess the binding affinity of the 
OT1scTCR monomer and dimer against the biotinylated OVA (aa257-264) peptide-loaded H2-Kb/birA 
complexes immobilized on a streptavidin sensor chip.  The apparent binding affinity (KD) of the 
OT1scTCR dimer to OVA peptide/H-2Kb complexes was estimated to be about 30 μM, whereas no 
binding was observed for the monomeric OT1scTCR/birA fusion protein (Table 3.1).  These data confirm 
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that dimerization through hIL-15:hIL-15Rα interaction preserves the biological activity of the scTCRs and 
increases the effective affinity of the scTCR molecule to its cognate pMHCI complexes through increased 
avidity.  
 
3.3.2 Creation of a Biologically Active Heterodimer 
Since the CD8 molecule has been previously demonstrated to play a pivotal role in the interaction 
between OT1 TCR and its cognate OVA peptide/H2-Kb complex (67), the hIL-15:hIL-15RαSu scaffold 
provides an opportunity to assess whether CD8 molecule enhances OT1 TCR binding affinity to OVA 
peptide/H-2Kb expressed on the cell surface and under cell-free and adhesion molecule-free conditions.  
To achieve this, we first created a murine CD8 molecule in single-chain format (scCD8) by fusing the 
extracellular domains of the α and β chains of the murine CD8 using a flexible linker.  This fusion gene 
was fused to the hIL-15RαSu/birA construct in a retroviral expression vector.  Recombinant retrovirus 
was then used to infect a CHO cell line expressing the OT1scTCR/hIL-15 fusion protein in order to create 
an scTCR/scCD8 heterodimeric complex (Figure 3.1B).  The fusion protein complex was purified from the 
supernatant of the cultured recombinant CHO cells using the anti-TCR Ab-based affinity chromatography 
as described above.  SDS-PAGE analysis of the purified protein complex revealed protein bands of the 
appropriate molecular weight for the OT1scTCR/hIL-15D8N (calculated MW 56 kDa) and scCD8/hIL-
15RαSu/birA fusions (calculated MW 48 kDa) (Figure 3.1C, lane 7).  The protein complex was subjected 
to ELISA using anti-TCR Ab as the capture reagent and either the biotinylated anti-mCD8α or anti-mCD8β 
mAbs as probes.  As shown in Figure 3.4A, the anti-TCR Ab-immobilized fusion complex contains both 
the CD8α and CD8β and, thus, indicates formation of an OT1scTCR/scCD8 heterodimer.  We used flow 
cytometry analysis to compare the binding activity of the OT1scTCR/scCD8 heterodimer with the 
OT1scTCR dimer to varying amounts of OVA peptide/H-2Kb complexes displayed on the cell surface.  As 
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shown in Figure 3.4B, SA-PE staining reagents comprising the OT1scTCR/scCD8 heterodimer could 
readily detect OVA peptide/H-2Kb complexes on EL4 cells loaded with as little as 10 ng/ml OVA peptide, 
whereas little or no staining was observed at this peptide concentration when comparable reagents 
comprising the OT1scTCR dimer were used.  Higher background OT1scTCR/scCD8 heterodimer staining 
was observed on EL4 cells that were not pulsed with peptide, suggesting peptide-independent 
interactions were occurring between the CD8 domain and MHC molecules on the cell surface.  Similar 
effects have been reported for pMHCI tetramers binding to CD8 molecules expressed on T cells (68).   
The results for peptide-specific interactions of the OT1scTCR/scCD8 heterodimer were further 
confirmed by surface plasmon resonance analysis.  The binding affinity (KD) of the OT1scTCR/scCD8 
heterodimer to OVA peptide/H-2Kb complexes was estimated to be 2.6 μM, which is significantly higher 
than the ~30 μM observed for the OT1scTCR dimer (Table 3.1, Supplemental Figure 3.2-S).  Neither 
fusion protein showed any binding to control VSV peptide/H-2Kb complexes.  The difference in specific 
pMHCI binding activity is surprising given that the bivalent nature of the OT1scTCR dimer is expected to 
provide increased functional affinity in this assay format.  Additionally, similar SPR binding studies 
conducted with soluble TCR, CD8 α/β and pMHCI proteins as independent components showed only 
weak interactions (KD 30-100 μM) between CD8 protein and peptide/H-2Kb complexes and no apparent 
cooperative effects of CD8 on TCR:peptide/H-2Kb interactions (69, 70).  Taken together, these data 
indicate that the addition of the CD8 α/β domain to the OT1scTCR fusion has a greater impact on pMHCI 
binding than creation of the bivalent OT1scTCR molecule.   
 
3.3.3 Creation of Functional Two-Chain Heterodimers  
As indicated above, the N-termini of the hIL-15 and hIL-15Rα domains are at distal ends of the complex 
raising questions as to whether this scaffold is suitable for fusions to polypeptides of a multi-chain 
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protein.  To determine whether a soluble, biologically active, heterodimeric TCR α/β could be 
constructed using the hIL-15 and hIL-15RαSu scaffold, the C-terminal ends of the extracellular OT1 TCR 
Vα-Cα and Vβ-Cβ domains were linked to the N-termini of hIL-15 and hIL-15RαSu/birA chains, 
respectively.  Based on the published α/β TCR crystal structures, the TCR Cα and Cβ C-terminal amino 
acids of the properly folded OT1 TCR α/β molecule are expected to be ~18 Å apart (71).  The OT1 
TCRα/hIL-15 and OT1 TCRβ/hIL-15RαSu/birA fusion genes were cloned into two separate expression 
vectors and co-transfected into CHO cells to generate a heterodimeric TCR α/β complex (Figure 3.1B).  
The secreted fusion protein complex was purified using anti-TCR Cβ mAb affinity chromatography as 
described above.  When analyzed by SDS-PAGE under reducing condition, the purified protein bands 
migrated at 50-60 kDa, consistent with the calculated monomeric MW (40 kDa) of each of the two 
fusion molecules (Figure 3.1C. lane 8).  The purified protein was further characterized in the functional 
ELISA (anti-TCR Cβ mAb capture: OVA peptide/H2-Kb tetramer probe).  As shown in Figure 3.5A, the 
purified protein was found to have equivalent pMHCI binding activity as OT1 TCR in the single-chain 
format.  Similar results were observed for hIL-15:hIL-15RαSu/birA fusions to the Vα-Cα and Vβ-Cβ chains 
of the p53-specific 264 TCR (Figure 3.5B).  Previous attempts to produce soluble α/β TCR heterodimers 
in mammalian cells have been largely unsuccessful (72, 73).  Thus, our results suggest that the TCR α and 
β chains were appropriately folded through the association of the hIL-15 and hIL-15RαSu/birA domains 
within the transfected cells.  Intriguingly, the fusion to N-termini of the hIL-15:hIL-15RαSu scaffold is 
able to provide the spatial arrangement sufficient for functionally independent binding domains as 
observed with the c264scTCR/c149scTCR heterodimeric complex while retaining flexibility to permit 
folding of closely paired chains such as the α and β chains of OT1 TCR and 264 TCR. 
 
3.3.4 Biological Activity of the hIL-15 Domain for the hIL-15:hIL-15RαSu Fusion Complexes 
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The IL-15 receptor (IL-15RβγC) binding capability of the hIL-15:hIL-15Rα domain of the c264scTCR dimer 
was evaluated by flow cytometry analysis using 32Dβ cells which carry the hIL-15Rβ and the murine γC 
(mγC) chains.  These studies were carried out using c264scTCR dimers containing the wild-type hIL-15 
domain, as well as dimers with hIL-15 mutein domains previously shown to enhance (N72D) or reduce 
(D8N) binding to the hIL-15Rβ chain without affecting formation of the hIL-15:hIL-15RαSu complex (56).  
Following incubation with the c264scTCR dimers, the 32Dβ cells were stained with anti-TCR mAb to 
detect cell-bound fusion protein dimers.  As shown in Figure 3.6A, the 32Dβ cells were stained positively 
by the c264scTCR dimers containing hIL-15 wild-type or hIL-15N72D domains but not with those 
containing the hIL-15D8N domain, indicating that the IL-15:hIL-15RαSu portion of the complex retains 
the expected IL-15RβγC binding activity.   
The hIL-15 biological activity of the fusion protein dimers were also examined in cell 
proliferation assays using 32Dβ cells.  As shown in Figure 3.6B, the hIL-15 wild-type domain in the 
scTCR/hIL-15 fusion or scTCR/hIL-15:scTCR/hIL-15RαSu fusion complex was able to support the growth 
of 32Dβ cells in a concentration-dependent manner, exhibiting half-maximal stimulation (EC50) at ~300 
pM.  The hIL-15N72D or D8N domains either increased or eliminated the biological activity of the fusion 
proteins, respectively, regardless whether they were present in the monomeric or dimeric fusions.  
These results are consistent with the functional activity observed for non-fusion IL-15 cytokine carrying 
the N72D or D8N mutations (56).  Thus, formation of the fusion protein complex containing two 
independent TCR domains does not significantly change the biological activity of the IL-15 domain.  In 
contrast, there was at least a 3 fold loss of IL-15 activity for the OT1 TCRα/β heterodimer complex (data 
not shown), suggesting formation of the heterodimeric TCR structure inhibits, to some extent, the ability 
of the hIL-15 domain to interact with hIL-15RβmγC.  Additionally, these results indicate that the hIL-15 
domain can be readily manipulated to allow enhanced or reduced receptor binding and functional 
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activity, thus providing additional flexibility for the use of the hIL-15:hIL-15RαSu scaffold in different 
applications. 
 
3.4 DISCUSSION 
In these studies, we demonstrate the potential uses of a hIL-15:hIL-15RαSu-based scaffold to create 
novel, dimeric targeting molecules.  The dimeric fusion protein complexes retained immunostimulatory 
effects and binding activity of their hIL-15 domains and target-specific recognition domains, 
respectively.  These results indicate that the addition of hIL-15 and hIL-15Rα did not significantly alter 
the spatial arrangement of the fusion domains and provided an adequate degree of conformational 
flexibility without eliminating cytokine activity.  Thus, this scaffold could be used to form multivalent 
fusion complexes, such as the c264scTCR dimer, to increase the overall binding affinity of molecules, or 
bispecific molecules, such as the c264scTCR/c149scTCR heterodimer.  In all cases, the soluble fusion 
proteins were produced at relatively high levels in recombinant CHO cell culture (up to 8 mgs per liter 
purified from cell culture supernatant without extensive cell line screening or process optimization) and 
could be readily purified from the cell culture supernatants.  We also demonstrated that the utility of 
the hIL-15:hIL-15RαSu-based scaffold could be expanded to create soluble, biologically active, two-chain 
molecules, such as α/β TCR heterodimers, by fusing the extracellular domains of the two polypeptide 
chains to the N-termini of hIL-15 and hIL-15RαSu.  This format resulted in a moderate decrease in hIL-15 
activity, possibly due to steric hindrance between the interfolded TCR α/β chains (fused at distal ends of 
the hIL-15:hIL-15RαSu complex) and the hIL-15RβγC binding site located in the middle of the complex.  
We are currently assessing the activity of additional heterodimeric complexes and different linker 
formats to further optimize the biological activity of these fusions. 
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We have previously shown in xenograft tumor models that tumor antigen specific scTCR-IgG 
dimers exhibit potent antitumor activity via IgG effector activity (53).  The results presented here 
indicate that the hIL-15:hIL-15RαSu scaffold could be exploited much like the IgG scaffold to generate 
multivalent or multispecific targeted therapeutics.  With its potent activity for stimulating proliferation 
and activation of effector NK and CD8+ memory T cells, the hIL-15 domain expands the scope of 
immunotherapeutic mechanisms beyond antibody-dependent cellular cytotoxicity and complement 
activation associated with IgG-based approaches.  Based on its immunostimulatory activity, IL-15 has 
been recently viewed as the most promising anti-cancer candidate among twelve immunotherapy drugs 
(74).  Moreover, disease-targeting approaches, such as those using Ab or TCR recognition domains, 
could further enhance IL-15’s therapeutic potential while limiting systemic toxicities.  Indeed, it has been 
shown that a fusion protein composed of IL-15 linked to an anti-fibronectin single-chain Ab exhibits 
targeted, CD8 T cell-mediated antitumor activity against both subcutaneous and metastatic tumors in 
immunocompetent murine models (75). 
Employing approaches similar to those previously used to manipulate the IgG Fc domain activity, 
we have also found that the IL-15 domain can be mutated to increase or decrease its functional activity.  
We have shown that hIL-15:hIL-15RαSu fusion molecule containing an N72D mutation in the IL-15 
domain exhibit a 3-4 fold increase in biological activity, whereas IL-15 D8N mutation exhibit little or no 
activity (56).  While IL-15 superagonist-based fusion proteins could serve as targeted 
immunotherapeutics for cancer and infectious diseases, an IL-15 antagonist capable of inhibiting IL-15 
responsive cells at the disease site may have therapeutic potential in treating allograft rejection and 
inflammatory autoimmune diseases, particularly if memory CD8 T cells play a role in disease pathology 
(51).  A non-targeted IL-15 mutant/Fcγ2a antagonist protein has already been shown to be effective at 
inhibiting islet and cardiac allograft rejection and preventing development and progression of arthritis in 
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experimental animal models (76, 77).  We are investigating similar approaches with IL-15 antagonist 
domains in the context of the hIL-15:hIL-15RαSu fusion proteins.  In addition, under certain 
circumstances, it may desirable to have a functionally inert scaffold for generation of multimeric 
molecules.  For example, we have found that scTCR/hIL-15:scTCR/hIL-15RαSu fusions containing an IL-15 
D8N mutation, which eliminates interactions with IL-15Rβγ, provide better TCR antigen-specific staining 
of cells displaying IL-15 receptor complex. 
Additionally, we demonstrate that the hIL-15:hIL-15RαSu scaffold could be used to create 
heterodimer comprising CD8 α/β and TCR domains capable of binding the same pMHCI complex but at a 
spatially distinct sites.  Previous studies using soluble pMHCI reagents have determined that CD8 
stabilizes and enhances TCR:pMHCI interactions at the cell surface through effects on both the off-rate 
and the on-rate (70, 78, 79).  However, several binding studies using soluble purified CD8 α/β, TCR and 
pMHCI proteins have shown that TCR:pMHCI interactions are not affected by the presence or absence of 
CD8, suggesting no cooperative binding effects (70, 80).  The results of our cell-based and SPR binding 
studies with the OT1scTCR/scCD8 heterodimer are in contrast with these earlier reports in showing that 
TCR and CD8 domains displayed on the same soluble molecule exhibited much better peptide/MHC 
binding activity than was observed with molecules carrying monovalent or divalent TCR domains.  This 
effect is reflected in a faster on-rate of the pMHCI:OT1scTCR/scCD8 heterodimer complex, consistent 
with the observations for pMHCI binding to CD8 and TCR molecules on T cells (79).  Thus, the 
OT1scTCR/scCD8 heterodimer mimics binding of the OT1 TCR on T cells, which exhibits a strong 
dependence of CD8 coreceptor activity for pMHC interactions.  These results indicate that the 
scTCR/scCD8 heterodimer and variants of this molecule could serve as very useful tools for further 
dissecting molecular interactions between the tertiary TCR:pMHCI:CD8 complex in a cell-free system.   
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The results of our SPR experiments on the OT1scTCR fusions differ from those reported by Alam 
et al. where the binding affinity of monovalent OT1 TCRα/β heterodimer to immobilized OVA peptide/H-
2Kb complex was shown to be approximately 6 μM (81).  In our studies, we were unable to detect OVA 
peptide/H-2Kb-binding of the OT1scTCR/birA monomer and the OT1scTCR dimer exhibited an apparent 
KD of 30 μM.  It is possible that the OT1 TCR exhibited decreased binding activity when formatted as a 
single-chain Vα-linker-Vβ-Cβ molecule.  However, we observed equivalent activity when comparing 
OT1scTCR/birA and a two-chain construct.  Moreover, previous studies have shown that OVA peptide/H-
2Kb tetramers with Kb mutations that abrogate CD8 binding exhibit little or no specific binding activity to 
OT1 TCR-bearing cells whereas tetramers without these mutations brightly stain OT1 TCR cells.  These 
results are consistent with the very low binding affinity between OT1 TCR and its cognate pMHCI and 
the CD8 dependence effects on these interactions observed in our studies.   
Although we have focused on TCRs and CD8 molecules as target recognition domains for 
demonstration purposes in this study, it is conceivable that the hIL-15:hIL-15RαSu scaffold could be used 
to construct other novel binding molecules with protein domains derived from Abs, adhesion molecules, 
or other receptors.  It may also be possible to create protein domain fusions to the C-termini of the hIL-
15 and hIL-15RαSu which, based on the crystal structure, are accessible for modification.  The resulting 
molecules could contain up to four different target-recognition capabilities.  With the appropriate fusion 
partners, these types of molecules could promote the conjugation of immune effectors cells and target 
cells and achieve effective killing of target cells.  As noted above, the IL-15 domain of the complex could 
further augment these processes by providing immunostimulatory activity to support effector cell 
proliferation and cytotoxicity.  Currently, we have constructed a variety of multi-functional molecules 
based on this concept and are in the process of characterizing them as anti-cancer and anti-viral 
immunotherapeutic agents. 
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Previously, the poor expression level in standard mammalian cell system limited the 
development of recombinant hIL-15 as a therapeutic (82).  In this study, we found that expression of 
scTCR/hIL-15:scTCR/hIL-15RαSu complexes is at levels capable of supporting clinical development and 
potentially product commercialization.  In addition, it has been shown that the IL-15Rα chain enhances 
the in vivo activity of hIL-15, possibly by improving the pharmacokinetics of the cytokine (83-86).  These 
two characteristics of hIL-15:hIL-15RαSu complexes, in combination with its multivalent nature and/or 
multispecific targeting design, may provide an opportunity to capture the full potential of hIL-15 as an 
immunotherapeutic agent against cancer and viral infections.  
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Figure 3.1.  Schematic diagrams and characterization of dimer constructs. A)  Schematic diagram of the 
c264scTCR/hIL-15:c264scTCR/hIL-15RαSu/birA complex (c264scTCR dimer).  The model of the dimeric 
hIL-15:hIL-15RαSu domains is based on the published crystal structure of the human IL-15:IL-15Rα 
complex (65) (PDB 2Z3Q).  B)  Schematic diagram of the hIL-15:hIL-15Rα fusion protein constructs 
described in this study: S, signal peptide; L, peptide linker; B, linker-birA tag sequence.  Linker sequences 
between the protein domains of the fusion proteins are provided in Supplemental Table 3-S.  C)  SDS-
PAGE analysis of purified hIL-15 and hIL-15Rα fusion proteins under reducing conditions.  Lanes: 1) 
c264scTCR/hIL-15, 2) c264scTCR/hIL-15N72D, 3) c264scTCR/hIL-15D8N, 4) c264scTCR/hIL-15RαSu/birA, 
5) OT1scTCR/hIL-15D8N, 6) OT1scTCR/hIL-15RαSu/birA, 7) OT1scTCR/hIL-15D8N:scCD8αβ/hIL-
15RαSu/birA complex, 8) OT1 TCRα/hIL-15:OT1TCRβ/hIL-15RαSu/birA complex, and 9) OT1scTCR/birA.  
D)  SEC analysis of c264scTCR fusion proteins.  Panels show comparative analysis of c264scTCR/hIL-15 
(top), c264scTCR/hIL-5RαSu/birA (middle) and c264scTCR/hIL-15:c264scTCR/hIL-15RαSu/birA complex 
(c264scTCR dimer) (bottom) with dashed lines indicating relative protein peaks.  
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Figure 3.2.  Characterization of c264scTCR dimer and c264scTCR/c149scTCR heterodimer binding 
activity.  A)  T2 cells were pulsed with 0-62.5 nM of p53 (aa264-272) peptide as described in the Material 
and methods.  The cells were stained with equivalent amounts (80 nM) of PE-conjugated multimers of 
the c264scTCR dimer or c264scTCR/birA.  B) The relative increase in cell staining comparing c264scTCR 
dimer with c264scTCR/birA reagents was determined at different peptide concentrations.  Fold increase 
= (Geo mean of T2 cells stained by c264scTCR dimer) / (Geo Mean of T2 cells stained by 
c264scTCR/birA).  C)  The p53 peptide/HLA-A*0201 binding activity of c264scTCR/c149scTCR 
heterodimer was determined by ELISA.  Anti-hIL-15 mAb was used as a capturing reagent.  A2/p53.264-
272.HRP (open triangles) or A2/p53.149-157.HRP (closed squares) tetramers were used as the probes.  
The data represent the means ± SD of triplicate determinations.  The results are representative of at 
least two independent assays. 
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Figure 3.3.  Characterization of OT1scTCR dimer binding activity.  EL4 cells were loaded with OVA 
(aa257-264) peptide and stained with OT1scTCR/birA-SA-PE (left) and OT1scTCR dimer-SA-PE (right) at 
200 nM. 
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Figure 3.4.  OTscTCR/scCD8 heterodimer exhibits enhanced pMHCI binding activity.  A)  Murine CD8 
expression of OT1scTCR/scCD8 heterodimer was determined by ELISA.  Anti-mTCR H57-597 mAb was 
used as a capturing reagent.  The biotinylated anti-murine CD8α (closed squares) or CD8β (open 
triangles) mAb was used as a probe followed by SA-HRP.  The data represent the means ± SD of triplicate 
determinations.  The results are representative of at least two independent assays.  B)  EL4 cells were 
loaded with OVA (aa257-264) peptide at the indicated concentration and stained with OT1scTCR dimer-
SA-PE (left) and OT1scTCR/scCD8 heterodimer-SA-PE (right) at 200 nM. 
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Figure 3.5.  Fusion proteins containing TCR α/β heterodimers retain pMHCI binding activity.  A)  Binding 
activity of OT1scTCR/birA (closed squares) and OT1 TCRα/β heterodimer (open triangles) to OVA (aa257-
264)/H-2Kb complex was determined by ELISA.  Anti-mTCR H57-597 mAb was used as a capturing 
reagent.  Kb/OVA.257-264.HRP tetramer was used as a probe.  B)  Binding activity of 264scTCR/birA 
(closed squares) and 264 TCRα/β heterodimer (open triangles) to p53 (aa264-272)/HLA-A*0201 complex 
was determined by ELISA.  Anti-TCR mAb was used as a capturing reagent.  A2/p53.264-272.HRP 
tetramer was used as a probe.  The data represent the means ± SD of triplicate determinations.  The 
results are representative of at least two independent assays. 
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Figure 3.6.  IL-15 binding and functional activity of fusion proteins.  A) 32Dβ cells were incubated with 
320 nM of the c264scTCR dimers comprising IL-15 wild type or IL-15N72D or IL-15D8N mutein domains.  
The binding of the fusion proteins was in turn detected with anti-human TCR Cβ Ab.  B)  The ability of 
the c264scTCR dimers comprising IL-15 wild type or mutein domains to support proliferation of 32Dβ 
cells was determined as described in the Material and methods.  The data represent the means ± range 
of duplicate determinations.   
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Supplemental Figure 3.1.  OVA (aa257-264)/H-2Kb binding activity of OT1scTCR/hIL-15D8N, 
OT1scTCR/hIL-15RαSu/birA and OT1scTCR dimer determined by ELISA.  Anti-mTCR H57-597 mAb was 
used as capturing antibody.  Kb/OVA.257-264.HRP tetramer was used as a probe.    The data represent 
the means ± SD of triplicate determinations. 
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Supplemental Figure 3.2.  OT1scTCR fusion protein binding curves determined by SPR. 
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Table 3.1.  OT1scTCR fusion protein binding kinetic and affinity values determined by SPR. 
Analyte Immobilized Ligand kon (M
-1s-1) koff (s
-1) KD (μM) 
OT1scTCR/birA (monomer) OVA-(257-264)/H-2Kb No binding 
OT1scTCR dimer OVA-(257-264)/H-2Kb 8.9 x 102 0.029 32 
OT1scTCR dimer VSV/H-2Kb No binding 
OT1scTCR/scCD8 heterodimer OVA-(257-264)/H-2Kb 1.0 x 104 0.027 2.6 
OT1scTCR/scCD8 heterodimer VSV/H-2Kb No binding 
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Supplemental Table 3.1.  Protein domain linker sequences. 
Linker Linker Sequences Fusion Protein 
Single-chain 
TCR linker 
TCR Vα - DTSGGGGSGGGGSGGGGSGGGGSSS - TCR Vβ 
c264scTCR/hIL-15N72D 
c264scTCR/hIL-15RαSu/birA 
TCR Vα- TSGGGGSGGGGSPGGGGSGGGGSSS  - TCR Vβ c149scTCR/hIL15N72D 
TCR Vα- DTSGGGGSGGGASGGGGSGGGGSSS  - TCR Vβ OT1scTCR/birA 
TCR Vα- SGGGGSGGGASGGGGSGGGGS  - TCR Vβ 
OT1scTCR/hIL-15D8N 
OT1scTCR/hIL-15RαSu/birA 
Mutated 
human IgG1 
hinge 
TCR domain - VNEPKSSDKTHTSPPSPTR - hIL-15RαSu 
c264scTCR/hIL-15RαSu/birA 
OT1scTCR/hIL-15RαSu/birA 
OT1TCRβ/hIL-15RαSu/birA 
264TCRβ/hIL-15RαSu/birA 
TCR domain - VNEPKSSDKTHTSPPSPTR - hIL-15 
264TCRα/hIL-15D8N 
OT1TCRα/hIL-15 
OT1scTCR/hIL-15D8N 
BirA linker hIL-15RαSu - SGGGSGGGGSID - birA tag 
c264scTCR/hIL-15RαSu/birA 
OT1TCRβ/hIL-15RαSu/birA 
scCD8αβ/hIL-15RαSu/birA 
Single-chain 
CD8 linker 
CD8α - SGGGGSGGGGSGGGGSGGGGS - CD8β scCD8 αβ /hIL-15RαSu/birA 
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CHAPTER 4 – TARGETED NANOPARTICLES FOR CANCER DIAGNOSTICS 
 
Includes material previously presented in: Wong R, Wang Y. International Society of Magnetic Resonance 
in Medicine 2010 – Stockholm, SE -  Creation of a Multimeric Anti-P53 ScTCR-SPIO Conjugate for the 
Detection of Cancer in MR, Poster Presentation  
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4.1 INTRODUCTION 
The concept of targeted contrast agents can be readily adapted for use in other applications, such as for 
the specific and selective detection of cancer using MRI.  Common implementations of this targeted 
approach have used targeting proteins specific to biomarkers overexpressed on the surface of certain 
cancer cells, including the antibody trastuzumab for the detection of ErbB2 expressing breast cancers 
(87) (88) (89), the antibody rituximab for the detection of CD20 expressing lymphomas(90) (91), and 
Anti-Epideral Growth Factor Receptors (EGFR) for the detection of high-grade astrocytic gliomas (92) 
(93).  These targeting proteins are then conjugated to common contrast agents, such as 
superparamagnetic iron oxide (SPIOs) nanoparticles or Gd-based constructions for use as MR contrast 
agents.   
A key aspect in creating such a molecule is selecting an ideal biomarker target for detection.  As 
with targeting proteins such as trastuzumab, rituximab, and EGFRs, most commonly used ligands are 
specific only to a very limited subset of cancers. In many circumstances where generalized detection is 
more desirable, a biomarker such as tumor suppressor protein p53 would be ideal.  p53 is an 
intracellular tumor suppressor protein acts to arrest abnormal cells in the G1/S phase of the cell cycle.  
When p53 is mutated, it loses its function as a tumor suppressor, thus allowing abnormal cells to 
continue to proliferate.  The p53 protein is one of the most important factors that protects humans from 
developing cancer and is also one of the most frequently mutated genes in most major forms of human 
cancers (94, 95).  Moreover, for any given cancer type, p53 dysfunction generally correlates with poor 
treatment and poor prognosis.  For instance, overexpression of p53 in breast cancer cells has been 
correlated with aggressiveness of the tumor such that individuals bearing p53-overexpressing tumors 
have shorter disease-free time and lower overall survival rates (96, 97).  In some tumors, p53 
mutation/overexpression also is associated with resistance to chemotherapeutic intervention (98).  
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Recently, it has been shown that p53 also modulates the balance between the utilization of respiratory 
and glycolytic pathways in cells and that the inactivation of p53 in cancer cells leads to preferential use 
of glycolysis for energy generation (99).  This metabolic change is one of the alterations in cancer cells 
believed to provide these cells with a survival advantage.  Mutated p53 has been shown to have a longer 
half-life than the wild type protein, and this longer half-life allows for accumulation and thus, 
overexpression.  However, p53 cannot be used as a target for antibody-based approaches because it is 
not displayed independently on the cell surface.  Instead the p53 gene product is processed and certain 
peptide epitopes are displayed on the cell surface in the context of HLA molecules, which are recognized 
by the T-Cell Receptors TCRs) of T-cells.  As a result, we are investigating the use of soluble TCRs rather 
than antibodies in targeting p53 for this application. 
Previously, we isolated a T-cell receptor from a p53 (aa 264-272)-specific high avidity CTL clone 
derived from HLA-A*0201 transgenic mice (sc264TCR).  The epitope is within a region that is rarely 
mutated, making it a broad-based target for HLA-A*0201+ tumors.  From this TCR, a three-domain 
single-chain format of the TCR (scTCR) was constructed and designated c264scTCR.  This molecule can 
be produced by mammalian cell fermentation and purified by immunoaffinity chromatography as a 
soluble, single-chain, biologically-active protein which retains the ability to specifically recognize the p53 
antigen (aa 264-272)/HLA-A*0201 complex (53, 61, 64).  We further increased the affinity of c264scTCR 
by producing a dimeric variant of c264scTCR based on a novel IL-15/IL-15Rα scaffold to create soluble 
homodimers with increased functional binding affinity toward target antigens.(33)  IL-15 is a member of 
the small four α-helix bundle family of cytokines that associates with the IL-15 receptor α-chain and is 
then trans-presented to IL-15Rβ γC complexes displayed on the surface of T cells and NK cells.  This 
cytokine/receptor interaction results in expansion and activation of effector T cells and NK cells, which 
play an important role in eradicating virally infected and malignant cells.  Importantly, IL-15 binds to the 
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IL-15Rα chain with exceptional binding affinity (Ka value of ~10-11M-1).  Moreover, IL-15 and IL-15Rα are 
co-produced in dendritic cells to form complexes intracellularly that are subsequently secreted and 
displayed as heterodimeric molecules on cell surfaces.  These two characteristics of IL-15 and IL-15Ra 
interactions suggest that these inter-chain binding domains could serve as a novel, human-derived 
immunostimulatory scaffold to make soluble dimeric molecules capable of target-specific binding.   This 
increase of affinity through an increase in avidity is similarly attractive in the construction of MR 
contrast agents, whereby contrast agents with high affinity to tumorous cells could translate to greatly 
improved imaging sensitivity and vastly improved clinical diagnostic accuracy. 
In this study, we created a high affinity dimeric c264scTCR-coated super paramagnetic iron 
oxide (SPIO) conjugate capable of specific contrast agent delivery to p53-expressing cells.  By selectively 
delivering SPIO nanoparticles to p53-expressing cells and probing their presence using quantitative MRI 
quantitative susceptibility mapping (QSM) techniques, were able to measure specific scTCR-SPIO 
conjugate adhesion in in vitro conditions to various cancer cell lines known to express cell-surface p53 in 
the context of HLA.  The results of this study suggest future applicability for p53-specific SPIO 
nanoparticles for use as targeted generalized cancer contrast agents. 
 
4.2 METHODS AND MATERIALS 
4.2.1 Creating Multimeric scTCRs 
Generation of a soluble monomeric single-chain (sc) three-domain TCR construct, c264scTCR, has been 
described previously.(59)  This protein recognizes the human p53 peptide (aa264-272) presented in the 
context of HLA-A*0201.  Fusions between the c26t4scTCR domain and human IL-15 (hIL15) or the sushi 
domain of human IL-15Ra (aa1-66 of hIL-15Ra; hIL-15RaSU) linked via a mutated human IgG1 hinge 
region were generated as described previously.(56)   Dimeric c264scTCR fusion protein complexes 
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(referred to as c264scTCR dimer) were constructed by mixing equal moral amounts of purified 
c264scTCR/hIL-15 and c264scTCR/hIL-15Rasu/birA fusion proteins and were allowed to associate at 
room temperature for 1 hour.  Proteins were biotinylated with biotin ligase followed by complexing with 
streptavidin-phycoerythrin (SA-PE) to generate multimeric flow cytometry staining reagents, or with 
streptavidin-coated super paramagnetic iron oxide (SA-SPIO) nanoparticles (50nm diameter, Ocean 
Nanotech) to generate multimeric contrast agents suitable for use in MRI. 
 
4.2.2 scTCR Specificity Assay (Flow Cytometry) 
scTCR specificity against p53-expressing cells was characterized using flow cytometry.  Subconfluent 
A37545N human melanoma tumor cells (ATCC, Manassas, VA), and T2 human lymphoblast cells (ATCC, 
Manassas, VA) pulsed with 50µM p53 (aa264-272) peptide at 37°C for 2 h in the presence of peptide 
loading enhancer (PLE, Altor BioScience Corp., Miramar, FL), were stained with 80nM monomeric or 
dimeric scTCRs or with non-specific Mart1TCR labeled with Phycoerythrin, and incubated at 4°C for 1 h.  
The samples were washed two times with 0.5% BSA-PBS and analyzed on a FACScan flow cytometer 
using CellQuest software (BD Biosciences, San Jose, CA).    Staining curves were obtained at FL-2, 575nm. 
 
4.2.3 scTCR-Conjugate Formation and Validation 
scTCR-SPIO conjugates were constructed through interaction between streptavidin-coated SPIO 
nanoparticles and biotinylated monomeric or dimeric scTCRs.  20ug of 0.3 µM iron oxide nanoparticles, 
50 nm in diameter with a streptavidin surface (Ocean Nanotech, Fayetteville, AR), were incubated with 3 
uM biotinylated monomeric 264scTCR or dimeric 264scTCR at a 1:20 nanoparticle:TCR molar ratio at 4°C 
for 1 hour.  Conjugates were purified using a MiniMACS magnetic cell separation column (Mitenyi) and 
washed twice with PBS.  Conjugate formation was validated through ELISA.  scTCR-SPIO conjugates were 
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captured using BF1 mAb coated plates, specific to the β1 constant region of the scTCR.  Streptavidin-HRP 
dye was linked using WF1-biotin mAb linker, specific to the β1 constant region of the scTCR, and 
developed with ABTS.  Absorbance was read at 405nm using a 96-well plate reader. 
 
4.2.4 Quantitative MR Imaging 
A37545N cells, T2 cells pulsed with p53 peptide, and unpulsed T2 cells were incubated with 20ug 0.3 µM 
scTCR-SPIO conjugates constructed from monomeric or dimeric c264scTCRs.  After two hours of 
incubation, cells were washed and centrifuged into a pellet in a standard centrifuge tube.  The cell 
apparatus was scanned using a 3T Signa GE scanner (General Electric, Milwaukee, WI) with a custom 
birdcage coil and using a 3D multi-echo gradient echo sequence.  Imaging parameters were as follows: 5 
total TEs; TEs 3.696ms, 4.196ms, 5.696ms, 11.696ms, 35.696ms; TR 40ms; flip angle 30°; matrix size 
256x64x64; 500µm3 isotropic resolution.  A 3D Fourier transform was applied to the raw k-space data to 
reconstruct T2* weighted images.  Qualitative Susceptibility Maps (QSMs) were reconstructed using the 
Calculation of Susceptibility through Multiple Orientation Sampling (COSMOS) technique, as described in 
Liu 2009. (18)  In brief, each sample was scanned at three different orientations by rotating the sample 
about the B0 axis.  Phase information was extracted from the complex MRI data to obtain a background-
corrected field map.  The resulting field map served as the input for a field-to-source susceptibility 
inverse problem. Total susceptibility was calculated for each region of interest (ROI), segmented around 
cell pellet identified using T2* weighted images, and was used to quantitatively determine total SPIO 
nanoparticle presence in each ROI.  Results were calibrated against a standard developed through 
analysis of an image phantom with known amounts of SPIO. 
 
4.3 RESULTS AND DISCUSSION 
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4.3.1 scTCR Specificity Assay 
To confirm the specificity of c264scTCR monomers and dimers against cell surface p53 in the context of 
HLA, c2664scTCR-SAPE conjugates were created and stained against p53-expressing cells and measured 
using flow cytometry.  Staining curves of 80nM c264scTCR/hIL15Su/birA (monomeric c264scTCR)-SAPE, 
80nM c264scTCR/hIL15-c264TCRhIL15-15RaSu/birA (dimeric c264scTCR)-SAPE, and 80nM Mart1scTCR-
SAPE (non-p53-specific isotype control) stained against T2 cells pulsed with 50nM p53 peptide, unpulsed 
T2 cells, and A37545N cells are shown in Figure 4.1A.  Staining profiles for p53-pulsed T2 cells exhibited 
positive fluorescent staining with monomeric c264scTCR-SAPE and was further enhanced with dimeric 
c264scTCR-SAPE, compared to that observed from non-specific Mart1scTCR-SAPE.  Unpulsed T2 controls 
did not demonstrate positive staining with monomeric and dimeric 264scTCR-SAPE over isotype 
controls.  A37545N human melanoma tumor cells, a cell line known to have a low to moderate degree of 
p53 expression, demonstrated moderate staining with monomeric c264scTCR-SAPE conjugates, and is 
further enhanced with dimeric c264scTCR-SAPE.   
These results confirm the specificity and selectivity of c264scTCRs against cells expressing p53.  
In the case of p53-pulsed T2 cells, cells artificially induced to express high levels of p53 on the cell 
surface in the context of HLA, dimeric c264scTCR-based conjugates exhibited a significant degree of 
staining, readily surpassing that of monomeric c264scTCR-based conjugates and non-specific controls.  
While c264scTCR-SAPE stained p53-pulsed T2 cells demonstrated by far the greatest degree of staining, 
c264scTCR-SAPE stained A37545N also exhibited observable amounts of positive staining.  As the 
A37445N cell line is known to have a relatively low degree of surface-expressed p53, these results 
support the viability of using c264scTCR-based conjugates to specifically target tumors cell with 
relatively low, but still physiologically-relevant amounts of p53 surface expression.  Furthermore, the 
increase in observable staining between the use of monomeric and dimeric c264scTCR against p53-
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expressing cells demonstrates that the increased avidity of the dimeric forms contributes to quantifiably 
increased affinity against p53 peptide. 
 
4.3.2 scTCR-Conjugate Formation and Validation 
To validate that dimeric c264scCR-SPIO conjugates were correctly formed and subsequently isolated 
from unbound  scTCRs through magnetic separation, we captured c264scTCR-SPIO conjugates and 
measured its activity through an ELISA-like assay.  Dimeric c264scTCR-SPIO conjugates were created by 
combining c264scTCR/hIL15, c264scTCR/hIL15RaSu/birA, and SA-SPIO at a molar ratio of 1:1:10 and 
passed through a magnetic separation to collect magnetically susceptible SPIO-conjugated scTCRs.  
Collected particles were captured on BF1 antibody-coated plates, linked to biotinylated WF4 antibodies, 
linked to streptavidin-HRP.  The relative concentration of each dimeric c264scTCR-SPIO conjugate was 
plotted against the optical density at 405nM after serial dilution and subsequent HRP development with 
ABTS (Figure 4.1B).  A nonlinear concentration-dependent response was observed at optical density 
405nm only with complete forms of c264scTCR/hIL15-c264TCRhIL15-15RaSu/birA-SPIO.  Incomplete 
forms of the conjugate (SPIO only or c264scTCR/hIL15-c264TCRhIL15-15RaSu/birA only) show a no 
observable response, indicating an effective formation of dimeric c264scTCR-SPIO conjugates.  As BF1 
and WF4 antibodies bind only to each of two distinct regions of the β1-constant region of c264scTCRs, 
and the magnetic filtration process captures magnetic SPIOs while eliminating all unbound scTCRs, only 
scTCR-SPIO conjugates should be detected by this assay.  The concentration-dependent nature of the 
results indicates that the magnetic purification process effectively removes unbound scTCRs from the 
preparation while preserving the scTCR-SPIO conjugates. 
 
4.3.3 Quantitative MR Imaging 
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To demonstrate that monomeric and dimeric c264scTCR-SPIO conjugates can be used as a contrast 
agent for use in selectively delivering contrast for MRI applications, we incubated cell surface p53-
expressing cells with c264scTCR-SPIO conjugates and quantified the amount of observable SPIO 
accumulation using MRI-based quantitative susceptibility mapping (MRI-QSM).  The amount of 
accumulated SPIO in 1 x 107 A37545N cells, p53-pulsed T2 cells, or unpulsed T2 cells,  each incubated 
with 20µg  monomeric or dimeric 0.3 uM scTCR-SPIO conjugates for two hours, was measured using 
MRI-COSMOS (Figure 4.1C).  Representative T2* weighted imagines, relative field maps, and results of 
the MRI-QSM COSMOS reconstruction for select samples are shown (Figure 4.2).  C264scTCR-SPIO 
conjugates incubated with T2 cells pulsed with p53 exhibited the greatest degree of SPIO accumulation, 
up to 5.23 times more when dimeric c264scTCR-SPIOs were used, compared to unpulsed T2 cells 
incubated similarly with dimeric c264scTCR-SPIO.  Moderate amounts of measureable SPIO 
accumulation was seen with conjugates incubated with A37545N, up to 3.27 times more when dimeric 
c264scTCR-SPIOs were used, compared to similarly treated unpulsed T2 cells.  Minimal SPIO 
accumulation was observed with unpulsed T2 cells.  Overall, dimeric c264scTCR-SPIO contributed to the 
greatest degree of SPIO, increasing SPIO accumulation by 21% and 38% over monomeric c264scTCR-
SPIO for p53-pulsed T2 cells and A37545N cells, respectively.  Nonspecific Mart1scTCR-SPIO binding was 
minimal across all cell types.  Qualitatively, T2* weighted images depict negative contrast enhancement 
consistent with the presence of SPIO.  MRI-QSM reconstructions show positive contrast.  Larger, more 
intense voxels can be seen in p53-expressing cells treated with c264scTCR-SPIO conjugates, indicating 
greater and more concentrated SPIO accumulation.  Field maps for each condition exhibit an 
increasingly large “dipole” pattern of magnetic field perturbations with p53-expressing cells treated with 
c264scTCR-SPIO conjugates, likewise consistent with the presence of increasingly greater amounts of 
SPIO accumulation. 
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Overall, the resulting SPIO accumulation is readily observable using both traditional T2* 
weighted imaging techniques and MR-QSM based techniques, allowing for a qualitative and quantitative 
measure of overall contrast agent delivery.  The effectiveness of the dimeric form over the monomeric 
form of c264scTCR-SAPE conjugates for p53-specific staining under flow cytometry, and the 
effectiveness of the dimeric form over the monomeric form of the c264scTCR-SPIO conjugates for MR 
labeling under MRI-QSM, demonstrates that an increase in avidity corresponds to an increase in affinity, 
resulting in a greater degree of staining and a greater degree of contrast agent accumulation among 
p53-expressing cells in both fluorescent and MR applications.  Further, MR imaging demonstrates that 
positive labeling can be observed even against cell lines with relatively low levels of p53 expression, and 
can be readily imaged and quantified using MRI-QSM techniques.   
The results suggest a use for dimeric c264scTCR-SPIO contrast agents for in vivo applications to 
selectively deliver contrast agents to tumor sites to assist in cancer diagnosis.  In addition, when 
combined with MRI-QSM analysis, c264scTCR-SPIO contrast agents can be quickly and non-invasively 
tracked, and accumulation can be quantifiably measured, giving direct observation of spatiotemporal 
information about the biodistribution of contrast agents, a task not easily obtainable with current 
clinical techniques.  Likewise, the ability to quantitatively track contrast agents can be extended to drug 
delivery applications, whereby precise amounts of a specifically delivered agent can be non-invasively 
tracked to better monitor and refine diagnostic and therapeutic agents. 
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Figure 4.1.  Characterization of scTCR binding and scTCR-SPIO conjugate binding in vitro.  A) Flow 
Cytometry – Staining profiles for T2 cells pulsed with p53 peptide (50nM) exhibit positive fluorescent 
staining with 80nM c264scTCR/hIL15Su/birA (monomeric c264scTCR)-SAPE and further enhanced 
staining with 80nM c264scTCR/hIL15-c264TCRhIL15-15RaSu/birA (dimeric c264scTCR)-SAPE, compared 
to isotype control 80nM Mart1scTCR-SAPE.  Unpulsed T2 controls do not demonstrate positive staining 
with monomeric and dimeric 264scTCR-SAPE over isotype controls.  A37545N demonstrates moderate 
staining with monomeric c264scTCR-SAPE, and is moderately enhanced with dimeric c264scTCR-SAPE.  
B) ELISA – scTCR-SPIO conjugates were isolated using magnetic separation and captured by BF1 
antibody-coated plates, linked to biotinylated WF4 antibodies, linked to streptavidin-HRP, and 
developed with ABTS.  Concentration-dependent response was observed at optical density 405nm only 
with complete forms of c264scTCR/hIL15-c264TCRhIL15-15RaSu/birA-SPIO.  Incomplete forms of the 
conjugate (SPIO only or c264scTCR/hIL15-c264TCRhIL15-15RaSu/birA only) show a minimal response, 
indicating effective conjugation of scTCRs and SPIOs.  C) Quantitative MRI – c264scTCR-SPIO conjugates 
incubated with T2 cells pulsed with p53 exhibited the greatest degree of SPIO accumulation, as 
measured by MRI-QSM.  Moderate amounts of measureable SPIO accumulation was seen with 
conjugates incubated with A37545N, and minimal SPIO accumulation was observed with unpulsed T2 
cells.  Overall, dimeric c264scTCR-SPIO contributed to the greatest degree of SPIO, regardless of cell type 
and condition.  Nonspecific Mart1scTCR-SPIO binding was minimal across all cell types.  Error bars 
indicate a 95% confidence interval across three repeated samples. 
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Figure 4.2.  Representative MRI images from varying cell and scTCR-SPIO conditions.  Traditional T2 
weighted images (top) depict negative contrast with increasing SPIO accumulation.  MRI-QSM 
reconstructions (middle) show positive contrast; larger, more intense pixels represent more 
concentrated SPIO accumulation.  Relative field maps (bottom) exhibit an increasingly large “dipole” 
pattern with increasing SPIO accumulation. 
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CHAPTER 5 – TARGETED NANOPARTICLES TO VISUALIZE ACTIVE 
INFLAMMATION: PART 1 
 
Includes material previously published in: Chen X, Wong R, Wang YA, Wang Y, Jin MM. Inflamed 
leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials. 2011 
Oct;32(30):7651-7661. Epub 2011 Jul 23. (100) 
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5.1 INTRODUCTION 
Dysregulated inflammatory responses of the host are implicated in the pathogenesis of many human 
diseases (101). Acute inflammation from infection can cause sepsis (102), while chronic inflammation, 
and continual coexistence between acute and chronic inflammation are associated with various 
neurodegenerative (103) and cardiovascular diseases (104), metabolic disorders (105), and cancer (106, 
107). Accordingly, sensitive and early detection of inflammation and site-specific delivery of anti-
inflammatory agents will have a wide-ranging impact on the treatment of various inflammation-related 
diseases. Upon induction of inflammation, a set of adhesion molecules are upregulated in endothelium, 
with which immune cells interact using counter adhesion molecules such as integrins to adhere to 
endothelium and to initiate diapedesis. Many existing studies have investigated targeted nanoparticles 
for the detection and treatment of inflammation employing antibodies or peptides specific to adhesion 
molecules such as intercellular adhesion molecule (ICAM)-1 (108-110), vascular cell adhesion molecule 
(VCAM)-1 (111-113), selectins (114), and collagen (115), all of which display distinct spatiotemporal 
responses to inflammation. Among these molecules, ICAM-1 has caught a particular interest because of 
its highly inducible and localized expression upon inflammatory signals, serving as a marker for 
inflammation despite its constitutive low level expression (116, 117).  
In this study, we developed nanomicelle encapsulating superparamagnetic iron oxide (SPIO) 
nanoparticles, designed for facile and robust conjugation with targeting moieties and in vivo detection 
by optical imaging and magnetic resonance imaging (MRI). In order to design nanoparticles to mimic the 
behavior of inflamed leukocytes in their ability to locate to the inflamed site, SPIO nanoparticle was 
coated with an optimum number of high affinity inserted (I) domain of integrin called lymphocyte 
function-associated antigen (LFA)-1 (118), a physiological receptor for ICAM-1. Leukocyte-mimetic 
nanoparticles were examined for detection of ICAM-1 overexpression in tumor cells, tumor vascular 
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microenvironment, and acute inflammation in vivo. With our recently developed MRI technique for 
quantitative mapping of contrast agent (18, 119), we explored the possibility of quantitative 
spatiotemporal mapping of iron oxide distribution in vivo using a mouse model of acute inflammation. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Preparation and characterization of protein coated SPIO nanomicelles  
Oleic acid-capped super paramagnetic iron oxide (SPIO) nanocrystals (Ocean Nanotech, LLC) in 5 mg 
were suspended in 1 ml chloroform with 12 mg 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DPPE-PEG) and 3 mg 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-
carboxypentyl)iminodiacetic acid)succinyl] nickel salt (DOGS-NTA) (Avanti Polar Lipids, Inc.). For 
radiolabeled nanoparticles, 60 μCi of L-α-Dipalmitoyl-Phosphatidylcholine, [Choline-Methyl-3H] (Perkin 
Elmer) was also added at this step. After 10 min sonication and overnight desiccation, 1 ml of water was 
added to the residue to form a micelle layer on SPIO. After another 10 min sonication and filtration 
through 0.22 μm filters (Millipore), optically clear suspension containing SPIO micelles were obtained. 
Empty micelles without SPIO in the core were removed by ultracentrifugation. SPIO nanoparticles were 
purified and resuspended in pH 7.4 phosphate-buffered saline (PBS) by size exclusion S200 column (GE 
Healthcare). The wild-type (wt), D137A, and F265S/F292G mutants of LFA-1 I domains fused to His tag (6 
histidine residues) at the N-terminal were produced as previously described (117). Conjugation of SPIO 
with His-tagged I domains was obtained by incubation at 4 °C overnight. Free proteins were removed by 
size exclusion. All fluorescently labeled SPIO nanoparticles were prepared by covalently conjugating 
Alexa Fluor (AF) succinimidyl esters (Invitrogen) to the I domains. Conjugation of fluorescence dyes to 
the proteins rather than to phospholipid was chosen due to significant fluorescence quenching between 
iron oxide and AF-phospholipids. The coating density of proteins on SPIO was determined from the ratio 
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of SPIO amount (OD600nm 1 = 0.42 mg/ml) and the concentration of the proteins bound to SPIO (by 
Lowry's method). Specific activities of radiolabeled SPIO were measured by scintillation counter 
(Beckman Coulter LS6500). Dynamic light scattering (DLS, Malvern Instruments) was used to measure 
the average hydrodynamic size of SPIO after assembly and protein conjugation. Transmission electron 
microscopy (TEM; FEI Tecnai) images of SPIO were also taken before and after protein conjugation. 1% 
uranyl acetate was used for protein staining. 
   
5.2.2 Cell culture  
All mammalian cells used in this study were cultured in Advanced Dulbecco’s modified Eagle’s medium 
containing 10% (v/v) fetal bovine serum and 2 mM L-glutamine (Invitrogen) at 37 °C in a 5% CO2 
humidified incubator. For induction of inflammation, bEnd.3 (ATCC) cells were treated with 1 μg/ml of 
LPS (E. coli. 026:B6, Sigma) for 12 hr. HeLa and 293T cells stably expressing GFP were established using 
pSMPUW-miR-GFP/Puro Lentiviral Expression Vector system (Cell Biolabs). 
 
5.2.3 Immunofluorescence flow cytometry 
Cells were trypsinized and washed once with the ice-chilled labeling buffer (pH 7.4 PBS, 1% (w/v) BSA, 1 
mM MgCl2). 100,000 cells were incubated in 100 μl of the labeling buffer for 30 min on ice with 10 μg/ml 
of Alexa Fluor labeled proteins or SPIO conjugated with the same amount of proteins. For competition 
assay, 50 μg/ml of unlabeled proteins were included in the labeling buffer during incubation. Cells were 
washed twice and resuspended in 300 μl of the labeling buffer and subjected to flow cytometer 
(Beckman Coulter EPICS XL-MC). 
 
5.2.4 Microscopy visualization of cell labeling in vitro  
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For immunofluorescence microscopy detection of protein labeling, cells were plated, washed in pH 7.4 
PBS, and fixed with 4% paraformaldehyde for 15 min. After washing three times, cells were incubated 
with 10 μg/ml of Alexa Fluor labeled proteins in PBS/Triton (pH 7.4 PBS, 0.3% (v/v) Triton X-100, 1 mM 
MgCl2) at room temperature for 1 hr. Cells were rinsed once with pH 7.4 PBS and twice with high salt 
PBS (pH 7.4 PBS, 0.4 M NaCl, 1 mM MgCl2). 300 nM DAPI (4',6-diamidino-2-phenylindole, Invitrogen) in 
PBS was then added and incubated for 10 min for nucleus staining. Stained cells were washed and 
imaged with a confocal microscope (Zeiss LSM 710). For detection of SPIO labeling, HeLa cells were 
plated and incubated with 50 μg/ml of SPIO coated with Alexa fluor 488 conjugated proteins in culture 
media for 2 hr at 37 °C. Cells were washed in pH 7.4 PBS, incubated for 1 hr in serum-free medium for 
chasing, and imaged using confocal microscopy (Leica TCS SP2). After fluorescence imaging, cells were 
then prepared for Perl’s Prussian blue staining for iron detection. Labeled cells were fixed with 4% 
paraformaldehyde, followed by incubation in a freshly prepared solution of 2% potassium ferrocyanide 
in 2% HCl for 20 min and counterstaining with 1% neutral red. 
 
5.2.5 Magnetic cell labeling and quantification 
Trypsinized cells were incubated for 4 hr at 37 °C in the labeling buffer (PBS, 1 mM MgCl2) under 
constant rotating with different concentrations of radiolabeled SPIO, washed and then fixed in 4% 
paraformaldehyde. Cells were divided into two conditions, half of which were used for radioactivity 
measurement using scintillation counter (Beckman Coulter LS6500), while the remaining half for MRI 
scanning and QSM measurement after imbedding in 100 μl 2% agarose block. MR imaging of the 
magnetically labeled cells were performed on a 3T MRI scanner (Signa, GE, Milwaukee, WI). A 3D multi-
echo gradient sequence was used to sample multiple TEs in one TR. Imaging parameters were as 
follows: TEs 3.696 ms, 4.196 ms, 5.696 ms, 11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; matrix size 
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256×64×64; voxel size 500 μm3 isotropic. A 3D Fourier transform was applied to the raw k-space data to 
reconstruct T2* weighted images. QSM was obtained through Multiple Orientation Sampling (COSMOS) 
technique, as previously described (18). 
 
5.2.6 Subcutaneous tumor model  
3×106 human cervical cancer HeLa cells and human embryonic kidney 293T cells stably expressing GFP 
mixed in Matrigel (BD) were injected bilaterally into the front lower flank areas of 8-wk-old female nude 
mice. Mice were used for experiments 16-20 days after injection when tumor size reached about 300 
mm3. All animal experiments were conducted in compliance with the regulations defined by the 
Institutional Laboratory Animal Use and Care Committee of Cornell University.  
 
5.2.7 Acute LPS-inflammation model  
For subcutaneous LPS, 1 mg/ml LPS in 100 μl PBS and 100 μl PBS were injected bilaterally into the lower 
flank areas of 8-wk-old female BALB/c mice. For systemic LPS, 1 mg/ml LPS in 100 μl PBS were injected 
into 8-wk-old female BALB/c mice. Prior to imaging hair was removed to reduce background 
fluorescence.  
 
5.2.8 Near-IR optical imaging of mice 
Animals were anesthetized with isoflurane mixed with oxygen at 5% and maintained at 2% isoflurane 
during whole body imaging (Olympus, OV100). Mice were administered with SPIO coated with AF750-
conjugated proteins in 150 μl PBS via retro-orbital injection. 500 and 100 μg of SPIO were used for 
tumor imaging and acute inflammation models, respectively. Near-IR images were taken at different 
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time points post-injection of SPIO. Tumor growth was detected by imaging green fluorescence. Image 
analysis was performed with Matlab R2007a (MathWorks). 
 
5.2.9 MR imaging of mice with acute inflammation 
For subcutaneous LPS model, prior to nanoparticle injection mice were exposed to LPS/PBS for 12 hr. At 
4 hr after injection of SPIO in 150 μl PBS, mice were euthanized by intraperitoneal injection of 2.5% 
tribromoethanol (20 μl/g), transcardially perfused with PBS, and fixed in paraformaldehyde. Prepared 
mice were scanned on a 7T scanner (Bruker BioSpin, Biospec 70/30 USR) with 3D FLASH sequence. 
Imaging parameters were as follows: TEs (echo time) 5 ms, 6 ms, 30 ms, 35 ms; TR (repetition time) 35 
ms; excitation pulse angle 15°; matrix size 150×150×100; voxel size 200 μm3 isotropic; NEX 1. A 3D 
Fourier transform was applied to the raw k-space data to reconstruct the images (18). For systemic LPS 
model, prior to nanoparticle injection mice were exposed to LPS for 12 hr. At 1, 8, and 25 hr post-
injection of SPIO coated with proteins in 150 μl PBS, mice were euthanized likewise. Prepared mice were 
scanned on a 3T scanner (GE Signa Excite) with 3D multi-echo EFGRE sequence (18). Imaging parameters 
were as follows: TEs 3.696 ms, 4.196 ms, 5.696 ms, 11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; 
matrix size 256×64×64; voxel size 500 μm3 isotropic. QSMs were reconstructed using the COSMOS 
technique, as previously described. 
 
5.2.10 Histology 
Tumor and normal tissues were collected from tumor-bearing mice before or at the end of in vivo 
imaging experiments. 10 μm frozen tissue sections were sliced, fixed in paraformaldehyde, and stained 
with hematoxylin and eosin (H&E) or in Perl’s Prussian blue. Images of the tissue sections were acquired 
by scanscope (Aperio). For immunofluorescence, antibodies used include rat anti-mouse CD31 (BD, 
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MEC13.3) and goat anti-rat IgG labeled with AF350 (Invitrogen). Six different fields of view containing 
CD31 staining for each sample were counted using 25 Chalkley's random point method over an area of 
0.16 mm2 for vascularity analysis (Figure 5.3D). To quantify the level of staining, three different regions 
of interest (ROI) with 0.50 mm2 area were sampled for each condition in immunofluorescence staining 
(Figure 5.3C) and four ROI with 0.04 mm2 area in each Prussian blue staining (Figure 5.4F). Specific colors 
(blue for endothelium and Prussian blue, red for F265S/F292G) were extracted and intensities were 
measured using Image-Pro Plus 6.0 (Media Cybernetics) and ImageJ 1.41 (NIH). 
 
5.2.11 Statistical analysis 
Data were expressed as mean ± standard deviation of no smaller than triplicates, and analyzed for 
statistical significance using GraphPad Prism 5 (Graphpad Software). Linear regression was used to 
examine the correlation between SPIO measurements by radioactivity and QSM (Figure 5.2C). One-way 
ANOVA was used to compare the staining and vascularity levels between different tissues, followed by 
Tukey's post-hoc test to determine statistical significance (Figures 5.3C & D). Two-way ANOVA was used 
to compare the mean responses of different nanoparticles to different time points or to different 
tumors, followed by Bonferroni post-hoc test to determine statistical significance (Figures 5.4D & F, 
Figures 5.5B & Figures 5.6C & D). 
 
5.2.12 QSM video of mice with systemic LPS injection 
The videos corresponding to the data in Figure 5.6B are uploaded, providing sagittal, coronal, and axial 
views of the whole body with the accumulation of LMN or NTN into the liver indicated with the same 
color scheme as in Figure 5.6B. ‘a1.mp4’, ‘a8.mp4’, and ‘a25.mp4’ correspond to the movies of mice at 
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1, 8, 25 hr post-injection of LMN, respectively. ‘i1.mp4’, ‘i8.mp4’, and ‘i25.mp4’ correspond to 1, 8, 25 hr 
post-injection of NTN, respectively. 
 
5.3 RESULTS 
5.3.1 Synthesis and characterization of leukocyte-mimetic nanoparticles 
Selective binding of SPIO nanoparticles to overexpressed ICAM-1 was conferred by surface coating at an 
optimal density (~100 molecular/particle) with the I domain of LFA-1 integrin, engineered for high 
affinity by mutations of F265S/F292G (denoted as F265S/F292G, KD = 6 nM) (118). Among physiological 
ligands for LFA-1 such as ICAMs and junctional adhesion molecule (JAM)-1 (120), ICAM-1 is most 
important in the setting of leukocyte adhesion to inflamed endothelium due to its highest affinity to 
LFA-1 (121), being highly inducible over basal low level expression, and localized expression upon 
inflammatory signals (116, 122). In order to fine-tune coating density of F265S/F292G and present 
targeting moiety in a most functional orientation, oleic acid capped SPIO nanocrystals (Ocean Nanotech) 
were encapsulated with a layer of phospholipid consisting of 80% n-poly(ethylene glycol) 
phosphatidylethanolamine (DPPE-PEG) and 20% dioleoyl-glycero-succinyl-nitrilotriacetic acid (DOGS-
NTA) (Figure 5.1A). DOGS-NTA was used for non-covalent conjugation of targeting moieties with His tag 
in a robust and reproducible manner via high affinity binding to nickel ions chelated by NTA (Ni-NTA) 
(117, 123). DPPE-PEG was included to maintain solubility, stability, and for its low immunogenicity and 
non-specific binding to cells and tissues in vivo (124). Transmission electron microscope (TEM) images 
revealed monodispersed SPIO nanocrystals with an outer layer of micelle-like structure (Figure 5.1B; 
dark ring density corresponds to uniformly distributed nickel ions (the black arrow in top right) and 
diffuse dark density to His-tagged proteins attached to Ni-NTA (the white arrow in bottom right)). 
Hydrodynamic size of SPIO with or without protein conjugation was measured to be 60±10 nm by 
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dynamic light scattering (DLS), an increase from 15 nm diameter SPIO core mainly due to the addition of 
phospholipid and PEG.  
Prior to detecting ICAM-1 with nanoparticles, we first examined by immunofluorescence flow 
cytometry (Figure 5.1C) and fluorescence microscopy (Figure 5.1D) soluble I domain (labeled with Alexa 
Fluor 488 (AF488), Invitrogen) binding to ICAM-1 expressed in monolayer culture of cervical cancer cells 
(HeLa). Specific binding to ICAM-1 was detected with the F265S/F292G, which was inhibited by 
unlabeled F265S/F292G. In contrast, no significant binding was observed with the wt I domain (KD = 1.7 
mM) (121) and the I domain containing a mutation of D137A (117), which disrupts the metal-ion 
dependent adhesion site (MIDAS) and abolishes ICAM-1 binding. The level of nanoparticle binding 
coated with the I domain variants was overall in good agreement with the soluble I domain binding, 
which varied in order from highest to lowest, F265S/F292G, wt, and D137A (Figure 5.1E). Markedly, 
specific binding of SPIO conjugated with F265S/F292G (abbreviated as Leukocyte-Mimetic Nanoparticle 
or ‘LMN’) was not inhibited by competition with soluble I domain, presumably due to multivalent 
interaction between nanoparticles and HeLa cells. Enhanced binding due to avidity effect was also 
observed in the binding of nanoparticle coated with the wt I domain to HeLa, which resulted in greater 
binding than with the free wt I domain. ICAM-1-mediated binding of LMN but not with the nanoparticles 
coated with D137A (abbreviated as Non-Targeted Nanoparticle or ‘NTN’) led to significant cell surface 
labeling and internalization into the cells, evidenced by fluorescence microscopy and Perl’s Prussian blue 
staining (Figure 5.1F). 
 
5.3.2 Quantitative measurement of selective binding of LMN by MRI 
SPIO nanoparticles are being used in clinics as T2* negative contrast agent for MRI. In order to validate 
SPIO as MRI contrast agent as well as to test the accuracy of our MRI technique for quantitative mapping 
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of SPIO (18), 3H-labeled phospholipid was additionally incorporated into the outer phospholipid layer of 
SPIO. When HeLa cells were incubated with LMN for 4 hr at 37°C, an increase in concentration led to an 
increase in cellular uptake of nanoparticles, reaching a plateau at 450 ng/106 cells (Figure 5.2A). LMN 
delivery was specific to ICAM-1 expression, evidenced by little accumulation into HeLa with NTN and 
much lower delivery with LMN into 293T, a cell line with no or little expression of ICAM-1. HeLa cells 
with known amount of internalized LMN by 3H-radioisotope decay were then embedded into agarose 
and scanned with a MRI scanner. As expected, T2* showed a decrease in magnitudes with an increase in 
the amount of SPIO (Figure 5.2B). With quantitative susceptibility mapping (QSM) algorithm was 
observed a close agreement with ~30% standard deviation from direct radioactivity measurements of 
free or intracellular SPIO, highlighting the ability of QSM in detecting as low as 1 μg accumulation into 
100 μl in volume (Figure 5.2C).  
 
5.3.3 Ex vivo detection of ICAM-1 induction in human tumor xenograft and in inflamed stroma  
Not only is ICAM-1 upregulated in several carcinomas compared to respective normal epithelium, 
implicating active involvement of ICAM-1 in cancer development, its induction has also been observed in 
tumor vasculature caused by an inflamed network encompassing tumor and tumor microenvironment 
(125-127). Previously, we have found that human LFA-1 I domain cross-reacted with murine ICAM-1 
(117), which was recapitulated by the staining of ICAM-1 induced in murine brain endothelium (b.End3) 
after lipopolysaccharide (LPS) treatment (Figure 5.3A). When tissue sections of GFP-expressing HeLa 
xenograft were analyzed for ICAM-1 detection by soluble F265S/F292G labeled with AF594 (Invitrogen), 
most of the GFP signal was overlapped with red fluorescence (Figure 5.3B). Notably, we found that the 
majority of endothelial cells (PECAM-1 (CD31) positive) within the tumor were also stained by 
F265S/F292G. In contrast, the level of ICAM-1 induction and colocalization with CD31 staining in the 
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vasculature away from the tumor, such as those in the skin, was far lower, amounting to ~15% 
compared to 70% and 35% of the vasculature within the tumor and its periphery (defined as a region 
within 300 μm distance from the edge of tumor), respectively (Figures 5.3B-D).  
 
5.3.4 In vivo detection of ICAM-1 induction in human tumor xenograft and in inflamed stroma 
After confirming specific detection of ICAM-1 in ex vivo tumor slice by free F265S/F292G, we then 
examined if systemically delivered nanoparticles would accumulate to the tumor and inflamed stroma 
by ICAM-1 targeting. To validate that nanoparticle localization is ICAM-1 specific and not due to an 
increased permeability of the tumor vasculature, NTN and ICAM-1 negative 293T cell xenograft were 
used as controls. The growth of HeLa and 293T xenograft in mice was confirmed by whole body imaging 
of GFP (Figure 5.4A). At 50 hr after intravenous injection of nanoparticles, whole body imaging of near-
infrared (near-IR) fluorescence (AF750 attached to the I domains) indicated accumulation of LMN into 
HeLa but much less into 293T xenograft (Figure 5.4A & B). Subsequent ex vivo imaging of the tumor and 
the major organs harvested from the mice further confirmed a greater level of delivery into HeLa 
xenograft with LMN (Figure 5.4C). The signal from the kidney was by far greater than those from other 
organs both for LMN and NTN, indicating ICAM-1 independent clearance through the kidney (Figure 
5.4C). Interestingly, higher fluorescence was also detected in the liver with LMN, presumably caused by 
persistent, low-level inflammation in the liver. Whole body imaging of nanoparticles localized to HeLa 
and 293T xenograft over the time course of 30 min to 50 hr post-injection showed that the peak 
accumulation occurred at 1-3 hr post-injection, followed by a gradual decrease over 3 days and a 
complete clearance by 7 days (Figure 5.4D). The presence of LMN into HeLa was also confirmed by direct 
staining of iron with Prussian blue (Figure 5.4E & F). To map the distribution of LMN by fluorescence 
microscopy, SPIO nanoparticles conjugated with AF594-labeled I domains were intravenously injected 
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into the mice with HeLa/293T xenograft. When the xenograft tissue was examined 4 hr after 
nanoparticle injection, specific accumulation of LMN into HeLa tumor was observed, judging from 
colocalization between GFP expression in HeLa and AF594 fluorescence (Figure 5.4G & H). Importantly, 
consistent with the detection of ICAM-1 in the tumor vasculature by direct staining of the tissue (Figure 
5.3B), a high percentage of CD31 positive cells in HeLa as well as in 293T xenografts were also targeted 
by LMN. The localization of ICAM-1 specific nanoparticles within the tumor-associated vasculature, 
therefore, was likely responsible for higher signals detected within 293T xenograft at earlier time points 
(Figure 5.4D), despite the fact that 293T itself exhibited almost no binding of LMN (Figure 5.4E & F). This 
finding highlights a potential use of LMN for detection of tumor growth by their accumulation into 
inflamed tumor vasculature, irrespective of the type of tumor surface antigen. 
 
5.3.5 In vivo detection of temporal dynamics of inflammation by optical imaging and MRI 
In order to further confirm that our leukocyte-mimetic nanoparticles sensitively detect the induction of 
ICAM-1 not only due to an inflammatory milieu in the tumor but also by acutely induced inflammation, 
we imaged mice after subcutaneous (Figure 5.5) or intravenous injection of LPS (Figure 5.6). Temporal 
mapping of nanoparticle distribution demonstrated a greater localization of LMN into the LPS injection 
site over PBS injection site as a control, peaking at 12 hr post-injection of LPS and gradually decaying 
over 72 hr (Figures 5.5A & B). Higher accumulation into the liver was also observed with LMN, attributed 
to the inflammatory response induced by the leakage of locally injected LPS into circulation. We also 
observed a rapid increase in fluorescence in the bladder, irrespective of targeting moieties, attributed to 
renal clearance of some fraction of proteins dissociated from nanoparticles. Interestingly, NTN 
accumulated more into the LPS site than into the PBS site, presumably due to non-specific phagocytosis 
of nanoparticles by immune cells. Selected mice treated with systemic delivery of 100 μg LMN were 
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then subjected to MRI after whole body optical imaging to demonstrate that our nanoparticles could be 
used for quantitative detection of inflammation by a clinically relevant imaging technique (Figure 5.5C). 
T2* magnitude images identified the presence of LMN in the LPS injection site as darkness, which could 
be confused with other dark regions. QSM revealed the accumulation of ~0.3 μg of iron oxide 
(corresponding to detection of less than 1% of injected dose) into the LPS injection site, colocalized with 
the site identified by near-IR imaging (Figure 5.5A).  
In response to systemic inflammation caused by intravenous injection of LPS for 12 hr prior to 
nanoparticle (~200 μg) injection, optical mapping of nanoparticle distribution demonstrated greater 
localization of LMN in the liver compared to that of NTN in mice (Figure 5.6A & C), peaking at 1hr post-
injection of nanoparticles and subsequently diminishing at later time points. The level of delivery overall 
was higher with LPS even with NTN, indicating some of nanoparticles accumulated into the liver was 
caused by ICAM-1 independent phagocytosis. After optical imaging, mice were transcardially perfused 
with PBS for MRI, which would have removed nanoparticles retained in the blood pool in the liver. 
Temporal mapping of SPIO distribution using MRI QSM measured about 20% of the total dose of LMN 
was specifically uptaken by the liver 1 hr post injection due to LPS-induced inflammation (Figures 5.6B & 
D and supplementary videos). QSM quantification also demonstrated a similarly greater localization of 
LMN into the liver under acute inflammation at different time points, exhibiting qualitative agreement 
with the temporal mapping using optical imaging (Figures 5.6B & D). Discrepancy between optical 
intensity and QSM was unavoidable as MRI was performed after perfusion of the mice as well as due to 
the different kinetics of degradation for fluorescence dye (AF750) and SPIO.  
 
5.4 DISCUSSION 
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Sensitive detection of inflammation will be of high significance for diagnosis of diseases caused directly 
by host inflammatory response such as sepsis, allograft rejection, lupus, as well as those that are 
influenced by inflammation such as cardiovascular disease and cancer. In this study, we designed MRI-
compatible SPIO nanoparticles, and demonstrated a successful detection of constitutive expression of 
ICAM-1 in tumor, as well as ICAM-1 induction in tumor-associated vasculature, where tumor growth and 
angiogenesis are active. Prior approaches to inflammation detection have been largely based on 
antibodies that are against cell adhesion molecules such as ICAM-1 and VCAM-1 (108-113, 128), lacking 
in the ability to fine tune affinity and avidity of targeting moieties on nanoparticles that are critical to 
inflammation-specific targeting. From our previous in vitro studies (117, 123), we have demonstrated 
specific localization into inflamed but not to resting endothelium and immune cells of nanoparticle (50-
100 nm in diameter) coated with integrin LFA-1 I domain engineered for high affinity to ICAM-1. 
Furthermore, combining recently developed quantitative susceptibility mapping technique, we 
quantified sub-microgram quantity of iron oxide accumulated in both ICAM-1-expressing cell phantom in 
vitro and acute inflammation induced by LPS in vivo, corresponding to less than 1% of injected dose.  
Despite the fact that ICAM-1 is basally expressed in all endothelium (116, 122) and therefore the 
notion that ICAM-1 may not be a suitable target for inflammation, our studies emphasize selective 
delivery by targeting molecules that are induced greatly under inflammation (129, 130). Nanoparticles of 
~100 nm will experience hydrodynamic force generated by the blood flow (131, 132), such that there 
should be sufficient simultaneous molecular interactions with the cells for nanoparticles to remain on 
cell surface. The number of minimum molecular interactions required for stable adhesion of 
nanoparticles will also depend on the adhesion strength of each interaction. Therefore, specificity 
toward high ICAM-1 site will be influenced by the affinity of molecular interaction and the valency 
between nanoparticles and target cells, where the design of nanoparticles to permit tunable affinity and 
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avidity of physiological interaction is of significant advantage. Our nanoparticles to a great extent mimic 
the behavior of activated leukocytes, which would adhere much better to inflamed endothelium.  
Increasing number of studies have begun to focus on the crosstalk between the immune 
activation of vascular niche, angiogenesis, and tumor progression (133, 134). Upregulated levels of 
ICAM-1 in tumor have been linked to two different contexts, one serving as a marker for the recruitment 
of effector immune cells and tumor killing (135), while it was also observed in malignant and metastatic 
tumors with poor prognosis (136). Seemingly contradicting roles of ICAM-1 may be due to the 
complexity of inflammation in various phases of tumor development, which can be better examined by 
in vivo imaging tools. Our nanoparticles did indeed show the localization into the tumor vasculature, 
while their localization into the vasculature elsewhere was non-detectable. With human tumor 
xenograft model, we observed that the majority of tumor mass was comprised of tumor cells with poor 
vascularity present therein. Higher vascularity was found in the periphery of the tumor, often called the 
invasive tumor front, where ICAM-1 overexpression associated with higher immune activity has also 
been reported in many carcinoma cases (126, 137-140). Notably, we have demonstrated that 
intravenously injected nanoparticles targeting ICAM-1 specifically localized into the vasculature 
associated with the tumor progression. With further improvement of detection sensitivity in addition to 
more native tumor models containing not only tumor cells themselves but also fully-developed 
vasculatures and other stroma cells such as macrophages, our nanoparticles may provide a universal 
tumor imaging strategy not by tumor surface markers limited to specific cancer types but by the 
inflamed microenvironment which is associated with almost all cancer development.  
Besides sensitive detection of chronic inflammation implicated in cancer, prompt and accurate 
detection of acute inflammation induced by bacterial or viral infection such as sepsis is also of clinical 
importance. Acute inflammation dramatically induces ICAM-1 induction not only in endothelium but 
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also in immune cells, such that both cellular components become the targets by I domain-coated 
nanoparticle. Using LPS-induced acute inflammation model, we demonstrated optical imaging of the 
temporal dynamics of inflammation. Specific localization of LMN was also confirmed by QSM technique 
using MRI. The degree of localization of ICAM-1 targeting nanoparticles into an inflamed site will closely 
reflect different phases of inflammation, from the onset of inflammation to resolution phase. Therefore, 
quantitative prediction of spatiotemporal distribution of nanoparticles may provide critical information 
on diagnosis and the choice of therapy regimen in clinics. 
In summary, our ICAM-1 targeting strategy by mimicking the behavior of leukocytes in their 
ability to localize to the inflamed endothelium was able to detect ICAM-1 overexpression in tumor cells, 
tumor vascular microenvironment, and acute inflammation. In the design of ICAM-1 targeting 
nanoparticles by conjugation with LFA-1 I domain, we employed His-tag binding to nickel-NTA, which we 
previously found (117) to be critical in order to fine-tune the coating density of targeting moieties to be 
specific to ICAM-1 overexpression but not to basally present ICAM-1. The idea of optimizing molecular 
interactions by tuning the avidity between ligands and receptors could provide a useful strategy to 
molecular targeting of some important targets that are basally expressed elsewhere. Inflammation-
targeting nanoparticles with the lipid layer shell can also be used to carry small, hydrophobic drugs, 
achieving simultaneous imaging and targeted drug delivery. 
 
5.5 CONCLUSION 
This study presents physiology-inspired design of SPIO nanoparticles for in vivo detection by optical 
imaging and MRI, mimicking activated leukocyte in its ability to recognize inflamed endothelium. 
Nanoparticles in vivo will experience hydrodynamic force induced by the blood flow, requiring 
simultaneous molecular interactions with sufficient adhesion strength with the cells for nanoparticles to 
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remain on cell surface. Therefore, the design of nanoparticles with tunable affinity and avidity of 
physiological interactions would be critical to selectivity and efficiency of leukocyte-mimetic 
nanoparticles in targeting inflammation. Notably, we observed specific accumulation of systemically-
delivered nanoparticles into the vasculature within the tumor and invasive tumor front where the tumor 
growth and angiogenesis were active, while their localization into the vasculature elsewhere was much 
lower. The use of two different nanoparticles differed only by the type of I domains (active vs. inactive) 
as targeting moieties against ICAM-1 enabled us to discriminate inflammation-driven accumulation into 
the tumor microenvironment from passive distribution, which may result from the leakiness of the 
vasculature within the tumor. Inflammation-targeting nanoparticles such as SPIO with the layer of 
phospholipid are also suitable for carrying small molecule drugs, achieving simultaneous imaging and 
targeted drug delivery. 
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Figure 5.1. Synthesis, characterization, and in vitro delivery of leukocyte-mimetic nanoparticles. (A) A 
schematic diagram of iron oxide nanocrystals encapsulated into a micelle-like layer composed of 
amphiphilic phospholipid copolymers (stage I–II) and subsequent protein conjugation for molecular 
targeting (stage III). (B) Uniformly sized, monodispersed SPIO with 15 nm core revealed by TEM. A close 
up view on top demonstrates a dark halo corresponding to nickel ions (black arrow) chelated by NTA 
groups surrounding SPIO. On the bottom is the negative staining of protein-conjugated SPIO with 
proteins and PEG groups darkly stained (white arrow), in contrast to a brighter phospholipid layer. (C) 
Flow cytometry measurements of HeLa cells stained with different I domains (10 μg/ml) labeled with 
AF488. Non-stained HeLa cells are shown in grey shaded histograms. In a competition assay, non-labeled 
I domains were used at 50 μg/ml. (D) Shown in green is immunofluorescence staining of ICAM-1 in HeLa 
cells using F265S/F292G labeled with AF488. Nuclei staining by DAPI is shown in blue. (E) Flow cytometry 
measurements of HeLa cells stained with nanoparticles (25 μg/ml of SPIO and 10 μg/ml of I domains) 
conjugated with different I domains. Non-labeled I domains as a competitor were used at 50 μg/ml. (F) 
ICAM-1 dependent internalization of SPIO into HeLa cells was confirmed with confocal fluorescence 
microscopy and Perl’s Prussian blue staining. 
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Figure 5.2. Quantitative measurement of selective binding of SPIO to ICAM-1 by MRI. (A) The amount of 
SPIO internalized into HeLa or 293T was measured by radioisotope measurement of 3H-phospholipid 
incorporated into SPIO nanoparticles. SPIO nanoparticles were coated with either F265S/F292G (LMN) 
for ICAM-1 targeting or with D137A (NTN) as a control. (B) T2* and susceptibility images of agarose-
embedded HeLa cells that were labeled with 200-0 μg/ml of LMN. (C) A comparison of iron mass 
estimated by QSM technique and radioisotope measurement. Shown are the measurements of agarose-
embedded free LMN (closed circles) and LMN internalized into HeLa cells (closed circles).  
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Figure 5.3.  Ex vivo molecular imaging of tumor and tumor-associated vasculature. (A) Confocal 
fluorescence images of murine b.End3 cells before and after LPS treatment and HeLa cells stained with 
murine (top) and human (bottom) I domains (F265S/F292G) labeled with AF594. Nuclei staining by DAPI 
is shown in blue. (B) Immunofluorescence images of GFP-expressing HeLa xenograft tumor tissue 
costained with F265S/F292G-AF594 and anti-murine CD31 antibodies. Skin tissues from non-tumor 
bearing mice were used as control. (C) The percentages of endothelium costained with CD31 and 
F265S/F292G within the tumor, in the periphery (300 μm from the tumor), and in the skin were 
determined from immunohistology (n = 6). (D) Vascularity within the tumor, in the periphery (300 μm 
from the tumor), and in the skin was quantified using Chalkley's method (25 random points per field of 
view) (n = 3; *p < 0.05, **p < 0.01). 
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Figure 5.4. In vivo molecular imaging of tumor and tumor-associated vasculature. In vivo (A, B) and ex 
vivo (C) near-IR imaging of mice at 50 hr after intravenous injection of NTN vs. LMN. GFP indicates the 
growth of HeLa (‘1’) and 293T (‘2’) tumors. The distribution of nanoparticles into the major organs (‘3’-
‘8’) were also examined. (D) Near-IR fluorescence intensities of HeLa and 293T tumors at different time 
points after intravenous injection of LMN vs. NTN (n = 4; **P < 0.01, ***p < 0.001). (E) Perl’s Prussian 
blue staining of tumor sections collected at 50 hr after the injection of LMN vs. NTN. Stained iron is 
marked with black arrows. (F) Percentage of cells stained in Prussian blue (top) and the intensity of 
Prussian blue in the field of view (bottom) within tumor sections (n = 3; ***p < 0.001 between LMN vs. 
NTN in HeLa tumor. †††p < 0.001 between HeLa and 293T tumor using LMN). (G) Immunofluorescence 
imaging of tumors at 4 hr post-injection of LMN. Tumor sections were also stained with anti-CD31 
antibody for delineating vasculature. LMN localization into the tumor vasculatures was indicated with 
white arrows. (H) Fluorescence imaging of tumors at 4 hr post-injection of NTN. 
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Figure 5.5. In vivo molecular imaging of subcutaneous acute inflammation using near-IR camera and 
MRI. (A) In vivo near-IR whole body imaging of LMN vs. NTN distribution in mice 1 hr after nanoparticle 
injection. Mice were exposed to LPS (‘1’) and PBS (‘2’) for 3, 12, 24, or 72 hr at the time of nanoparticle 
delivery. (B) Fluorescence intensities of LMN at LPS vs. PBS injection sites were shown (n = 3; **p < 0.01, 
***p < 0.001 between LPS and PBS site at specific time points; †p< 0.05 between 12 hr and 72 hr at LPS 
site). (C) T2* magnitude and susceptibility mapping images of nanoparticle distribution in mice at 4 hr 
after nanoparticle injection. Mice were exposed to LPS/PBS for 12 hr at the time of nanoparticle 
injection. Bright spot identified by susceptibility mapping as the accumulation of SPIO was indicated with 
crosshair.  
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Figure 5.6.  In vivo molecular imaging of systemic acute inflammation using near-IR camera and MRI. In 
vivo near-IR whole body imaging (A) or MRI (B) of LMN vs. NTN distribution in mice at 1, 8, 25 hr post-
injection of nanoparticles in mice exposed to systemic LPS for 12 hr or control mice with no treatment. 
LMN vs. NTN distributions into the liver were quantified by near-IR optical imaging (C) and MRI (D) (n = 
3; *p < 0.05, ***p < 0.001 between LMN vs. NTN at specific time points). 
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CHAPTER 6 – TARGETED NANOPARTICLES TO VISUALIZE ACUTE INFLAMMATION: 
PART II 
 
Includes material previously published in: Wong R, Chen X, Wang Y, Hu X, Jin MM. Visualizing and 
Quantifying Acute Inflammation Using ICAM-1 Specific Nanoparticles and MRI Quantitative Susceptibility 
Mapping. Ann Biomed Eng. 2011.(141) 
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6.1 INTRODUCTION 
Nonresolving inflammation contributes significantly to the pathogenesis of a variety of human diseases 
and represents one of the most significant factors of medical burden worldwide(101). While 
inflammation is typically initiated in response to harmful stimuli, dysregulation of the inflammation 
pathways can result in prolonged and excessive inflammation, leading to host damage that can surpass 
the harm inflicted by the original pathogen(142). Indeed, unresolving chronic inflammation has been 
linked to atherosclerosis(143), obesity(144), and cancer(106), prolonged acute inflammation has been 
closely associated with sepsis(145) and local infections(146), and the cyclic coexistence of acute and 
chronic inflammation has been implicated in rheumatoid arthritis(147), asthma(148), multiple sclerosis, 
Crohn’s disease, and ulcerative colitis(101). Of particular concern of inflammatory dysregulation is the 
intense localized recruitment of macrophages, lymphocytes, and neutrophils to otherwise healthy 
tissue, resulting in necrosis of vital tissues and organs, contributing greatly to increased patient 
morbidity and mortality(149). Thus, identifying localized inflammation in the context of broader 
inflammation-driven diseases can aid in isolating regions at risk of host-response necrosis and can 
provide a valuable insight into the progression and severity of the condition.  
Current approaches to inflammation detection employ various markers as targets for 
biospecificity, including soluble extracellular molecules, such as fibrinogen(150), factor XIII(151), and 
collagen(152), as well as cell surface molecules such as tissue factor(153), chondroitin sulfate 
proteoglycans(154), vascular adhesion molecule (VCAM-1)(155), and ICAM-1(123, 156, 157). Of 
particular interest is ICAM-1, a transmembrane molecule that displays a distinct spatiotemporal 
response to inflammation. While basally expressed at low levels throughout the body under normal 
conditions, ICAM-1 is highly inducible under inflammatory stimuli(158) and exhibits highly localized cell 
surface expression on immune and non-immune cells, such as endothelial cells, fibroblasts, 
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lymphocytes, and myeloid cells(116). Furthermore, cell surface ICAM-1 overexpression has been linked 
to various diseases and conditions, and correlates well with inflammation-related tissue and organ 
damage resulting from hepatic ischemia(159, 160), intestinal and colon ischemias(161), hepatitis, 
cirrhosis, Wilson’s disease, transplantation rejection(162), pancreatitis(163), type 1 diabetes(164), and 
multiple organ dysfunction syndrome in sepsis(145). To target cell surface ICAM-1, we previously 
employed a high affinity variant of the domain called inserted (I) domain(118), present in the α subunit 
of the integrin lymphocyte function-associated antigen (LFA)-1 and solely responsible for LFA-1 
interaction with ICAM-1(122).  
One potential application for specific inflammation imaging is for the detection of sepsis. Sepsis 
is the leading cause of death in critically ill patients admitted to the medical intensive care unit (ICU) in 
the United States(27), defined as a systemic inflammatory response to infection manifested by two or 
more systemic inflammatory response syndrome (SIRS) criteria (such as changes in body temperature, 
tachycardia, and changes in the number and/or immaturity of white blood cells)(145). Under sepsis, the 
endothelium experiences sustained and generalized activation, resulting in procoagulant phenotype, 
increased endothelial cell apoptosis, increased expression of adhesion molecules, and ultimately organ-
specific coagulation and dysfunction(145). As ICAM-1 plays a significant role in mediating leukocyte 
adhesion as a part of inflammatory response and has been linked to organ-specific inflammation-driven 
necrosis, identifying sites of high ICAM-1 expression may offer detection or even additional insight into 
the progression of sepsis or other systemic inflammatory response not offered by existing diagnostic 
techniques.  
In this study, we demonstrate that high resolution spatiotemporal imaging of LPS-induced 
systemic inflammation through the use of inflammation-specific nanoparticles termed leukocyte-
mimetic nanoparticles (LMN)(100), a fluorescently tagged ICAM-1 specific nanomicelle encapsulating 
 
 
108 
 
 
superparamagnetic iron oxide nanoparticle as a targeted bimodal near-infrared (IR) optical/magnetic 
resonance imaging (MRI) contrast agent. Using optical imaging and a novel MRI quantitative 
susceptibility mapping (QSM) technique(18), and directly corroborated by radiolabeled isotope 
measurement, we utilize LMN to quantitatively observe the degree of localized acute inflammation as 
an indicator of sepsis progression. By tracking the biodistribution of nanoparticles using whole body 
imaging techniques, we have found greater accumulation of LMN than that of non-ICAM-1 specific 
controls in the liver of septic mice, while this difference in accumulation was absent in the liver of non-
septic mice. In contrast, greater accumulation of nanoparticles irrespective of ICAM-1 targeting was 
observed in the spleen of septic mice than that of non-septic control, suggesting that localization into 
the spleen was mainly a result of ICAM-1 independent phagocytic activity. Our study demonstrates the 
utility of quantitative MRI-based detection of ICAM-1 specific nanoparticles in the major organs 
including the liver and spleen, organs closely associated with systemic inflammatory response, as a 
diagnosis method for systemic inflammation through the imaging and quantification of localized 
inflammation. 
 
6.2 MATERIALS AND METHODS 
6.2.1 Preparation of ICAM-1 specific nanoparticles (Leukocyte-mimetic nanoparticles (LMN))  
Details in the synthesis of LMN were described previously(100). Briefly, oleic acid-capped 
superparamagnetic iron oxide (SPIO) nanocrystals (15 nm in diameter, Ocean Nanotech, LLC) were 
additionally coated with an outer layer of phospholipid, consisting of 1,2-dipalmitoyl-snglycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG) and 1,2-dioleoyl-sn-glycero-
3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] nickel salt (DOGS-NTA) (Avanti Polar Lipids, 
Inc.). Radiolabeled lipid-coated SPIO nanoparticles were synthesized by addition of 3H-DPPC (L-α-
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Dipalmitoyl-Phosphatidylcholine) (Perkin Elmer) at less than 5% of the total phospholipid to the mixture 
of DPPE-PEG and DOGS-NTA. The lipid layer on SPIO nanoparticles was formed by hydration of the 
mixture of lipid-film and SPIO, and lipid-coated SPIO were then purified by density centrifugation, 
followed by a gel filtration technique. LFA-1 I domains containing mutations of Asp137->Ala (D137A; 
non-ICAM-1 specific) and Phe265->Ser/Phe292->Gly (F265S/F292G; ICAM-1 specific) fused to His tag (6 
histidine residues) at the N-terminal were produced as previously described(100). Conjugation of lipid-
SPIO with His-tagged I domains was obtained by incubation of nanoparticles with I domains at 4°C 
overnight, forming LMN (with F265S/F292G) and non-targeting nanoparticle (NTN) (with D137A). All 
fluorescently labeled nanoparticles were prepared by covalently conjugating Alexa Fluor 750 (AF750) 
(succinimidyl esters (Invitrogen) to the I domains.  
 
6.2.2 Animal Model of Acute Inflammation 
All animal experiments were conducted in compliance with the regulations defined by the Institutional 
Laboratory Animal Use and Care Committee of Cornell University. 1 mg/ml LPS in 100 μl PBS were 
injected intravenously through retroorbital vein into 8-wk-old female BALB/c mice 12 hr before 
nanoparticle administration. Prior to imaging hair was removed to reduce background fluorescence. 
Mice with no treatment were used as negative control. Three mice per group were used for each 
treatment and imaging regimen. 
 
6.2.3 Near-IR Optical and MR Imaging of Mice 
Animals were anesthetized with isoflurane mixed with oxygen at 5% and maintained at 2% isoflurane 
during whole body imaging (Olympus, OV100). After 12 hour treatment with LPS or no-treatment 
control, mice were administered with 100 μg of nanoparticles coated with AF750-conjugated I domains 
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in 150 μl pH 7.4 PBS via retro-orbital injection. Near-IR images of the same mice were taken three times 
at 1, 8, and 25 hours after nanoparticle injection. Image analysis was performed with Matlab R2007a 
(MathWorks). Mice were euthanized at 1, 8, or 25 hours after injection of nanoparticles for MRI by 
intraperitoneal injection of 2.5% tribromoethanol (20 μl/g), transcardially perfused with pH 7.4 PBS, and 
fixed in 4% paraformaldehyde. Prepared mice were scanned on a 3T scanner (GE Signa Excite) with 3D 
multi-echo enhanced fast gradient echo (EFGRE) sequence. Imaging parameters were as follows: TEs 
3.696 ms, 4.196 ms, 5.696 ms, 11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; matrix size 256x64x64; 
voxel size 500 μm isotropic. A 3D Fourier transform was applied to the raw k-space data to reconstruct 
the images. QSMs were reconstructed using the COSMOS technique, as previously described(100). 
Regions of interest were segmented for the liver, spleen, and kidneys, and SPIO localization was 
estimated using QSM, normalized to a calibration standard.  
 
6.2.4 Histological Sections 
At 1 hour post nanoparticle injections, mice were euthanized and perfused with PBS transcardially. Liver 
tissues were then collected from animals. Part of the tissues were fixed in 4% paraformaldehyde, 
embedded in paraffin, sliced into 4 μm slides, and stained with hematoxylin and eosin (H&E) or with 
Perl’s Prussian blue. The rest of the tissues were frozen in OCT compounds (Sakura Finetek), sectioned 
to 10 μm slides, and immunostained with rat anti-mouse CD68 (BioLegend) for detection of 
macrophages.  
 
6.2.5 Quantification of Radiolabeled LMN 
Animals were anesthetized with isoflurane and each was administered with 100 μg 3H-labeled SPIO (600 
nCi per mouse) in 100 μl PBS via retro-orbital injection. At 1 hour post injection, blood samples were 
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first collected and mice were perfused with PBS and sacrificed. Major organs were harvested, 
homogenized, lysed in tissue solubilizer (Fisher), and then mixed with scintillation counter fluid for 
radioactivity measurement (Beckman Coulter). Percent distribution into the major organs was obtained 
after normalization to the total counts of radioisotope decay per animal. 
 
6.2.6 Surface Plasmon Resonance (SPR) Analysis 
The affinity of human LFA-1 I domains, F265S/F292G and D137A, to murine ICAM-1 was determined by 
SPR using BIAcore (BIA2000), as previously described(118). In brief, a CM5 sensor chip was prepared 
using an amine coupling kit (BIAcore) to immobilize recombinant murine ICAM-1fusion with human IgG1 
Fc (R & D Systems). Then F265S/F292G and D137A were injected over the chip in injection buffer (20 
mM Tris HCl, pH 8.0, 150 mM NaCl, 10 mM MgCl2) at a flow rate of 10 µl/min at RT. In order to examine 
the specificity of nanoparticle to the level of ICAM-1 expression, CM5 sensor chip was immobilized with 
three different concentrations of ICAM-1, representing basal to highly induced cell surface density (200, 
1000 and 3,250 molecules/μm2)(165). Nanoparticles were then flowed over the chip at a flow rate of 15 
μl/min to approximate the shear force on nanoparticles in vivo.  
 
6.2.7 Statistical Analysis 
Statistical analysis was performed using two-way analysis of variance and one-way analysis of variance 
with Tukey’s HSD post-hoc test at 95% confidence interval (GraphPad Prism). 
 
6.3 RESULTS 
Previously, we validated the suitability of I domain as a targeting moiety for selective binding of 
nanoparticles to ICAM-1 overexpression(100, 123, 156). In order to design control nanoparticles, termed 
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non-targeted nanoparticle (NTN), we used the same LFA-1 I domain but containing a mutation of D137A, 
which abolished a ligand-binding site called a metal-ion adhesion site (MIDAS) and subsequently its 
binding to ICAM-1 (Figure 6.1A). SPR measurement confirmed our previous observation with cell 
staining(100) that human I domain cross-reacted with murine ICAM-1 with comparable affinity to 
human ICAM-1 (KD = 2 nM to murine ICAM-1 vs. 6 nM to human ICAM-1(118); Figure 6.1B). Subsequent 
conjugation of F265S/F292G and D137A to prepared lipid-coated SPIO nanoparticles produced LMN and 
NTN, respectively, through spontaneous assembly from binding of His tag (6 x histidine residues) to 
Nickel-NTA (Figure 6.1C).  
Prior studies demonstrated that the number of targeting moieties on nanoparticles affected 
selectivity and targeting efficiency of nanoparticles in binding to cells(100, 166). In order to 
preferentially target ICAM-1 induced under inflammation but not basally expressed ICAM-1, an optimal 
ratio of I domain to nanoparticle was empirically determined (~100 molecules per nanoparticle(156)). 
When an SPR chip was prepared with varying ICAM-1 densities representing basal to high levels of 
ICAM-1 expression (200, 1000 and 3,250 molecules/μm3), LMN binding was limited to the surface 
coating with higher than normal ICAM-1 site density, while LMN binding to the basal ICAM-1 surface was 
the same as the background levels seen with NTN (Figure 6.1D). 
To obtain qualitative assessment of nanoparticle biodistribution, we first imaged each mouse 
using near-IR optical fluorescence camera. Near-IR optical temporal mapping of the nanoparticle 
distribution demonstrated greater localization of LMN into the liver in mice treated with LPS (Figures 
6.2A & 6.3A). Control nanoparticles (NTN) also exhibited slightly higher accumulation into the liver of 
LPS-treated mice, which might be attributed to increased ICAM-1 independent phagocytic activity of 
immune cells or increased blood pool retention due to the inflammation in the liver. Higher fluorescence 
in the bladder was found to be due to some degree of shedding of the I domains from the nanoparticles, 
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which would be small enough to pass through glomerular capillaries in the kidney and collected into the 
bladder. After optical imaging, mice were sacrificed, transcardially perfused with PBS to remove 
nanoparticles in the blood, and subjected to MRI to quantitatively map nanoparticle distribution by 
QSM. Full body temporal mapping of the SPIO distribution was conducted and individual organs were 
segmented for analysis (Figures 6.2B & C, Supplemental Figures 6.1A & B). Specific SPIO quantification of 
each organ revealed a greater localization of LMN in the liver compared to that of NTN in mice with LPS 
treatments (Figure 6.2B, S6.1A), peaking at one hour and progressively diminishing at each subsequent 
time point. In contrast to higher accumulation of NTN by optical imaging in the liver of LPS-treated mice 
(Figure 6.2A), QSM quantification (Figures 6.2B & 6.3B, Supplemental Figures 6.1A & B) and radioisotope 
measurement (Figure 6.3C) performed after perfusion revealed that NTN accumulation in the liver was 
not augmented by LPS treatment, indicating that the higher fluorescence with LPS treatment is due to 
the increase in the blood pool retention of NTN. While the presence of LPS or the type of nanoparticles 
administered each independently influenced the magnitude of observable nanoparticle accumulation in 
the liver, the simultaneous interaction of LMN and LPS had a statistically significant effect in all 
measured time points (Table 5.1). In the spleen, higher amounts of nanoparticle accumulation were 
detected for LPS treated mice versus untreated controls, regardless of the type of nanoparticles used 
(Figures 6.2C & 6.3B, Supplemental Figure 6.1B). Therefore, LPS treatment was the predominant 
differentiating factor in observable nanoparticle accumulation in the spleen, independent of the 
targeting moiety or the interaction between LPS treatment and type of nanoparticle injected (Table 6.1). 
Negligible amounts of SPIO were detected in the kidneys, supporting the speculation that nanoparticles 
of ~60nm in size(100) would be too large for renal filtration.  
To further validate MRI quantification of nanoparticles, the values obtained with QSM technique 
were directly compared to those quantified by measuring radioisotope decay of 3H-labeled 
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nanoparticles. Mice were treated with LPS for 12 hours and subsequently injected with 3H-labeled LMN 
or NTN. At 1 hour post nanoparticle injection, blood was collected and after perfusion and sacrifice of 
the mice, organs were harvested. Radioactivities of the blood and major organs such as liver, kidney, 
and spleen were measured and normalized to the total radioactivity of each mouse in order to quantify 
percent nanoparticle biodistribution in the major organs (Figure 6.3C). Highest radioactivity, irrespective 
of LMN vs. NTN and LPS vs. no treatment, was observed in the blood with a mean radioactivity of ~40%, 
followed by the levels in the liver with significantly higher radioactivity detected in LPS/LMN-treated 
mice (31.3 ± 6.7%) than those in non-LPS/LMN-treated (14.8 ± 9.9%), LPS/NTN-treated (13.6 ± 6.6%), or 
non-LPS/NTN-treated controls (17.2 ± 5.7%). Significantly lower amounts (less than 10% of the total) 
were detected in the lung, kidney, and spleen (Figure 6.3C and not shown). Consistent with the QSM 
measurement of nanoparticle distribution in the spleen, slightly higher amounts of radioactivity were 
observed in the spleen of LPS-treated (2.7 ± 0.7%) than non-treated (1.5 ± 0.5%) mice. Values obtained 
by radioisotope measurement and by QSM showed overall an excellent linear relationship (sy.x = 1.60 %), 
with QSM overestimating radioisotope measurements by approximately 25% (Figure 6.3D). 
In order to examine cellular basis for the increase in LMN accumulation into the liver in LPS-
treated mice, selected liver tissues were stained for identification of different types of cells (hepatocyte, 
endothelium, and Kupffer cells) and localization of nanoparticles (Figure 6.4). Vasculature dilatation was 
apparent in LPS-treated liver tissue (Figure 6.4A) with LMN deposited primarily on endothelial cells and 
Kupffer cells (Figure 6.4B). Simultaneous detection of Kupffer cells (CD68) and nanoparticles by Prussian 
Blue staining revealed that most large deposits of LMN were accumulated into Kupffer cells, implying 
that higher accumulation of LMN over NTN in the liver of LPS-treated mice is mainly due to ICAM-1 
induction and uptake by Kupffer cells. 
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6.4 DISCUSSION 
With developments in quantitative MRI techniques, this study presents a clinically adaptable method for 
organ-level mapping of inflammation by quantifying the susceptibility of SPIO-based contrast agents, a 
measure directly proportional to SPIO concentration. While existing methods for detecting inflammation 
exist in the context of sepsis diagnosis, such detection methods typically rely on bulk measurements of 
the presence of pathogens, blood-borne cytokines, and other inflammatory markers, lacking in the 
spatiotemporal progression and detection of inflammation locally in the body. Central to inflammation is 
the adhesion of leukocytes to vascular endothelium, a process mediated by molecular interactions 
between cell adhesion molecules such as integrins and ICAM-1. Toward a sensitive molecular imaging of 
inflammation, we designed nanoparticles to mimic the ability of leukocyte to preferentially adhere to 
inflamed vasculature, which was achieved by attaching the high affinity I domain of LFA-1 to 
nanoparticles. Despite the fact that ICAM-1 is basally expressed in many different types of cells including 
endothelium and immune cells, our nanoparticles were shown to be selective to vasculature under 
inflammation with upregulated ICAM-1 expression(100). Capable of in vivo detection by optical imaging 
and MRI techniques, leukocyte-mimetic nanoparticle has previously been shown to specifically localize 
to the areas of acutely induced local inflammation and to the vasculature within and in the vicinity of 
the tumor growth, providing spatial and temporal insight into various inflammation-related diseases and 
conditions. In this study, we demonstrated the potential use of LMN as a bimodal diagnostic agent for 
the early detection of sepsis or systemic inflammatory response using quantitative MRI techniques. 
Previously, we have described a tunable approach to creating nanoparticles that mimic an 
intrinsic behavior of leukocytes that bind selectively to inflammatory sites(156). By modulating the 
affinity and avidity of surface-bound I domains for targeting inflammation, we were able to construct 
nanoparticles that can resist thermal diffusion and detachment forces exerted by fluid-induced shear 
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stress, while allowing little binding to cells with only basal levels of ICAM-1 expression. Approximately 
100 I domains were conjugated to the surface of each LMN, roughly comparable to that of a surface 
density-optimized approach to ICAM-1 specific nanoparticle design(156, 166). While prior approaches 
have demonstrated the appeal of employing both selectin ligands and anti-ICAM-1 antibodies to more 
accurately mimic the rolling and adhesion characteristics of leukocytes(167, 168), we chose to utilize as 
the targeting moiety for LMN the I domain of LFA-1 integrin, which has been engineered to engage with 
ICAM-1 with high affinity without prior dependence on interaction with selectins. We found that a 
targeting moiety derived from physiological molecules, optimized for affinity and avidity, gave superior 
selectivity and targeting efficiency to inflamed cells in in vitro and in vivo settings(100, 156). 
In treating mice with ICAM-1-specific LMN, we were able to readily differentiate between mice, 
either pre-treated with LPS or left untreated, by quantitatively measuring nanoparticle localization in 
various abdominal organs in each of the subjects. This differential effect is most apparent when 
measuring nanoparticle localization in the liver; a temporal mapping of nanoparticle distribution 
through MRI QSM demonstrated significantly greater localization of LMN into the liver of sepsis-induced 
mice compared to that of non-septic subjects, or of those treated with ICAM-1 independent NTN. The 
observed differences by QSM, corroborated qualitatively by near-IR optometry, were most pronounced 
one hour after the treatment of nanoparticles, gradually decaying over time while persisting through at 
least 24 hours after nanoparticle injection. While particles of ~100 nm in diameter in systemic 
circulation may accumulate in the liver regardless of targeting moiety due to phagocytic activity of 
immune cells within the liver, the ICAM-1 specificity conferred by the surface conjugation of high affinity 
I domain (F265S/F292G) of LFA-1 on LMN led to a close to a 2-fold increase in the accumulation in the 
liver to enable quantitative differentiation. NTN nanoparticles, conjugated with the same LFA-1 I domain 
but with an inactivating mutation, D137A, did not exhibit higher accumulation into the inflamed liver. 
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This observation was corroborated through histology using iron stating of tissue sections of the liver, 
revealing a greater degree of nanoparticle accumulation in LPS-treated LMN cases with specific staining 
observed in both endothelial cells and Kupffer cells with the most significant nanoparticle accumulations 
co-localized in the Kupffer cells. Thus, while ICAM-1 is basally expressed in all endothelium and utilizing 
it as a molecular target for inflammation and sepsis imaging techniques may lead to a background signal, 
it was found that this background binding was negligible, judging from no difference between LMN and 
NTN accumulations into the liver by radioactivity measurement and QSM. The relationship between 
LMN biodistribution independent of ICAM-1 expression can be further characterized through the use of 
ICAM-1 knockout mice or through the use of blocking antibodies to systemically eliminate available 
ICAM-1 binding sites.   
A high degree of nanoparticle localization was also observed in the spleen of LPS-treated mice 
through optical imaging and QSM. However, unlike the observations in the liver, increases in 
nanoparticle accumulations to the spleen were observed in all LPS-treated subjects, regardless of the 
targeting moiety employed, suggesting that localization is a result of phagocytic activity rather than 
ICAM-1 biospecificity. Severe and pervasive inflammation, such as that prompted by LPS-induced 
systemic endotoxic shock, may result in increased phagocytic uptake of nanoparticles in areas in the 
immediate proximity of major monocyte sources in the spleen, an organ that functions as a major 
reservoir for undifferentiated monocytes before inflammation-initiated recruitment(169), and is 
responsible for the release of splenic lymphokines necessary for the increase of phagocytic activity of 
macrophages cells in response to inflammatory stimuli(170-172). While studies have indicated high 
ICAM-1 expression in the epithelial cells of the lungs due to endotoxin-induced inflammation(173, 174), 
MRI-based techniques such as QSM cannot quantitatively differentiate between signal voids resulting 
from SPIO-based spin dephasing and signal voids created by air. This difficulty with reliably 
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differentiating QSM-based quantification of SPIO deposits and air may be overcome by multiple data 
acquisition at differing magnetic field strengths (175). 
Using radiolabeled SPIO nanoparticles, we were able to provide a quantitative mapping of 
nanoparticle distribution by the measurement of radioactivity  and at the same time clinically relevant 
QSM technique based on MRI. At one hour post nanoparticle injection, QSM determined that ~39% of 
injected nanoparticles were localized into the liver of LPS/LMN mice, a value 70% greater than that of 
negative controls. In comparison, radioisotope quantification found ~31% of the total body radioactivity 
was located in the liver of LPS/LMN treated mice, a value 81% greater than that of negative controls. 
However, some difference in QSM quantification vs. radioactivity measurement of nanoparticles was 
unavoidable as it was found that the lipid layer outside of SPIO was subject to some degree of shedding 
during circulation. This may explain, in the course of optical imaging, varying degrees of fluorescence 
(conjugated to the I domains) observed in the bladder of each subject, regardless of the nanoparticle 
targeting moiety. The decoupling of the fluorescence or protein from nanoparticles was found to be 
caused by shedding of the phospholipid lipid layer from SPIO or lipid degradation by phospholipase 
activity in the plasma, but not due to dissociation between His tag and Ni-NTA, judging from a dramatic 
decrease in decoupling when crosslinkable fatty acids were used to cage SPIO (data not shown).  
Sepsis represents a continuum in clinical-pathologic severity with definable phases that 
characterize patients at risk for increased mortality. Current diagnosis techniques have limited windows 
of detection and may rely on transient biology and physiological conditions that may not persist across 
all phases of sepsis progression. Moreover, the onset of sepsis can be linked to a widely heterogeneous 
set of initial risk factors, further complicating diagnosis and delaying treatment. In particular, the 
endothelium is crucial in regulating a local balance between pro-inflammatory and anti-inflammatory 
mediators; under sepsis, endothelium undergoes excessive, sustained, and generalized activation, 
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resulting in unregulated expression of inflammation-associated products. Among these, adhesion 
molecule ICAM-1 has been implicated as a highly localized biomarker for inflammation induced under 
organ damage(160-162), one of the most significant mortality risks in septic patients(145). By specifically 
targeting ICAM-1 using bimodal LMN, we were able to readily differentiate septic and non-septic mice 
using optical imaging and quantitative MRI techniques, both non-invasive modalities. Most significantly, 
the observed differences were pronounced as soon as one hour after the treatment of the nanoparticle, 
and persist through at least 25 hours after injection. In this study, our temporal mapping of 
inflammation was focused on following nanoparticle distribution over 25 hours in mice exposed to LPS 
for 12 hours. However, as surface-expressed ICAM-1 is induced rapidly under inflammation, with some 
studies observing peak expression as quickly as 1-2 hours after the introduction of stimuli(158), 
additional information on spatiotemporal dynamics of inflammation can be obtained by subjecting mice 
to different durations of LPS while maintaining similar post-treatment imaging protocols. Such 
information on spatiotemporal dynamics of inflammation would be necessary to better understand the 
distinct yet common processes of inflammation in reticuloendothelial systems such as the liver and 
spleen. 
This study also reveals the strength of MRI QSM in quantitatively measuring contrast agent 
localization into specific structures within the body. While optical imaging provides a gross view of the 
overall biodistribution of a fluorescent marker, the results are coarse, qualitative in nature, and prone to 
confounding effects due to the relatively shallow penetration depth of common fluorescent 
wavelengths, and the technique is not ideal for most clinical applications. Alternatively, traditional MRI 
techniques, such as typical T2* weighted imaging, provide significantly greater spatial resolution, but 
visualization is hindered by large obscuring signal voids resulting from SPIO use, and the resulting images 
are largely qualitative in nature, making it difficult to precisely estimate SPIO localization. In contrast, 
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QSM technique offers a quantitative, high resolution method of tracking the biodistribution of 
paramagnetic contrast agents to specific organs and structures through mapping of magnetic 
susceptibility, a physical property of paramagnetic materials that relates linearly to its concentration, 
allowing for direct determination of the amount and spatial location of contrast agent accumulation. 
Moreover, while SPIO-based contrast agents may result in signal voids in traditional T2* imaging and 
obscured underlying structure, QSM reconstruction techniques enable unimpeded analysis of the 
distribution of contrast agent and spatiotemporal mapping of inflammation. Given the speed and 
robustness by which these differences can be observed after administration of LMN, this technique 
offers temporal flexibility ideal for clinical applications, while granting dramatically increased spatial 
fidelity not offered by existing bulk measurement diagnostic techniques. 
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Figure 6.1. Construction of ICAM-1 specific leukocyte-mimetic nanoparticles. (A) Structural model of the 
complex of ICAM-1 domain 1 and LFA-1 I domain. White spheres depict allosteric activation sites along 
the peptide backbone. Metal ion and two oxygen atoms of water molecules are depicted as colored 
spheres. Residues that coordinate to the metal ion are shown as sticks. Mutations of Phe265->Ser 
(F265S), Phe292->Gly (F292G), and Asp137->Ala (D137A), and N and C termini are indicated. Figure 
adapted from Figure 5 of Hu et al(176). (B) SPR measurement of the binding kinetics of I domain variants 
F265S/F292G and D137A to immobilized murine ICAM-1. F265S/F292G exhibits high ICAM-1 binding 
affinity (KD = 2 nM), while variant D137A indicates no (not determinable) binding affinity. (C) Schematic 
diagram of LMN and NTN. LMN (ICAM-1 specific) and NTN (non-ICAM-1 specific) differ only in surface-
conjugated targeting moiety. (D) SPR measurement of the binding kinetics of LMN and NTN to varying 
concentrations of immobilized ICAM-1 (low, intermediate, and high correspond to approximately 200, 
1000 and 3,250 molecules/μm2, respectively). LMN binding was limited to the surface coating with 
higher than normal ICAM-1 site density, while LMN binding to the basal ICAM-1 surface was the same as 
the background levels seen with NTN. 
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Figure 6.2. Representative images for each treatment regimen obtained using near-IR optical imaging 
and MRI QSM. (A) Fluorescent heat maps (color) are superimposed over brightfield images (grey scale), 
indicating greater nanoparticle localization in the liver in LPS/LMN-treated mice compared to that of 
negative controls, with observable localization diminishing over time. (B-C) MRI-QSM reconstructions of 
the (B) liver and (C) spleen. QSM technique reveals greater nanoparticle localization in the liver of 
LMN/LPS-treated mice compared to that of negative controls, while greater nanoparticle localization is 
observed in the spleen in LPS-treated mice, regardless of injected nanoparticle. Portions of these results 
were previously described in Chen et al(100), and reproduced here. Representative QSM maps at each 
time point post-injection (p.i.) of nanoparticles are shown: organ-specific QSM heat maps (color) are 
superimposed over MRI T2* weighted EFGRE scans used for navigational reference (gray). 
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Figure 6.3. Multi-modal quantification of organ-specific nanoparticle localization. (A) Fluorescence 
detected in the liver region of mice analyzed using near-IR optical imaging at 1, 8, and 25 hours post 
nanoparticle injection. (B) Measurement of nanoparticle accumulation in the liver, spleen, and kidneys 
from MRI-QSM analysis. (C) Radioactivity measurement of 3H labeled nanoparticles from the liver, 
kidney, spleen, and blood 1 hour post-nanoparticle injection, normalized to the total counts of 
radioisotope decay per mouse. All modalities measured high liver-specific nanoparticle localization in 
LPS/LMN-treated mice 1 hour post nanoparticle injection over controls. QSM measured high spleen-
specific nanoparticle localization in LPS-treated mice, regardless of nanoparticle injected. Trends persist 
through 25 hours post nanoparticle injection. Portions of these results were previously described in 
Chen et al(100), and reproduced here. One-way analysis of variance with Tukey HSD post-test at 95% 
confidence interval are summarized in each figure (*** p < 0.001, ** 0.001 < p < 0.01, * 0.01 < p < 0.05). 
(D) Measurements of nanoparticles in the spleen and liver obtained from by radioisotope measurement 
and by QSM are linearly related. Error bars indicate 95% confidence interval. Dotted line indicates 95% 
confidence interval for linear regression fitting. n = 3 for each treatment and imaging regimen. 
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Figure 6.4. Histological sections of liver tissue. (A) H&E stain of liver tissue sections show distinct dilation 
of liver tissue, characteristic of sepsis. (B) Prussian Blue staining of liver tissue sections shows SPIO 
accumulation primarily in the endothelial cells and Kupffer cells, with markedly more staining in LPS 
treated subjects with injected LMN. (C) CD68 (brown) and Prussian Blue (blue) staining indicates primary 
localization of iron deposition in Kupffer cells. Examples of hepatocytes (arrow), endothelium (double 
headed arrow), and Kupffer cells (arrowhead) are marked. 
  
 
 
127 
 
 
Table 6.1. Two-way analysis of variance of organ-specific nanoparticle accumulation resulting from the 
treatment of LPS, the type of nanoparticle administered, or due to the interaction between both factors, 
quantified by QSM technique.  
 Liver Spleen Right Kidney Left Kidney 
Factors 1 hr 8 hr 25 hr 1 hr 8 hr 25 hr 1 hr 8 hr 25 hr 1 hr 8 hr 25 hr 
LPS *** ** ns *** *** ** ns ns * ns ns * 
Nanoparticle *** ** *** ** ** ns ns ns ns * * ns 
Interaction *** ** * ns ns ns ns ns ns ns * ns 
 
*** p < 0.001, ** 0.001 < p < 0.01, * 0.01 < p < 0.05, n.s. no significance. 
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Supplemental Figure 6.1 (continued)
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Supplemental Figure 6.1. Representative MRI and MRI QSM imaging slices of each treatment regime.  
Figure originally published as an electronic video and has been adapted to static formatting.  The videos 
were constructed from representative images of each treatment regimen obtained using MRI QSM – (A) 
liver and (B) spleen. Representative QSM maps at 1 hour post-injection of nanoparticles are shown: 
organ-specific QSM heat maps (color) are superimposed onto MRI T2* weighted EFGRE scans used for 
navigational reference (gray). 
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CHAPTER 7 – GRADUATE STEM FELLOWS IN K-12 EDUCATION (GK-12) PROGRAM 
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7.1 INTRODUCTION 
During the 2010-2011 academic year, I was a participant in Cornell’s Learning Initiative in Medicine and 
Bioengineering (CLIMB) GK-12 program, an NSF funded program that partners graduate fellows in the 
field of Biomedical Engineering with science teachers in middle and high schools in districts around 
Ithaca.  The aims of CLIMB are two-fold.  First, graduate fellows provide teachers with in-class scientific 
support.  By coordinating hands-on demonstrations, interactive labs, and inquiry-based lesson plan 
design, graduate fellows are able to provide students with a greatly enhanced learning experience 
through the introduction of modern scientific principles, applied in the classroom in a through a 
contextually relevant curriculum.  By bridging the gap between academic research and classroom 
studies in an engaging, relevant, and approachable manner, CLIMB aims to give students a greater 
understanding of key scientific topics and instills a greater appreciation for science, mathematics, and 
engineering that will persist well after the lessons are complete.  Second, CLIMB provides an opportunity 
for graduate fellows to improve upon personal communication skills necessary to convey scientific 
concepts to vastly differing demographics that are otherwise not accustomed to interacting with 
scientists and researchers on a regular basis.   
 
7.2 CLASSROOM BACKGROUND 
My work with the CLIMB program was conducted in partnership with Sydney Mendez, an educator from 
Nottingham High School in Syracuse, New York.  During the 2010-2011 academic year, Sydney Mendez 
taught Syracuse University Project Advance (SUPA) Forensic Science.  SUPA, a cooperative partnership 
between Syracuse University and local high schools, gives qualified high school students the opportunity 
to study college-level material while earning college course credit in a variety of disciplines.  SUPA 
Forensic Science specifically focuses upon the application of scientific methods and techniques in the 
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context of criminal investigation and its implications on the criminal justice system.  Students are 
provided with an introduction to the scientific principles between crime detection and analysis with an 
emphasis on topics such as organic and inorganic material analysis, fingerprinting, ballistic analysis, and 
blood typing.  Conceptual lessons are supplemented with hands-on demonstrations, allowing students 
to experience first-hand the essential techniques used to process a crime scene.  Student enrollment 
was approximately 60 students spread over two individual classes. 
Nottingham High School is a public school in the Syracuse City School District.  Enrollment 
totaled approximately 1300 students in grades 9-12 during the 2009-2010 academic year. (177)  Four-
year graduation rate was 51% among students who began high school in 2006, compared to the New 
York State average of 74%, and the Syracuse city average of 46%.(178)  In 2009-2010, 59% of students 
scored at or above Level 3 on the State assessments in English Language Arts (ELA) and 59% in State 
assessments in mathematics at the secondary level; Level 3 is defined as performance demonstrating an 
understanding of the content expected in the subject and grade level. (177) 
 
7.3 CURRICULUM DESIGN 
The lesson plan (reproduced in Appendix) was used as a capstone laboratory demonstration and was 
designed to supplement the standard SUPA curriculum regarding blood analysis.  This lab allows 
students to conduct blood analysis first hand in small groups, an opportunity that is typically not 
available in a high school environment.   
This lesson plan was constructed using elements of inquiry-based learning.  Students were 
allowed to conduct the experiment with fairly limited guidance and while a detailed list of procedures 
were given to the students to accurately run the experiment for themselves, very little information was 
on the interpretation of the result.  Students were required to consider the results in the context of 
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what they had previously learned, as well as diagnose problems that they encountered, based on their 
understanding of the lab.  Students were also asked to think about how the principles behind the 
laboratory demonstration can be translated from the classroom into the field of forensics, including any 
potential problems that could arise. 
Each group of students was provided with a synthetically produced DNA “sample” obtained 
from a fictitious crime scene, as well as DNA samples from each of four “suspects.”  For the sake of 
simplicity, the DNA samples had been preamplified using PCR, leaving the students to digest each of the 
samples with a provided set of enzymes.  The resulting digested samples were loaded into an 
electrophoresis gel and are allowed to separate by size.  By comparing the sample bands to a 
standardized DNA ladder, students were able to visually assess the results of their work. 
In addition to learning the physical technique involved in blood analysis during the course of a 
criminal investigation, students were asked to draw conclusion about the “guilt” of each suspect based 
on the results of the test.  This was done without prior instruction on how to interpret the results, and 
required that the students come to a determination through an intuitive understanding of the assay.  
Students were also asked to identify weaknesses in the assay in its current implementation and suggest 
improvements to eliminate or mitigate these problems. 
 
7.4 DISCUSSION 
7.4.1 Planned Curriculum 
The vast majority of students began the lesson with only a very basic conceptual understanding of DNA 
fingerprinting, and all lacked hands-on experience.  Through an informal classroom discussion, it was 
found that while PCR and DNA fingerprinting had been discussed multiple times in the past in SUPA 
Forensic Science as well as Biology and Chemistry, students drew much of their knowledge of DNA 
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fingerprinting from popular media, most predominantly police procedural television dramas, such as 
Law and Order and CSI.  Students readily understood DNA fingerprinting to be a powerful investigative 
tool, appreciated its relatively high accuracy at determining matching donors, and could identify 
potential weaknesses, such as “contamination,” often used in popular media as plot devices.  However, 
few students understood the scientific principles behind the technique and could not easily articulate 
why DNA fingerprinting was highly accurate, nor why contamination could affect the results of the 
analysis. 
Without prior experience with items such as micropipettes and microcentrifuge tubes, students 
needed time to adapt to their usage.  While instruction was given on general usage of the equipment 
and on the proper safety precautions, relatively little direction was given regarding minimization of 
cross-contamination.  Instructors stressed the importance of using sterile, unused tips and tubes, but did 
not explain why this procedure was necessary.   
Most groups successfully completed the lab and were able to determine the “guilty” suspect 
based on the unknown sample.  Students were able to conceptually understand the process of DNA 
fingerprinting from the crime scene to the conclusion, most notably that enzymes could cleave DNA into 
fragments, but only at sequences specifically recognized by the enzyme.  Students independently 
established that because each of the samples was potentially different from the rest, the enzymes 
would cut each DNA sample into different sized fragments.  After realizing that an electrophoresis is 
capable of separating DNA fragments by size, students could very readily identify identical fragments 
and could easily match up the unknown DNA with one of the donors, thereby incriminating one of the 
“suspects.” 
Some groups were unable to find a match between the unknown and donor samples.  Students 
were asked to consider why this could be the case, and came up with several possibilities: the criminal 
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was not among the suspects, the kit was defective, the enzymes were not working properly, the samples 
were mixed up with another group’s samples, or the samples were contaminated with something else.  
When asked to elaborate on possible sources of contamination, many realized that if the samples were 
not properly isolated from each other, the results of the test were meaningless, even if all other 
procedures were performed correctly.  Students were then able to trace by the cross-contamination to 
their pipette and sample separation technique, and were able to point out specific problems in their 
handling procedure.  Ultimately, it was concluded that while the “criminal” was among the suspects, it 
was impossible to identify him using the results of the analysis.  In a true criminal investigation, more 
evidence would have to be sought to order to draw an accurate conclusion. 
 After the completion of the lab, students were asked to share their thoughts on the 
accuracy of the test.  Students quickly pointed out that contamination was a very serious issue that can 
seriously affect the results, and that contamination could occur at any point, from the crime scene to 
the testing lab.  To ensure that the samples are properly obtained so that an accurate result can be 
determined, they concluded that it was essential that all people associated with the sample be properly 
trained, and that a clear chain of custody needed to be established so that the samples would not be 
tampered with, either accidentally or intentionally. 
Students also pointed out that while the DNA fingerprinting technique was exceptionally good at 
finding matching samples, the presence of a matching sample at a crime scene does not necessarily 
indicate guilt.  As there may be many reasons why a DNA sample was at the scene, they acknowledged 
that the results of DNA analysis need to be considered in conjunction with other evidence at the scene.  
Ultimately, students concluded that DNA fingerprinting, like older forms of investigative techniques, 
such as fingerprinting, were simply tools for the investigator and were not meant to be construed as 
absolute evidence of innocence or guilt. 
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7.4.2 Inquiry-Based Teaching 
Inquiry-based learning requires that the students be given adequate background on a topic so that they 
can largely self-direct their own lines of inquiry, while being given freedom to fully pursue these avenues 
of exploration. (179)  Teaching science as inquiry begins by giving students the knowledge base and the 
freedom necessary to explore the underlying mechanisms of scientific phenomena.  It allows students to 
actively direct their own research in a meaningful manner and allows for students to self-discover 
possible solutions to organically identified problems.  This laboratory demonstration was designed with 
these goals in mind.  Students were given the tools and sufficient background information to become 
immersed in the presented scenario, and were tasked with not only solving the immediately obvious 
problem of identifying the guilty subject, but were also encouraged to find limitations and potential 
pitfalls during the entire process.  This constant reflection and self-assessment is paramount in teaching 
critical thinking skills that are necessary for criminal investigators, as well as in any other field that 
stresses analytical thinking and problem solving. 
 While this approach certainly has benefits that cannot be easily paralleled by traditional, 
lecture-based teaching methods, there are also several major limitations that preclude its exclusive use 
in a classroom environment.  Most prominent is the modern school system’s reliance on standardized 
tests for the broad evaluation of student, teacher, and school system performance.  In New York State, a 
series of such tests is administered to students from grades 3-8 in the subjects of Mathematics, English, 
and Science, and in grades 9-12 in the subjects of English, Mathematics, Science, and Social Studies, 
known as the Regents Exams. (180)  These exams stress the fundamentals of each discipline and aim to 
assess a student’s mastery against specific learning standards established by the New York State 
Education Department (NYSED).  As students are required to demonstrate sufficient mastery of a 
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minimum number of subjects, quantifiably measured by a passing a specified number of Regents exams, 
successful completion of high school must, in part, consist of satisfactory performance on these 
standardized tests.  In turn, the professional performance of teachers, education administrators, and 
school districts, of which graduate rate is a major metric, is likewise highly dependent on the results of 
the Reagents exam.  Conceived as both a tool for political and educational accountability, as well as a 
measuring stick by which individual students can quantitatively assess their own understanding of core 
disciplines, the Regents Exam has become central to the education process, and directly influences 
matters of funding, policy, and rhetoric. (181) 
A typical Regents Exam in science consists of a multiple choice section and a short answer 
section that highly emphasizes the core knowledge-based principles of the subject.  In chemistry, for 
example, students are asked to be familiar with atomic concepts, the periodic table, stoichiometry, 
chemical bonding, kinetics, equilibrium, organic chemistry, oxidation-reduction, acids/bases/salts, as 
well as nuclear chemistry.(182)  While testing these topics is critical in fully assessing students’ 
understanding of chemistry, the topics and the test format do not lend themselves easily to assessing 
the free-form problem solving ability essential to becoming a successful researcher, and cultivated by 
many inquiry-based teaching techniques.  In fact, given the composition of the exam, consisting highly 
directed prompts with unequivocally correct solutions meant to provide graders with an objective 
means of evaluation, students are better served avoiding much of the techniques learned through 
inquiry-based teaching in favor of rote memory or highly drilled procedural techniques.(183)  
Unfortunately, due to the dominance of standardized test-driven school systems and the direct 
monetary incentive for succeeding in quantifiable measures, inquiry based learning may often have a 
tangible detrimental effect if applied too liberally, both on the students as well as the teachers. 
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Likewise, it is realistically not sustainable to apply inquiry-based techniques wholesale in every 
lesson plan, as inquiry based techniques must be implemented in moderation to maintain direction, 
organization, and continuity in a practical classroom setting.   Inquiry-based teaching, by design, 
encourages organic problem discovery and problem solving by each student with relatively little 
direction.  The success of this technique relies heavily on a carefully constructed curriculum, but is also 
greatly affected by the often-tangential “brainstorming” nature of free-form discovery.  Students must 
be reined in by their instructors in order to achieve certain goals, while doing so under time restrictions 
imposed by daily and annual class schedules.  Moreover, students’ progress is also affected by their 
interest level, which can fluctuate quickly depending on the perceived success or failure of their current 
path of reasoning.  To mitigate all of these potential factors, there is little alternative for an instructor 
but to step in and provide guidance, at the expense of student-driven self-discovery.  In practice, I have 
found that frequent “interventions” are paramount in ensuring that the students derive anything of 
value from each lesson plan. 
Ultimately, inquiry-based teaching is a powerful technique that encourages students to engage 
activity in their learning, as well as fosters many important problem solving skills that can be translated 
into a wide variety of research and non-academic career paths, but must be used in the moderation in 
the modern school system in which standardized accountability and metrics-based evaluation is 
predominant.  
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CHAPTER 8 – CONCLUSIONS AND FUTURE DIRECTION 
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8.1 FUTURE DIRECTION 
8.1.1 Targeted Contrast Agents In Vivo 
While exploring new uses and indications for already-existing, clinically approved contrast agents is 
undoubtedly the quickest path to translate bench research to the clinic, approaches using surface-bound 
ligands to create novel targeted contrast agents are potentially more powerful in expanding the 
capabilities of contrast agents in visualizing a wide variety of disease states.  In this thesis, two such 
constructs were described.  An anti-p53 SPIO was tested against in vitro cancer cell models, and a 
leukocyte mimetic nanoparticle was tested against in vivo mouse models and imaged post mortem.  In 
both cases, the targeted contrast agent was capable of readily differentiating between the disease state 
of interest and a healthy control.  Thus, the next steps would be to expand the scope of these studies to 
in vivo mouse models with live mouse imaging using MRI.   This presents many challenges, particularly 
with imaging.  Thus far, in vivo imaging was performed post mortem, and concerns such as time 
constraints and motion due to breathing or heart beat could be disregarded.  Likewise, as the mice were 
preserved and imaged post mortem, the analysis was that of a static subject that was no longer 
undergoing active change.  For live animal imaging, all of these new concerns must be addressed such 
that sufficient signal can be obtained from the subject, at a temporal resolution relevant for visualizing 
an actively changing phenomenon, while minimizing the deleterious imaging effects inherent with 
imaging living and involuntarily moving subjects.   
Preliminary studies were conducted concerning the feasibility of live mouse imaging in 
conjunction with the administration of targeted nanoparticles.  Initial results suggest that areas of the 
body not highly susceptible to involuntary motion, notably the brain, can be effectively imaged and 
analyzed using MRI-QSM techniques, suggesting that it is possible to quantitatively track nanoparticles 
delivered to areas of acute inflammation in the brain.  Imaging inflammation in the brain has particular 
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clinical significance, such as for the diagnosis of multiple sclerosis.  Multiple sclerosis is a disease of the 
central nervous system that is characterized by multifocal white matter lesions. (184) Current methods 
of diagnoses rely on the detection of the lesions using traditional MRI techniques, and utilize non-
specific gadolinium-based contrast agents to differentiate lesions from surrounding healthy tissue. (185)   
However, such an approach images only downstream injuries, indicated of advanced pathology, and 
cannot accurately assess disease activity. (186)  While typically not present to a large degree in the 
tissue of the CNS, ICAM-1 plays a key role in lymphocytic infiltration and interactions during tissue 
inflammation and is expressed at significantly higher levels in multiple sclerosis lesions of all ages and 
degree advancement. (187)  Thus, a method of non-invasively visualizing areas of high ICAM-1 
expression in the brain could prove valuable in the early and accurate diagnosis of multiple sclerosis. 
 
8.1.2 Constructing and Tracking Theranostic Nanoparticle 
As a long term goal, the studies described in this thesis suggest that MRI-QSM can be used to track and 
quantify the distribution of theranostic nanoparticles, complexes that contain a combination of 
components suitable as a contrast agent and components suitable as a therapeutic agent.   In doing so, 
it would be feasible to non-invasively quantitate the amount of therapeutic agents delivered to specific 
areas of the body with high spatiotemporal resolution.  Such an application has far reaching implications 
for both investigational research, as well as clinical treatment, and would allow investigators and 
clinicians to more accurately understand the spatiotemporal distribution of therapeutic agents.  
Likewise, this would vastly improve the ability to titrate therapeutic doses on a per patient basis, 
thereby improving treatment effectiveness while reducing side effects from over-administration.  
Ultimately, such a technique would pave way to “concierge” medicine, allowing clinicians to accurately 
tailor treatment protocols to the unique needs of each patient. 
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8.2 CONCLUSIONS 
In this thesis, two distinct strategies were described to deliver and quantifiably track contrast agents in 
MRI for the purposes of visualizing underlying disease states.  First, clinically approved non-biospecific 
nanoparticles were used to probe the onset and progression of induced systemic inflammation in in vivo 
mouse models, allowing for clinically relevant rapid differentiation of inflamed mice from healthy 
controls based on the rate of nanoparticle uptake by activated immune cells.  Second, targeted 
nanoparticles were constructed to specifically deliver contrast agents to sites with cellular targets closed 
associated with acute inflammation, sepsis, or cancer.  A first approach employed the development of a 
bivalent protein scaffold platform, resulting in increased effective binding affinity of targeting ligands 
through an increase in avidity or a broadened spectrum of recognition through the formation of 
heterogeneous dimers.  This platform was utilized in the formation of mutated p53-specific contrast 
agents, resulting in a generalized cancer-specific contrast agent suitable for selective enhancement of a 
wide variety of tumor cell lines.  A second approach resulted in the formation of ICAM-1-specific 
contrast agents, resulting in a contrast agent suitable for selective imaging enhancement of regions of 
acute inflammation.  In both strategies, contrast agents were tracked using MRI-QSM, a relatively new 
technique that allows for accurate and quantitative spatiotemporal analysis not feasible with traditional 
MRI-based imaging and analysis. 
MRI is a powerful technique that is commonly used in clinical settings.  It is non-invasive, does 
not employ ionizing radiation, and is capable of high spatial and temporal resolution, making it ideal for 
a wide variety of imaging applications, both for active diagnostic applications and preventative 
medicine.  The strategies described in this thesis further increase the diagnostic ability of MRI by 
selectively delivering contrast enhancing nanoparticles to areas of interest, either through changes in 
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cellular, organ, and systemic behavior as a result of disease states, or through biospecificity conferred by 
surface-bound targeting ligands.  In doing so, this allows MRI to accurately probe systemic processes or 
cellular targets previously not available as diagnostic indicators, and has the potential to dramatically 
expand the spectrum of biological characteristics that can be visualized and quantified using MRI.  The 
work in this study represents a step towards the creation of specialized, use-specific diagnostic agents 
that have the potential to improve the accuracy and speed of clinical diagnoses. 
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GK-12 LESSON PLAN 
DNA Fingerprinting in the Context of Criminal Forensics 
Author(s):   Richard Wong 
Date Created:  2011 
Subject:  Forensics 
Grade Level:  High School 
Standards:  Standard 1: Inquiry and Design 
Standard 4.2.1: Genetics 
Schedule:  3 Days (1 Day Overview, 2 Day Lab, 45 minutes per day) 
 
Description: 
 
Students will learn about DNA fingerprinting 
and its usefulness in the context of criminal 
forensics.  Students will use basic DNA 
fingerprinting techniques to solve a “crime” in 
which DNA evidence is present. 
Objectives: 
 
• Understand basic scientific concepts of 
DNA fingerprinting 
• Understand basic protocol for DNA 
fingerprinting 
• Understand proper handling 
techniques to avoid contamination 
• Interpret results in the context of 
criminal investigations 
 
 
Vocabulary: 
 
• DNA Fingerprinting 
• PCR 
• Electrophoresis 
• Restriction Enzymes 
 
Materials: 
 
• Biorad Biotechnology Explorer – 
Forensic DNA Fingerprinting Kit Cat 
#166-0007EDU (one kit supplies about 
15 groups)  
• Micropipetters (20uL and 200uL) 
• Gel Electrophoresis Chambers 
• Gel Electrophoresis Power Supplies 
• Microwave 
• Gloves 
• Goggles 
• Heat protective gloves 
• Lab coats 
• Beakers – 500ml 
• Bucket with Ice 
 
Safety: 
Student should use gloves.  Goggles and 
heat-protective gloves should be used when 
preparing agarose gels.  Lab coats should be 
worn at all times. 
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Science Content for the Teacher: 
DNA fingerprinting is a common technique used for linking genetic material found at crime 
scenes with genetic material obtained from suspects.  While DNA fingerprinting techniques have existing 
in some form since the 1980s, current techniques utilize polymerase chain reaction (PCR) amplification 
to rapidly and accurately analyze small amounts of DNA material.   
PCR: Polymerase chain reaction amplification is a technique that amplifies a single or few copies 
of DNA across several orders of magnitude, allowing for small quantities of DNA found at a crime scene 
to be analyzed easily.  Conceptually, PCR replies on thermal cycling of DNA in which cycles of heating 
and cooling allow for phased DNA melting and subsequent enzymatic replication.  The first step, the 
denaturation phase, consists of heating the reaction to 94-98C for 20-30 seconds, causing DNA melting 
through the disruption of hydrogen bonds between complementary bases, resulting in single stranded 
DNA.  The second step, the annealing phase consists of cooling the temperature to 50-65C for 20-40, 
allowing for DNA to anneal to primers.  The polymerase binds to the primer-DNA and begins synthesis.  
The third step, the extension phase, consists of raising the temperature to the DNA polymerases’ 
optimal temperature, and DNA is synthesized complementary to the DNA template.  The steps can be 
repeated to increase the number of DNA twofold for each cycle.  During this process, DNA can be “cut” 
and specific sequences can be selectively amplified through the use of restriction enzymes. 
Primers: Because DNA polymerases can only add new nucleotides to an existing strand of DNA, 
a “primer” must be used as a starting point for DNA synthesis.  A primer consists of a short strand of 
nucleic acids that is complementary to a sequence of DNA.  As DNA synthesis progresses, the primer is 
elongated into a full strand. 
DNA Polymerase: DNA polymerase is an enzyme that helps catalyze the polymerization of 
deoxyribonucleotides into a DNA strand.  Conceptually, DNA polymerases “read” a complete DNA strand 
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and append the complementary bases onto a partner strand, creating a full double-stranded DNA strand 
with complementary base pairs. 
Restriction Enzymes: Restriction enzymes are enzymes that cuts double or single stranded DNA 
at specific recognition nucleotide sequences, known as the restriction sites.  By using restriction 
enzymes, it becomes possible to selectively “cut” DNA, resulting in multiple fragments of varying sizes.  
If restriction enzymes are carefully chosen, the differences in DNA fragments resulting from the cuts can 
give information that can be used to differentiate between multiple unknown samples.  Identical DNA 
fragments may indicate that the DNA samples may have originated from the same source. 
Electrophoresis: Electrophoresis is a common laboratory technique by which DNA fragments are 
separated by size.  DNA fragments are loaded into an agarose gel slab and placed into a chamber with a 
conductive buffer solution.  A current is passed between electrodes at each end of the chamber.  Since 
DNA is negatively charged, DNA will migrate towards the positive electrode, through the agarose.  The 
agarose impedes the progression of DNA, acting as a sieve, and allowing small fragments to travel faster.  
Over time, smaller DNA fragments will be closer to the positive electrode, and larger fragments will be 
closer to the negative electrode. 
DNA Fingerprinting: DNA fingerprinting uses the combination PCR, carefully chosen restriction 
enzymes, and electrophoresis, to determine the similarities and differences between DNA strands.  In 
the context of criminal forensics, a small amount of DNA is obtained at a crime scene and is amplified 
dramatically using PCR.  The resulting DNA is also cut using restriction enzymes aimed at differentially 
cutting DNA sequences into fragments of various sizes, and the results are analyzed using 
electrophoresis.  If differences in DNA fragment sizes are detected using electrophoresis, one can 
conclude that the samples are dissimilar, and may suggest that they are from different sources.  If there 
are no differences in DNA fragment sizes, this may suggest that they are from the same source, or that 
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the restriction enzymes did not cut the sequence in a manner that differentiates between the two 
sources. 
 
Classroom Procedure: 
Overview 
The teacher provides an overview of DNA fingerprinting in the context of criminal forensics.  
Topics should include DNA and its makeup, PCR, restriction enzymes, and electrophoresis.  The above 
material can be used as a starting point for an overview lecture. 
 
Preparation (Before Students Arrive): 30 minutes 
Rehydrate DNA samples, enzymes, and mixes included in kit, according to directions listed in the 
kit. 
 
Day One: 45 minute class session – Restriction Digestion 
For the sake of simplicity in a high school laboratory environment, the samples in the included 
kit have already been pre-amplified using PCR.  It may be beneficial for the instructor to explain the 
significance of the pre-amplification in order for students to understand the procedural chain between 
obtaining a DNA sample from a crime scene and analyzing the sample using the amplified materials. 
1. The students are given 10uL of each of the suspects’ DNA in individual microcentrifuge tubes.  
They are also given a tube containing 10uL of an unknown DNA sequence from a fictitious crime 
scene, which must be matched to one of the five suspect’s samples.  10uL of a restriction 
enzyme mix is also given to each in separate tube. 
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2. The students will add 10uL of the enzyme mix to each of the sample tubes, mixing well by 
pipetting up and down. 
3. The caps for each sample are closed and the contexts are mixed by flicking the tubes gently with 
a finger. 
4. Tubes are incubated overnight at room temperature. 
5. Gels are prepared for the following day.   
a. Create a 1% agarose solution using 1 gram of agarose for each 100mL of 1X TAE 
electrophoresis buffer.  Add beaker. 
b. Boil agarose in a microwave.  Time varies, but should be roughly 3 minutes at medium 
power, depending on the amount of agarose used.  Caution must be used, as agarose is 
very hot. 
c. Seal ends of electrophoresis chamber and pour gel into mold to create agarose slabs.  
Insert a comb to create a parallel row of sample wells. 
d. Allow to cool.  Gels will be kept until the following day in a refrigerator. 
 
Day Two: 45 minute class session – Electrophoresis 
1. Tap DNA tubes (with added enzymes) on table to bring all liquid to the bottom of the tubes. 
2. Using a separate tip, add 5uL of loading dye into each tube.  Close tubes and mix gently. 
3. Place prepared agarose gels in electrophoresis chamber and all 1X TAE buffer to over the gel.  
Ensure that the top of the gel (with the wells) is by the negative electrode, and that the bottom 
of the gel is by the positive electrode. 
4. Using a separate tip for each sample, load the indicated volume of each sample into the wells in 
the following order: 
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a. Lane 1: DNA size standard (include) – 10uL 
b. Lane 2: Unknown Crime Scene sample – 20uL 
c. Lane 3: Suspect Sample 1 – 20uL 
d. Lane 4: Suspect Sample 2 – 20uL 
e. Lane 5: Suspect Sample 3 – 20uL 
f. Lane 6: Suspect Sample 4 – 20uL 
g. Lane 7: Suspect Sample 5 – 20uL 
5. Plug power supply leads electrophoresis chamber and run power supply at 100V for about 30 
minutes. 
6. Stain DNA using Fast Blast DNA 
a. Add 120mL of 100x Fast Blast DNA stain into staining tray 
b. Stain the gels for 2 minutes with gentle agitation.  Stain can be reused. 
c. Transfer gels to large washing container and rinse with warm (40-55C) tap water for 10 
seconds. 
d. Destain by washing twice in warm tap water for 5 minutes with gentle shaking 
7. Observe results and discuss.  Which suspect’s sample matches that found at the crime scene? 
 
Assessment: 
While the primary focus of this lab is to provide a basic overview of a simple DNA fingerprinting 
protocol and to give the student hands-on interaction with the process of cutting and analyzing DNA 
samples, it also encourages students to think about DNA fingerprinting as an evidence processing 
technique in the context of a criminal investigation.  In particular, while the successful completion of this 
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lab results in a visual separation of DNA and allows for an unknown sample to be matched with one of 
an array of suspect samples, it is important for students to understand the implications of this match. 
 
Useful questions to ask: 
• Which samples matches the one found at the crime scene?  What would this mean in a criminal 
investigation? 
• What if none of the samples matched the one at the crime scene?  What would this mean in a 
criminal investigation? 
• What if two or more samples matched the one at the crime scene?  What would this mean in a 
criminal investigation? 
• What would happen if the samples were contaminated?  What would the results of electrophoresis 
show?  What would this mean in a criminal investigation? 
• What are some of the limitations of this technique? 
o Can a crime scene sample be matched to any unknown person? 
o Is one restriction enzyme enough to differentiate between every suspect? 
o Is it possible for more than one person have similar electrophoresis results?  Why? 
 
Acknowledgements: 
Lesson adapted from BioRad’s Biotechnology Explorer Forensic DNA Fingerprinting Kit. 
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